Hospital Medicine

In this issue of the Journal of Hospital Medicine, Ellimoottil and colleagues examine characteristics of readmissions identified as planned by the planned readmission algorithm developed for the Center for Medicare & Medicaid Services (CMS) by using Medicare claims data from 131 hospitals in Michigan.¹ They found that a substantial portion of readmissions currently classified as planned by the algorithm appear to be nonelective, as defined by the presence of a charge by an emergency medicine physician or an admission type of emergent or urgent, making those hospitalizations unlikely to be planned. They suggest that the algorithm could be modified to exclude such cases from the planned designation.

To determine whether modifying the algorithm as recommended is a good idea, it is helpful to examine the origins of the existing planned readmission algorithm. The algorithm originated as a consequence of hospital accountability measures for readmissions and was developed by this author in collaboration with colleagues at Yale University and elsewhere.² Readmission measures have been controversial in part because clearly some (undetermined) fraction of readmissions is unavoidable. Many commentators have asked that readmission measures therefore capture only avoidable or related readmissions. Avoidable readmissions are those that could have been prevented by members of the healthcare system through actions taken during or after hospitalization, such as patient counseling, communication among team members, and guideline-concordant medical care. Related readmissions are those directly stemming from the index admission. However, reliably and accurately defining such events has proven elusive. One study, for instance, found the rate of physician-assessed preventability in published studies ranged from 9% to 48%.³ The challenge is even greater in trying to determine preventability using just claims data, without physician review of charts. Imagine, for instance, a patient with heart failure who is readmitted with heart failure exacerbation. The readmission preceded by a large fast-food meal is likely preventable; although even in this case, some would argue the healthcare system should not be held accountable for a readmission if the patient had been properly counseled about avoiding salty food. The one preceded by progressively worsening systolic function in a patient who reliably takes medications, weighs herself daily, and watches her diet is likely not. But both appear identical in claims. Related is also a difficult concept to operationalize. A recently hospitalized patient readmitted with pneumonia might have acquired it in the hospital (related) or from her grandchild 2 weeks later (unrelated). Again, both appear identical in claims.

In the ideal world, clinicians would be held accountable only for preventable readmissions. In practice, that has not proven to be possible.

Instead, the CMS readmission measures omit readmissions that are thought to be planned in advance: necessary and intentional readmissions. Defining a planned readmission is conceptually easier than defining a preventable readmission, yet even this is not always straightforward. The clearest case might be a person with a longstanding plan to have an elective surgery (say, a hip replacement) who is briefly admitted with something minor enough not to delay a subsequent admission for the scheduled surgery. Other patients are admitted with acute problems that require follow-up hospitalization (for instance, an acute myocardial infarction that requires a coronary artery bypass graft 2 weeks later).⁴ More ambiguous are patients who are sent home on a course of treatment with a plan for rehospitalization if it fails; for instance, a patient with gangrene is sent home on intravenous antibiotics but fails to improve and is rehospitalized for an amputation. Is that readmission planned or unplanned? Reasonable people might disagree.

Nonetheless, assuming it is desirable to at least try to identify and remove planned readmissions from measures, there are a number of ways in which one might do so. Perhaps the simplest would be to classify each hospitalization as planned or not on the UB-04 claim form. Such a process would be very feasible but also subject to gaming or coding variability. Given that there is some ambiguity and no standard about what types of readmissions are planned and that current policy provides incentives to reduce unplanned readmission rates, hospitals might vary in the cases to which they would apply such a code. This approach, therefore, has not been favored by payers to date. An alternative is to prospectively flag admissions that are expected to result in planned readmissions. In fiscal year 2014, the CMS implemented this option for newborns and patients with acute myocardial infarction by creating new discharge status codes of “discharged to [location] with a planned acute care hospital inpatient readmission.” Institutions can flag discharges that they know at the time of discharge will be followed by a readmission, such as a newborn who requires a repeat hospitalization for repair of a congenital anomaly.⁵ There is no time span required for the planned readmission to qualify. However, the difficulty in broadening the applicability of this option to all discharges lies in identification and matching; there also remains a possibility for gaming. The code does not specify when the readmission is expected nor for what diagnosis or procedure. How, then, do we know if the subsequent readmission is the one anticipated? Unexpected readmissions may still occur in the interim. Conversely, what if the discharging clinicians don’t know about an anticipated planned procedure? What would stop hospitals from labeling every discharge as expected to be followed by a planned readmission? These considerations have largely prevented the CMS from asking hospitals to apply the new code widely or from applying the code to identify planned readmissions.

Instead, the existing algorithm attempts to identify procedures that might be done on an elective basis and assumes readmissions with these procedures are planned if paired with a nonurgent diagnosis. Ellimoottil and colleagues attempt to verify whether this is accurate using a creative approach of seeking emergency department (ED) charges and admission type of emergent or urgent, and they found that roughly half of planned readmissions are, in fact, likely unplanned. This figure agrees closely with the original chart review validation of the algorithm. In particular, they found that some procedures, such as percutaneous cardiac interventions, appear to be paired regularly with a nonurgent principal diagnosis, such as coronary artery disease, even when done on an urgent basis.

This validation was performed prior to the availability of version 4.0 of the planned readmission algorithm, which removes several high-frequency procedures from the potentially planned readmission list (including cardiac devices and diagnostic cardiac catheterizations) that were very frequently mischaracterized as planned in the original chart validation.⁶ At least 8 such cases were also identified in this validation according to the table. Therefore, the misclassification rate of the current algorithm version is probably less than that reported in this article. Nonetheless, percutaneous transluminal coronary angioplasty remains on the planned procedure list in version 4.0 and appears to account for a substantial error rate, and it is likely that the authors’ approach would improve the accuracy even of the newer version of the algorithm.

The advantages of the suggested modifications are that they do not require chart review and could be readily adopted by the CMS. Although seeking ED charges for Medicare is somewhat cumbersome in that they are recorded in a different data set than the inpatient hospitalizations, there is no absolute barrier to adding this step to the algorithm, and doing so has substantial face validity. That said, identifying ED visits is not straightforward because nonemergency services can be provided in the ED (ie, critical care or observation care) and because facilities and providers have different billing requirements, producing different estimates depending on the data set used.⁷ Including admission type would be easier, but it would be less conservative and likely less accurate, as this field has not been validated and is not typically audited. Nonetheless, adding the presence of ED charges seems likely to improve the accuracy of the algorithm. As the CMS continues to refine the planned readmission algorithm, these proposed changes would be very reasonable to study with chart validation and, if valid, to consider adopting.

Disclosure 

Dr. Horwitz reports grants from Center for Medicare & Medicaid Services, grants from Agency for Healthcare Research and Quality, during the conduct of the study.

In this issue of the Journal of Hospital Medicine, Ellimoottil and colleagues examine characteristics of readmissions identified as planned by the planned readmission algorithm developed for the Center for Medicare & Medicaid Services (CMS) by using Medicare claims data from 131 hospitals in Michigan.¹ They found that a substantial portion of readmissions currently classified as planned by the algorithm appear to be nonelective, as defined by the presence of a charge by an emergency medicine physician or an admission type of emergent or urgent, making those hospitalizations unlikely to be planned. They suggest that the algorithm could be modified to exclude such cases from the planned designation.

To determine whether modifying the algorithm as recommended is a good idea, it is helpful to examine the origins of the existing planned readmission algorithm. The algorithm originated as a consequence of hospital accountability measures for readmissions and was developed by this author in collaboration with colleagues at Yale University and elsewhere.² Readmission measures have been controversial in part because clearly some (undetermined) fraction of readmissions is unavoidable. Many commentators have asked that readmission measures therefore capture only avoidable or related readmissions. Avoidable readmissions are those that could have been prevented by members of the healthcare system through actions taken during or after hospitalization, such as patient counseling, communication among team members, and guideline-concordant medical care. Related readmissions are those directly stemming from the index admission. However, reliably and accurately defining such events has proven elusive. One study, for instance, found the rate of physician-assessed preventability in published studies ranged from 9% to 48%.³ The challenge is even greater in trying to determine preventability using just claims data, without physician review of charts. Imagine, for instance, a patient with heart failure who is readmitted with heart failure exacerbation. The readmission preceded by a large fast-food meal is likely preventable; although even in this case, some would argue the healthcare system should not be held accountable for a readmission if the patient had been properly counseled about avoiding salty food. The one preceded by progressively worsening systolic function in a patient who reliably takes medications, weighs herself daily, and watches her diet is likely not. But both appear identical in claims. Related is also a difficult concept to operationalize. A recently hospitalized patient readmitted with pneumonia might have acquired it in the hospital (related) or from her grandchild 2 weeks later (unrelated). Again, both appear identical in claims.

In the ideal world, clinicians would be held accountable only for preventable readmissions. In practice, that has not proven to be possible.

Instead, the CMS readmission measures omit readmissions that are thought to be planned in advance: necessary and intentional readmissions. Defining a planned readmission is conceptually easier than defining a preventable readmission, yet even this is not always straightforward. The clearest case might be a person with a longstanding plan to have an elective surgery (say, a hip replacement) who is briefly admitted with something minor enough not to delay a subsequent admission for the scheduled surgery. Other patients are admitted with acute problems that require follow-up hospitalization (for instance, an acute myocardial infarction that requires a coronary artery bypass graft 2 weeks later).⁴ More ambiguous are patients who are sent home on a course of treatment with a plan for rehospitalization if it fails; for instance, a patient with gangrene is sent home on intravenous antibiotics but fails to improve and is rehospitalized for an amputation. Is that readmission planned or unplanned? Reasonable people might disagree.

Nonetheless, assuming it is desirable to at least try to identify and remove planned readmissions from measures, there are a number of ways in which one might do so. Perhaps the simplest would be to classify each hospitalization as planned or not on the UB-04 claim form. Such a process would be very feasible but also subject to gaming or coding variability. Given that there is some ambiguity and no standard about what types of readmissions are planned and that current policy provides incentives to reduce unplanned readmission rates, hospitals might vary in the cases to which they would apply such a code. This approach, therefore, has not been favored by payers to date. An alternative is to prospectively flag admissions that are expected to result in planned readmissions. In fiscal year 2014, the CMS implemented this option for newborns and patients with acute myocardial infarction by creating new discharge status codes of “discharged to [location] with a planned acute care hospital inpatient readmission.” Institutions can flag discharges that they know at the time of discharge will be followed by a readmission, such as a newborn who requires a repeat hospitalization for repair of a congenital anomaly.⁵ There is no time span required for the planned readmission to qualify. However, the difficulty in broadening the applicability of this option to all discharges lies in identification and matching; there also remains a possibility for gaming. The code does not specify when the readmission is expected nor for what diagnosis or procedure. How, then, do we know if the subsequent readmission is the one anticipated? Unexpected readmissions may still occur in the interim. Conversely, what if the discharging clinicians don’t know about an anticipated planned procedure? What would stop hospitals from labeling every discharge as expected to be followed by a planned readmission? These considerations have largely prevented the CMS from asking hospitals to apply the new code widely or from applying the code to identify planned readmissions.

Instead, the existing algorithm attempts to identify procedures that might be done on an elective basis and assumes readmissions with these procedures are planned if paired with a nonurgent diagnosis. Ellimoottil and colleagues attempt to verify whether this is accurate using a creative approach of seeking emergency department (ED) charges and admission type of emergent or urgent, and they found that roughly half of planned readmissions are, in fact, likely unplanned. This figure agrees closely with the original chart review validation of the algorithm. In particular, they found that some procedures, such as percutaneous cardiac interventions, appear to be paired regularly with a nonurgent principal diagnosis, such as coronary artery disease, even when done on an urgent basis.

This validation was performed prior to the availability of version 4.0 of the planned readmission algorithm, which removes several high-frequency procedures from the potentially planned readmission list (including cardiac devices and diagnostic cardiac catheterizations) that were very frequently mischaracterized as planned in the original chart validation.⁶ At least 8 such cases were also identified in this validation according to the table. Therefore, the misclassification rate of the current algorithm version is probably less than that reported in this article. Nonetheless, percutaneous transluminal coronary angioplasty remains on the planned procedure list in version 4.0 and appears to account for a substantial error rate, and it is likely that the authors’ approach would improve the accuracy even of the newer version of the algorithm.

The advantages of the suggested modifications are that they do not require chart review and could be readily adopted by the CMS. Although seeking ED charges for Medicare is somewhat cumbersome in that they are recorded in a different data set than the inpatient hospitalizations, there is no absolute barrier to adding this step to the algorithm, and doing so has substantial face validity. That said, identifying ED visits is not straightforward because nonemergency services can be provided in the ED (ie, critical care or observation care) and because facilities and providers have different billing requirements, producing different estimates depending on the data set used.⁷ Including admission type would be easier, but it would be less conservative and likely less accurate, as this field has not been validated and is not typically audited. Nonetheless, adding the presence of ED charges seems likely to improve the accuracy of the algorithm. As the CMS continues to refine the planned readmission algorithm, these proposed changes would be very reasonable to study with chart validation and, if valid, to consider adopting.

Disclosure 

Dr. Horwitz reports grants from Center for Medicare & Medicaid Services, grants from Agency for Healthcare Research and Quality, during the conduct of the study.

In this issue of the Journal of Hospital Medicine, Ellimoottil and colleagues examine characteristics of readmissions identified as planned by the planned readmission algorithm developed for the Center for Medicare & Medicaid Services (CMS) by using Medicare claims data from 131 hospitals in Michigan.¹ They found that a substantial portion of readmissions currently classified as planned by the algorithm appear to be nonelective, as defined by the presence of a charge by an emergency medicine physician or an admission type of emergent or urgent, making those hospitalizations unlikely to be planned. They suggest that the algorithm could be modified to exclude such cases from the planned designation.

To determine whether modifying the algorithm as recommended is a good idea, it is helpful to examine the origins of the existing planned readmission algorithm. The algorithm originated as a consequence of hospital accountability measures for readmissions and was developed by this author in collaboration with colleagues at Yale University and elsewhere.² Readmission measures have been controversial in part because clearly some (undetermined) fraction of readmissions is unavoidable. Many commentators have asked that readmission measures therefore capture only avoidable or related readmissions. Avoidable readmissions are those that could have been prevented by members of the healthcare system through actions taken during or after hospitalization, such as patient counseling, communication among team members, and guideline-concordant medical care. Related readmissions are those directly stemming from the index admission. However, reliably and accurately defining such events has proven elusive. One study, for instance, found the rate of physician-assessed preventability in published studies ranged from 9% to 48%.³ The challenge is even greater in trying to determine preventability using just claims data, without physician review of charts. Imagine, for instance, a patient with heart failure who is readmitted with heart failure exacerbation. The readmission preceded by a large fast-food meal is likely preventable; although even in this case, some would argue the healthcare system should not be held accountable for a readmission if the patient had been properly counseled about avoiding salty food. The one preceded by progressively worsening systolic function in a patient who reliably takes medications, weighs herself daily, and watches her diet is likely not. But both appear identical in claims. Related is also a difficult concept to operationalize. A recently hospitalized patient readmitted with pneumonia might have acquired it in the hospital (related) or from her grandchild 2 weeks later (unrelated). Again, both appear identical in claims.

In the ideal world, clinicians would be held accountable only for preventable readmissions. In practice, that has not proven to be possible.

Instead, the CMS readmission measures omit readmissions that are thought to be planned in advance: necessary and intentional readmissions. Defining a planned readmission is conceptually easier than defining a preventable readmission, yet even this is not always straightforward. The clearest case might be a person with a longstanding plan to have an elective surgery (say, a hip replacement) who is briefly admitted with something minor enough not to delay a subsequent admission for the scheduled surgery. Other patients are admitted with acute problems that require follow-up hospitalization (for instance, an acute myocardial infarction that requires a coronary artery bypass graft 2 weeks later).⁴ More ambiguous are patients who are sent home on a course of treatment with a plan for rehospitalization if it fails; for instance, a patient with gangrene is sent home on intravenous antibiotics but fails to improve and is rehospitalized for an amputation. Is that readmission planned or unplanned? Reasonable people might disagree.

Nonetheless, assuming it is desirable to at least try to identify and remove planned readmissions from measures, there are a number of ways in which one might do so. Perhaps the simplest would be to classify each hospitalization as planned or not on the UB-04 claim form. Such a process would be very feasible but also subject to gaming or coding variability. Given that there is some ambiguity and no standard about what types of readmissions are planned and that current policy provides incentives to reduce unplanned readmission rates, hospitals might vary in the cases to which they would apply such a code. This approach, therefore, has not been favored by payers to date. An alternative is to prospectively flag admissions that are expected to result in planned readmissions. In fiscal year 2014, the CMS implemented this option for newborns and patients with acute myocardial infarction by creating new discharge status codes of “discharged to [location] with a planned acute care hospital inpatient readmission.” Institutions can flag discharges that they know at the time of discharge will be followed by a readmission, such as a newborn who requires a repeat hospitalization for repair of a congenital anomaly.⁵ There is no time span required for the planned readmission to qualify. However, the difficulty in broadening the applicability of this option to all discharges lies in identification and matching; there also remains a possibility for gaming. The code does not specify when the readmission is expected nor for what diagnosis or procedure. How, then, do we know if the subsequent readmission is the one anticipated? Unexpected readmissions may still occur in the interim. Conversely, what if the discharging clinicians don’t know about an anticipated planned procedure? What would stop hospitals from labeling every discharge as expected to be followed by a planned readmission? These considerations have largely prevented the CMS from asking hospitals to apply the new code widely or from applying the code to identify planned readmissions.

Instead, the existing algorithm attempts to identify procedures that might be done on an elective basis and assumes readmissions with these procedures are planned if paired with a nonurgent diagnosis. Ellimoottil and colleagues attempt to verify whether this is accurate using a creative approach of seeking emergency department (ED) charges and admission type of emergent or urgent, and they found that roughly half of planned readmissions are, in fact, likely unplanned. This figure agrees closely with the original chart review validation of the algorithm. In particular, they found that some procedures, such as percutaneous cardiac interventions, appear to be paired regularly with a nonurgent principal diagnosis, such as coronary artery disease, even when done on an urgent basis.

This validation was performed prior to the availability of version 4.0 of the planned readmission algorithm, which removes several high-frequency procedures from the potentially planned readmission list (including cardiac devices and diagnostic cardiac catheterizations) that were very frequently mischaracterized as planned in the original chart validation.⁶ At least 8 such cases were also identified in this validation according to the table. Therefore, the misclassification rate of the current algorithm version is probably less than that reported in this article. Nonetheless, percutaneous transluminal coronary angioplasty remains on the planned procedure list in version 4.0 and appears to account for a substantial error rate, and it is likely that the authors’ approach would improve the accuracy even of the newer version of the algorithm.

The advantages of the suggested modifications are that they do not require chart review and could be readily adopted by the CMS. Although seeking ED charges for Medicare is somewhat cumbersome in that they are recorded in a different data set than the inpatient hospitalizations, there is no absolute barrier to adding this step to the algorithm, and doing so has substantial face validity. That said, identifying ED visits is not straightforward because nonemergency services can be provided in the ED (ie, critical care or observation care) and because facilities and providers have different billing requirements, producing different estimates depending on the data set used.⁷ Including admission type would be easier, but it would be less conservative and likely less accurate, as this field has not been validated and is not typically audited. Nonetheless, adding the presence of ED charges seems likely to improve the accuracy of the algorithm. As the CMS continues to refine the planned readmission algorithm, these proposed changes would be very reasonable to study with chart validation and, if valid, to consider adopting.

Disclosure 

Dr. Horwitz reports grants from Center for Medicare & Medicaid Services, grants from Agency for Healthcare Research and Quality, during the conduct of the study.

“Unnecessary noise is the most cruel abuse of care which can be inflicted on either the sick or the well.”

–Florence Nightingale¹

Motivated by the “unsustainable” rise in noise pollution and its “direct, as well as cumulative, adverse health effects,” an expert World Health Organization (WHO) task force composed the Guidelines for Community Noise, outlining specific noise recommendations for public settings, including hospitals.² In ward settings, these guidelines mandate that background noise (which is defined as unwanted sound) levels average <35 decibels (dB; ie, a typical library) during the day, average <30 dB at night, and peak no higher than 40 dB (ie, a normal conversation), a level sufficient to awaken someone from sleep.

Since the publication of these guidelines in 1999, substantial new research has added to our understanding of hospital noise levels. Recent research has demonstrated that few, if any, hospitals comply with WHO noise recommendations.³ Moreover, since 1960, hospital sound levels have risen ~4 dB per decade; based on the logarithmic decibel scale, if this trend continues, this translates to a 528% increase in loudness by 2020.³

The overwhelming majority of research on hospital noise has focused on the intensive care unit (ICU), where beeping machines and busy staff often push peak nighttime noise levels over 80 dB (ie, a kitchen blender).⁴ When evaluated during sleep, noise in the ICU causes frequent arousals and awakenings. When noise is combined with other factors, such as bright light and patient care interactions, poor sleep quality invariably results.⁴

While it has been known for years that critically ill patients experience markedly fragmented and nonrestorative sleep,⁵ poor sleep has recently gained attention due to its potential role as a modifiable risk factor for delirium and its associated consequences, including prolonged length of stay and long-lasting neuropsychological and physical impairments.⁶ Due to this interest, numerous interventions have been attempted,⁷ including multicomponent bundles to promote sleep,⁸ which have been shown to reduce delirium in the ICU.^9-12 Therefore, efforts to promote sleep in the ICU, including interventions to minimize nighttime noise, are recommended in Society of Critical Care Medicine clinical practice guidelines¹³ and are listed as a top 5 research priority by an expert panel of ICU delirium researchers.¹⁴

In contrast to the ICU, there has been little attention paid to noise in other patient care areas. Existing studies in non-ICU ward settings suggest that excessive noise is common,³ similar to the ICU, and that patients experience poor sleep, with noise being a significant disruptor of sleep.^5,15,16 Such poor sleep is thought to contribute to uncontrolled pain, labile blood pressure, and dissatisfaction with care.^16,17

In this issue of the Journal of Hospital Medicine, Jaiswal and colleagues¹⁸ report on an important study evaluating sound and light levels in both non-ICU and ICU settings within a busy tertiary-care hospital. In 8 general ward, 8 telemetry, and 8 ICU patient rooms, the investigators used meters to record sound and light levels for 24 to 72 hours. In each of these locations, they detected average hourly sound levels ranging from 45 to 54 dB, 47 to 55 dB, and 56 to 60 dB, respectively, with ICUs consistently registering the highest hourly sound levels. Notably, all locations exceeded WHO noise limits at all hours of the day. As a novel measure, the investigators evaluated sound level changes (SLCs), or the difference between peak and background sound levels, based on research suggesting that dramatic SLCs (≥17.5 dB) are more disruptive than constant loud noise.¹⁹ The authors observed that SLCs ≥17.5 dB occur predominantly during daytime hours and, interestingly, at a similar rate in the wards versus the ICU.

Importantly, the authors do not link their findings with patient sleep or other patient outcomes but instead focus on employing rigorous methods to gather continuous recordings. By measuring light levels, the authors bring attention to an issue often considered less disruptive to sleep than noise.^6,10,20 Similar to prior research,²¹ Jaiswal and colleagues demonstrate low levels of light at night, with no substantial difference between non-ICU and ICU settings. As a key finding, the authors bring attention to low levels of light during daytime hours, particularly in the morning, when levels range from 22 to 101 lux in the wards and 16 to 39 lux in the ICU. While the optimal timing and brightness of light exposure remains unknown, it is well established that ambient light is the most potent cue for circadian rhythms, with levels >100 lux necessary to suppress melatonin, the key hormone involved in circadian entrainment. Hence, the levels of morning light observed in this study were likely insufficient to maintain healthy circadian rhythms. When exposed to abnormal light levels and factors such as noise, stress, and medications, hospitalized patients are at risk for circadian rhythm misalignment, which can disrupt sleep and trigger a complex molecular cascade, leading to end-organ dysfunction including depressed immunity, glucose dysregulation, arrhythmias, and delirium.^22-24

What are the major takeaway messages from this study? First, it confirms that sound levels are not only high in the ICU but also in non-ICU wards. As hospital ratings and reimbursements now rely on favorable patient ratings, future noise-reduction efforts will surely expand more vigorously across patient care areas.²⁵ Second, SLCs and daytime recordings must be included in efforts to understand and improve sleep and circadian rhythms in hospitalized patients. Finally, this study provides a sobering reminder of the challenge of meeting WHO guidelines and facilitating an optimal healing environment for patients. Sadly, hospital sound levels continue to rise, and quiet-time interventions consistently fail to lower noise to levels anywhere near WHO limits.²⁶ Hence, to make any progress, hospitals of the future must entertain novel design modifications (eg, sound-absorbing walls and alternative room layouts), fix common sources of noise pollution (eg, ventilation systems and alarms), and critically evaluate and update interventions aimed at improving sleep and aligning circadian rhythms for hospitalized patients.²⁷

Acknowledgments

B.B.K. is currently supported by a grant through the University of California, Los Angeles Clinical Translational Research Institute and the National Institutes of Health’s National Center for Advancing Translational Sciences (UL1TR000124).

Disclosure

The authors have nothing to disclose.

“Unnecessary noise is the most cruel abuse of care which can be inflicted on either the sick or the well.”

–Florence Nightingale¹

Motivated by the “unsustainable” rise in noise pollution and its “direct, as well as cumulative, adverse health effects,” an expert World Health Organization (WHO) task force composed the Guidelines for Community Noise, outlining specific noise recommendations for public settings, including hospitals.² In ward settings, these guidelines mandate that background noise (which is defined as unwanted sound) levels average <35 decibels (dB; ie, a typical library) during the day, average <30 dB at night, and peak no higher than 40 dB (ie, a normal conversation), a level sufficient to awaken someone from sleep.

Since the publication of these guidelines in 1999, substantial new research has added to our understanding of hospital noise levels. Recent research has demonstrated that few, if any, hospitals comply with WHO noise recommendations.³ Moreover, since 1960, hospital sound levels have risen ~4 dB per decade; based on the logarithmic decibel scale, if this trend continues, this translates to a 528% increase in loudness by 2020.³

The overwhelming majority of research on hospital noise has focused on the intensive care unit (ICU), where beeping machines and busy staff often push peak nighttime noise levels over 80 dB (ie, a kitchen blender).⁴ When evaluated during sleep, noise in the ICU causes frequent arousals and awakenings. When noise is combined with other factors, such as bright light and patient care interactions, poor sleep quality invariably results.⁴

While it has been known for years that critically ill patients experience markedly fragmented and nonrestorative sleep,⁵ poor sleep has recently gained attention due to its potential role as a modifiable risk factor for delirium and its associated consequences, including prolonged length of stay and long-lasting neuropsychological and physical impairments.⁶ Due to this interest, numerous interventions have been attempted,⁷ including multicomponent bundles to promote sleep,⁸ which have been shown to reduce delirium in the ICU.^9-12 Therefore, efforts to promote sleep in the ICU, including interventions to minimize nighttime noise, are recommended in Society of Critical Care Medicine clinical practice guidelines¹³ and are listed as a top 5 research priority by an expert panel of ICU delirium researchers.¹⁴

In contrast to the ICU, there has been little attention paid to noise in other patient care areas. Existing studies in non-ICU ward settings suggest that excessive noise is common,³ similar to the ICU, and that patients experience poor sleep, with noise being a significant disruptor of sleep.^5,15,16 Such poor sleep is thought to contribute to uncontrolled pain, labile blood pressure, and dissatisfaction with care.^16,17

In this issue of the Journal of Hospital Medicine, Jaiswal and colleagues¹⁸ report on an important study evaluating sound and light levels in both non-ICU and ICU settings within a busy tertiary-care hospital. In 8 general ward, 8 telemetry, and 8 ICU patient rooms, the investigators used meters to record sound and light levels for 24 to 72 hours. In each of these locations, they detected average hourly sound levels ranging from 45 to 54 dB, 47 to 55 dB, and 56 to 60 dB, respectively, with ICUs consistently registering the highest hourly sound levels. Notably, all locations exceeded WHO noise limits at all hours of the day. As a novel measure, the investigators evaluated sound level changes (SLCs), or the difference between peak and background sound levels, based on research suggesting that dramatic SLCs (≥17.5 dB) are more disruptive than constant loud noise.¹⁹ The authors observed that SLCs ≥17.5 dB occur predominantly during daytime hours and, interestingly, at a similar rate in the wards versus the ICU.

Importantly, the authors do not link their findings with patient sleep or other patient outcomes but instead focus on employing rigorous methods to gather continuous recordings. By measuring light levels, the authors bring attention to an issue often considered less disruptive to sleep than noise.^6,10,20 Similar to prior research,²¹ Jaiswal and colleagues demonstrate low levels of light at night, with no substantial difference between non-ICU and ICU settings. As a key finding, the authors bring attention to low levels of light during daytime hours, particularly in the morning, when levels range from 22 to 101 lux in the wards and 16 to 39 lux in the ICU. While the optimal timing and brightness of light exposure remains unknown, it is well established that ambient light is the most potent cue for circadian rhythms, with levels >100 lux necessary to suppress melatonin, the key hormone involved in circadian entrainment. Hence, the levels of morning light observed in this study were likely insufficient to maintain healthy circadian rhythms. When exposed to abnormal light levels and factors such as noise, stress, and medications, hospitalized patients are at risk for circadian rhythm misalignment, which can disrupt sleep and trigger a complex molecular cascade, leading to end-organ dysfunction including depressed immunity, glucose dysregulation, arrhythmias, and delirium.^22-24

What are the major takeaway messages from this study? First, it confirms that sound levels are not only high in the ICU but also in non-ICU wards. As hospital ratings and reimbursements now rely on favorable patient ratings, future noise-reduction efforts will surely expand more vigorously across patient care areas.²⁵ Second, SLCs and daytime recordings must be included in efforts to understand and improve sleep and circadian rhythms in hospitalized patients. Finally, this study provides a sobering reminder of the challenge of meeting WHO guidelines and facilitating an optimal healing environment for patients. Sadly, hospital sound levels continue to rise, and quiet-time interventions consistently fail to lower noise to levels anywhere near WHO limits.²⁶ Hence, to make any progress, hospitals of the future must entertain novel design modifications (eg, sound-absorbing walls and alternative room layouts), fix common sources of noise pollution (eg, ventilation systems and alarms), and critically evaluate and update interventions aimed at improving sleep and aligning circadian rhythms for hospitalized patients.²⁷

Acknowledgments

B.B.K. is currently supported by a grant through the University of California, Los Angeles Clinical Translational Research Institute and the National Institutes of Health’s National Center for Advancing Translational Sciences (UL1TR000124).

Disclosure

The authors have nothing to disclose.

“Unnecessary noise is the most cruel abuse of care which can be inflicted on either the sick or the well.”

–Florence Nightingale¹

Motivated by the “unsustainable” rise in noise pollution and its “direct, as well as cumulative, adverse health effects,” an expert World Health Organization (WHO) task force composed the Guidelines for Community Noise, outlining specific noise recommendations for public settings, including hospitals.² In ward settings, these guidelines mandate that background noise (which is defined as unwanted sound) levels average <35 decibels (dB; ie, a typical library) during the day, average <30 dB at night, and peak no higher than 40 dB (ie, a normal conversation), a level sufficient to awaken someone from sleep.

Since the publication of these guidelines in 1999, substantial new research has added to our understanding of hospital noise levels. Recent research has demonstrated that few, if any, hospitals comply with WHO noise recommendations.³ Moreover, since 1960, hospital sound levels have risen ~4 dB per decade; based on the logarithmic decibel scale, if this trend continues, this translates to a 528% increase in loudness by 2020.³

The overwhelming majority of research on hospital noise has focused on the intensive care unit (ICU), where beeping machines and busy staff often push peak nighttime noise levels over 80 dB (ie, a kitchen blender).⁴ When evaluated during sleep, noise in the ICU causes frequent arousals and awakenings. When noise is combined with other factors, such as bright light and patient care interactions, poor sleep quality invariably results.⁴

While it has been known for years that critically ill patients experience markedly fragmented and nonrestorative sleep,⁵ poor sleep has recently gained attention due to its potential role as a modifiable risk factor for delirium and its associated consequences, including prolonged length of stay and long-lasting neuropsychological and physical impairments.⁶ Due to this interest, numerous interventions have been attempted,⁷ including multicomponent bundles to promote sleep,⁸ which have been shown to reduce delirium in the ICU.^9-12 Therefore, efforts to promote sleep in the ICU, including interventions to minimize nighttime noise, are recommended in Society of Critical Care Medicine clinical practice guidelines¹³ and are listed as a top 5 research priority by an expert panel of ICU delirium researchers.¹⁴

In contrast to the ICU, there has been little attention paid to noise in other patient care areas. Existing studies in non-ICU ward settings suggest that excessive noise is common,³ similar to the ICU, and that patients experience poor sleep, with noise being a significant disruptor of sleep.^5,15,16 Such poor sleep is thought to contribute to uncontrolled pain, labile blood pressure, and dissatisfaction with care.^16,17

In this issue of the Journal of Hospital Medicine, Jaiswal and colleagues¹⁸ report on an important study evaluating sound and light levels in both non-ICU and ICU settings within a busy tertiary-care hospital. In 8 general ward, 8 telemetry, and 8 ICU patient rooms, the investigators used meters to record sound and light levels for 24 to 72 hours. In each of these locations, they detected average hourly sound levels ranging from 45 to 54 dB, 47 to 55 dB, and 56 to 60 dB, respectively, with ICUs consistently registering the highest hourly sound levels. Notably, all locations exceeded WHO noise limits at all hours of the day. As a novel measure, the investigators evaluated sound level changes (SLCs), or the difference between peak and background sound levels, based on research suggesting that dramatic SLCs (≥17.5 dB) are more disruptive than constant loud noise.¹⁹ The authors observed that SLCs ≥17.5 dB occur predominantly during daytime hours and, interestingly, at a similar rate in the wards versus the ICU.

Importantly, the authors do not link their findings with patient sleep or other patient outcomes but instead focus on employing rigorous methods to gather continuous recordings. By measuring light levels, the authors bring attention to an issue often considered less disruptive to sleep than noise.^6,10,20 Similar to prior research,²¹ Jaiswal and colleagues demonstrate low levels of light at night, with no substantial difference between non-ICU and ICU settings. As a key finding, the authors bring attention to low levels of light during daytime hours, particularly in the morning, when levels range from 22 to 101 lux in the wards and 16 to 39 lux in the ICU. While the optimal timing and brightness of light exposure remains unknown, it is well established that ambient light is the most potent cue for circadian rhythms, with levels >100 lux necessary to suppress melatonin, the key hormone involved in circadian entrainment. Hence, the levels of morning light observed in this study were likely insufficient to maintain healthy circadian rhythms. When exposed to abnormal light levels and factors such as noise, stress, and medications, hospitalized patients are at risk for circadian rhythm misalignment, which can disrupt sleep and trigger a complex molecular cascade, leading to end-organ dysfunction including depressed immunity, glucose dysregulation, arrhythmias, and delirium.^22-24

What are the major takeaway messages from this study? First, it confirms that sound levels are not only high in the ICU but also in non-ICU wards. As hospital ratings and reimbursements now rely on favorable patient ratings, future noise-reduction efforts will surely expand more vigorously across patient care areas.²⁵ Second, SLCs and daytime recordings must be included in efforts to understand and improve sleep and circadian rhythms in hospitalized patients. Finally, this study provides a sobering reminder of the challenge of meeting WHO guidelines and facilitating an optimal healing environment for patients. Sadly, hospital sound levels continue to rise, and quiet-time interventions consistently fail to lower noise to levels anywhere near WHO limits.²⁶ Hence, to make any progress, hospitals of the future must entertain novel design modifications (eg, sound-absorbing walls and alternative room layouts), fix common sources of noise pollution (eg, ventilation systems and alarms), and critically evaluate and update interventions aimed at improving sleep and aligning circadian rhythms for hospitalized patients.²⁷

Acknowledgments

B.B.K. is currently supported by a grant through the University of California, Los Angeles Clinical Translational Research Institute and the National Institutes of Health’s National Center for Advancing Translational Sciences (UL1TR000124).

Disclosure

The authors have nothing to disclose.

Peripheral intravenous catheters (PIVCs) are the most frequently used vascular access devices (VADs) in all patient populations and practice settings. Because of its invasive nature and the fact that PIVCs are placed and medications are administered directly into the bloodstream, vascular access is risky. There are multiple factors to consider when placing a PIVC, the least of which is determining the most appropriate device for the patient based on the prescribed therapy.

VAD planning and assessment needs to occur at the first patient encounter so that the most appropriate device is selected and it aligns with the duration of the treatment, minimizes the number of unnecessary VADs placed, and preserves veins for any future needs. The level of the clinician’s expertise, coupled with challenging environments of care, add to the complexity of what most perceive to be a “simple” procedure—placing a PIVC. For these reasons, it’s imperative that clinicians are competent in the use and placement of VADs to ensure safe patient care.

Carr and colleagues¹ performed a notable scoping review to determine the existence of tools, clinical prediction rules, and algorithms (TRAs) that would support decision-making for the use of PIVCs and promote first-time insertion success (FTIS). They refined their search strategy to studies that described the use or development of any TRA regarding PIVC insertion in hospitalized adult patients.

The team identified 36 references for screening and based on their inclusion and exclusion criteria, were left with 13 studies in the final review. Inclusion criteria included TRAs for PIVC insertion in hospitalized adult patients using a traditional insertion approach, which was defined as “an assessment and/or insertion with touch and feel, therefore, without vessel locating technology such as ultrasound and/or near infrared technology.” ¹ Of note is that some of the exclusion criteria included pediatric studies, TRAs focused on postinsertion assessment, studies that examined VADs other than PIVCs, and studies in which vascular visualization techniques were used.

In general, the authors were unable to find reported evidence that the study recommendations were adopted in clinical practice or to what degree any TRA had on the success of a PIVC insertion. As a result, they were unable to determine what, if any, clinical value the TRAs had.

The review of the studies, however, identified 3 variables that had an impact on PIVC insertion success: patient, clinician, and product characteristics. Vein characteristics, such as the number, size, and location of veins, and patients’ clinical conditions, such as diabetes, sickle cell anemia, and intravenous drug abuse, were noted as predictors of PIVC insertion success. In 7 papers, the primary focus was on patients with a history of difficult intravenous access (DIVA). The definition of DIVA varied from time to insertion of the PIVC to the number of failed attempts, ranging from 1 to 3 or more attempts.

Clinician variables, such as specialty nurse certification, years of experience, and self-reporting skill level, were associated with successful insertions, and clinicians who predicted FTIS were likely to have FTIS. Product variables included PIVC gauge size and the number of vein options and the relationship with successful first attempts.

Limitations noted by the researchers were a lack of sufficient published evidence for TRAs for PIVC insertion and standardized definitions for DIVA and expert inserters. The number of variables and the dearth of standardized terms may also influence the ability to adopt any TRAs.

While the purpose of the research was to identify TRAs that could guide clinical practice for the use of PIVCs and successful insertions, the authors make an important point that dwell time was not considered. While a TRA may lead to a successful insertion, it may not transcend the intended life of the PIVC or the duration of the therapy. Therefore, TRAs should embed steps that ensure the appropriate device is selected at the start of the patient’s treatment.

The authors identified a need for undertaking and providing research in a critical area of patient care and safety. This article increases awareness of issues related to PIVCs and the impact they have on patient care. FTIS rates vary and the implications of their use are many. Patient satisfaction, no delay in treatment, vein preservation, a decreased risk of complications, and the cost of labor and products are factors to consider. Tools to improve patient outcomes related to device insertion, care, and management need to be developed and validated. The authors also note that future TRAs should integrate the use of ultrasound and vascular visualization technologies.

In a complex, challenging healthcare environment, tools and guidance that enhance practice do not only help clinicians; they have a positive impact on patient care. The need for research, so that gaps in knowledge and science can be bridged, is clear. Gaps must be identified, research conducted, and TRAs developed and adopted to enhance patient outcomes.

Disclosure

The author reports no conflicts of interest.

Peripheral intravenous catheters (PIVCs) are the most frequently used vascular access devices (VADs) in all patient populations and practice settings. Because of its invasive nature and the fact that PIVCs are placed and medications are administered directly into the bloodstream, vascular access is risky. There are multiple factors to consider when placing a PIVC, the least of which is determining the most appropriate device for the patient based on the prescribed therapy.

VAD planning and assessment needs to occur at the first patient encounter so that the most appropriate device is selected and it aligns with the duration of the treatment, minimizes the number of unnecessary VADs placed, and preserves veins for any future needs. The level of the clinician’s expertise, coupled with challenging environments of care, add to the complexity of what most perceive to be a “simple” procedure—placing a PIVC. For these reasons, it’s imperative that clinicians are competent in the use and placement of VADs to ensure safe patient care.

Carr and colleagues¹ performed a notable scoping review to determine the existence of tools, clinical prediction rules, and algorithms (TRAs) that would support decision-making for the use of PIVCs and promote first-time insertion success (FTIS). They refined their search strategy to studies that described the use or development of any TRA regarding PIVC insertion in hospitalized adult patients.

The team identified 36 references for screening and based on their inclusion and exclusion criteria, were left with 13 studies in the final review. Inclusion criteria included TRAs for PIVC insertion in hospitalized adult patients using a traditional insertion approach, which was defined as “an assessment and/or insertion with touch and feel, therefore, without vessel locating technology such as ultrasound and/or near infrared technology.” ¹ Of note is that some of the exclusion criteria included pediatric studies, TRAs focused on postinsertion assessment, studies that examined VADs other than PIVCs, and studies in which vascular visualization techniques were used.

In general, the authors were unable to find reported evidence that the study recommendations were adopted in clinical practice or to what degree any TRA had on the success of a PIVC insertion. As a result, they were unable to determine what, if any, clinical value the TRAs had.

The review of the studies, however, identified 3 variables that had an impact on PIVC insertion success: patient, clinician, and product characteristics. Vein characteristics, such as the number, size, and location of veins, and patients’ clinical conditions, such as diabetes, sickle cell anemia, and intravenous drug abuse, were noted as predictors of PIVC insertion success. In 7 papers, the primary focus was on patients with a history of difficult intravenous access (DIVA). The definition of DIVA varied from time to insertion of the PIVC to the number of failed attempts, ranging from 1 to 3 or more attempts.

Clinician variables, such as specialty nurse certification, years of experience, and self-reporting skill level, were associated with successful insertions, and clinicians who predicted FTIS were likely to have FTIS. Product variables included PIVC gauge size and the number of vein options and the relationship with successful first attempts.

Limitations noted by the researchers were a lack of sufficient published evidence for TRAs for PIVC insertion and standardized definitions for DIVA and expert inserters. The number of variables and the dearth of standardized terms may also influence the ability to adopt any TRAs.

While the purpose of the research was to identify TRAs that could guide clinical practice for the use of PIVCs and successful insertions, the authors make an important point that dwell time was not considered. While a TRA may lead to a successful insertion, it may not transcend the intended life of the PIVC or the duration of the therapy. Therefore, TRAs should embed steps that ensure the appropriate device is selected at the start of the patient’s treatment.

The authors identified a need for undertaking and providing research in a critical area of patient care and safety. This article increases awareness of issues related to PIVCs and the impact they have on patient care. FTIS rates vary and the implications of their use are many. Patient satisfaction, no delay in treatment, vein preservation, a decreased risk of complications, and the cost of labor and products are factors to consider. Tools to improve patient outcomes related to device insertion, care, and management need to be developed and validated. The authors also note that future TRAs should integrate the use of ultrasound and vascular visualization technologies.

In a complex, challenging healthcare environment, tools and guidance that enhance practice do not only help clinicians; they have a positive impact on patient care. The need for research, so that gaps in knowledge and science can be bridged, is clear. Gaps must be identified, research conducted, and TRAs developed and adopted to enhance patient outcomes.

Disclosure

The author reports no conflicts of interest.

Peripheral intravenous catheters (PIVCs) are the most frequently used vascular access devices (VADs) in all patient populations and practice settings. Because of its invasive nature and the fact that PIVCs are placed and medications are administered directly into the bloodstream, vascular access is risky. There are multiple factors to consider when placing a PIVC, the least of which is determining the most appropriate device for the patient based on the prescribed therapy.

VAD planning and assessment needs to occur at the first patient encounter so that the most appropriate device is selected and it aligns with the duration of the treatment, minimizes the number of unnecessary VADs placed, and preserves veins for any future needs. The level of the clinician’s expertise, coupled with challenging environments of care, add to the complexity of what most perceive to be a “simple” procedure—placing a PIVC. For these reasons, it’s imperative that clinicians are competent in the use and placement of VADs to ensure safe patient care.

Carr and colleagues¹ performed a notable scoping review to determine the existence of tools, clinical prediction rules, and algorithms (TRAs) that would support decision-making for the use of PIVCs and promote first-time insertion success (FTIS). They refined their search strategy to studies that described the use or development of any TRA regarding PIVC insertion in hospitalized adult patients.

The team identified 36 references for screening and based on their inclusion and exclusion criteria, were left with 13 studies in the final review. Inclusion criteria included TRAs for PIVC insertion in hospitalized adult patients using a traditional insertion approach, which was defined as “an assessment and/or insertion with touch and feel, therefore, without vessel locating technology such as ultrasound and/or near infrared technology.” ¹ Of note is that some of the exclusion criteria included pediatric studies, TRAs focused on postinsertion assessment, studies that examined VADs other than PIVCs, and studies in which vascular visualization techniques were used.

In general, the authors were unable to find reported evidence that the study recommendations were adopted in clinical practice or to what degree any TRA had on the success of a PIVC insertion. As a result, they were unable to determine what, if any, clinical value the TRAs had.

The review of the studies, however, identified 3 variables that had an impact on PIVC insertion success: patient, clinician, and product characteristics. Vein characteristics, such as the number, size, and location of veins, and patients’ clinical conditions, such as diabetes, sickle cell anemia, and intravenous drug abuse, were noted as predictors of PIVC insertion success. In 7 papers, the primary focus was on patients with a history of difficult intravenous access (DIVA). The definition of DIVA varied from time to insertion of the PIVC to the number of failed attempts, ranging from 1 to 3 or more attempts.

Clinician variables, such as specialty nurse certification, years of experience, and self-reporting skill level, were associated with successful insertions, and clinicians who predicted FTIS were likely to have FTIS. Product variables included PIVC gauge size and the number of vein options and the relationship with successful first attempts.

Limitations noted by the researchers were a lack of sufficient published evidence for TRAs for PIVC insertion and standardized definitions for DIVA and expert inserters. The number of variables and the dearth of standardized terms may also influence the ability to adopt any TRAs.

While the purpose of the research was to identify TRAs that could guide clinical practice for the use of PIVCs and successful insertions, the authors make an important point that dwell time was not considered. While a TRA may lead to a successful insertion, it may not transcend the intended life of the PIVC or the duration of the therapy. Therefore, TRAs should embed steps that ensure the appropriate device is selected at the start of the patient’s treatment.

The authors identified a need for undertaking and providing research in a critical area of patient care and safety. This article increases awareness of issues related to PIVCs and the impact they have on patient care. FTIS rates vary and the implications of their use are many. Patient satisfaction, no delay in treatment, vein preservation, a decreased risk of complications, and the cost of labor and products are factors to consider. Tools to improve patient outcomes related to device insertion, care, and management need to be developed and validated. The authors also note that future TRAs should integrate the use of ultrasound and vascular visualization technologies.

In a complex, challenging healthcare environment, tools and guidance that enhance practice do not only help clinicians; they have a positive impact on patient care. The need for research, so that gaps in knowledge and science can be bridged, is clear. Gaps must be identified, research conducted, and TRAs developed and adopted to enhance patient outcomes.

Disclosure

The author reports no conflicts of interest.

Up to a billion peripheral intravenous catheters (PIVCs) are inserted annually; therefore, the importance of this invasive device in modern medicine cannot be argued.¹ The insertion of a PIVC is a clinical procedure undertaken by a range of clinical staff and in a variety of patient populations and settings. In many clinical environments (for example, the emergency department [ED]), PIVCs are the predominant first-choice vascular access device (VAD).^2,3 Researchers in one study estimated over 25 million PIVCs are used in French EDs each year,³ and intravenous therapy is the leading ED treatment in the United States.⁴

First-time insertion success (FTIS) for PIVCs has been reported at 18% to 98% in adult populations.^5,6 The variability of FTIS likely reflects not just a variety of clinician groups and patient populations but also the absence of uniform approaches to PIVC insertion. Terms frequently used to describe or formalize a pattern of care or a clinical procedure include the following: diagnostic and prognostic tools and/or plans, frameworks, predictive assessment tools, prediction models, rules, decision-making rules, scores, scales, risk factors, risk algorithms, and algorithms.^7-12 In this paper, we use the terms tools, clinical prediction rules, and algorithms (TRAs) to review such frameworks that have been reported in the context of promoting FTIS for PIVCs.

The purpose of this systematic scoping review was to investigate what PIVC decision-making approaches exist to facilitate FTIS of PIVCs in adult hospitalized patients. Our intention was to systematically synthesize the research on TRAs, to review significant associations identified with these TRAs, and to critique TRA validity and reliability.

Scoping Review

We selected a scoping review method that, by definition, maps the evidence to identify gaps,^13,14 set research agendas, and identify implications for decision making. This allowed a targeted approach to answering our 3 research questions:

• What published clinical TRAs exist to facilitate PIVC insertion in adults?
• What clinical, patient and/or product variables have been identified using TRAs as having significant associations with FTIS for PIVCs in adult patients?
• What is the reported reliability, validity, responsiveness, clinical feasibility, and utility of existing TRAs for PIVC insertion in adults?

Our aim was to identify the amount, variety and essential qualities of TRA literature rather than to critically appraise and evaluate the effectiveness of TRAs, a process reserved for systematic review and meta-analysis of interventional studies.^13,14 We followed scoping review guidelines published by members and collaborators of the Joanna Briggs Institute, an internationally recognized leader in research synthesis, evidence use, and implementation. The guidance is based on 5 steps: (i) scoping review objective and question, (ii) background of the topic to support scoping review, (iii) study selection, (iv) charting the results, and (v) collating and summarizing results.¹⁵ Clinicometric assessment of a TRA or any clinical prediction rule requires 4 specific phases: (i) development (identification of predictors from data), (ii) validation (testing the rule in a separate population for reliability), (iii) impact analysis or responsiveness (How clinically useful is the rule in the clinical setting? Is it resource heavy or light? Is it cost effective?), and (iv) implementation and adoption (uptake into clinical practice).¹⁶

Search Strategy

We included studies that described the use or development of any TRA regarding PIVC insertion in the adult hospitalized population.

Inclusion Criteria

Studies were included if they were published in the English Language, included TRAs for PIVC insertion in adult hospital patients, and prospectively assessed a clinical category of patient for PIVC insertion using a traditional approach. We defined a traditional PIVC insertion approach as an assessment and/or insertion with touch and feel, therefore, without vessel-locating technology such as ultrasound and/or near infrared technology.

Exclusion Criteria

Exclusion criteria included pediatric studies, authors’ personal (nonresearch) experience of tools, TRAs focused on postinsertion assessment of the cannula (such as phlebitis, infiltration, and/or dressing failure), and papers with a focus on VADs other than PIVCs. We excluded studies using PIVC ultrasound and/or near infrared technology because these are not standard in all insertions and greatly change the information available for pre-insertion assessment as well as the likelihood of insertion success.

In June 2016, a systematic search of the Cochrane library, Ovid Medline® In-process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>, EBSCO CINAHL databases, and Google Scholar with specific keywords to identify publications that identified or defined TRAs was undertaken. Medical subject headings were created with assistance from a research librarian using tailored functions within individual databases. With key search terms, we limited studies to those related to our inclusion criteria. See Appendix 1 for our search strategy for Medline and CINAHL.

We used Covidence, a web-based application specifically designed for systematic reviews to screen and evaluate eligible publications.¹⁷ Two authors (PJC and NSH) screened the initial retrieved searches based upon the predetermined inclusion and exclusion criteria.

Data Extraction

A paper template was developed and used by 2 reviewers (P.J.C. and N.S.H.). Data included the following: study sample, aim(s), design, setting and country in which the study took place, clinical and patient variables, and how the TRAs were developed and tested. Studies were categorized by TRA type. We also sought to identify if clinical trial registration (where appropriate) was evidenced, in addition to evidence of protocol publication and what standardized reporting guidelines were used (such as those outlined by the EQUATOR Network).¹⁸

Data Synthesis

Formal meta-analysis was beyond the scope and intention of this review. However, we provide the FTIS rate and the ranges of odds ratios (ORs) with 95% confidence intervals (CIs) for certain independent predictors.

Thirty-six references were imported for screening against title and abstract content, with 11 studies excluded and 25 studies assessed for full-text eligibility (see Figure, PRISMA Flowchart). We then excluded a further 12 studies (6 did not meet inclusion criteria, 2 were focused on the prehospital setting, 2 were personal correspondence and focused on another type of VAD, 1 was a protocol to establish a TRA, and 1 was a framework for all device types), leaving 13 studies included in the final review (see Figure). These studies presented data on 4 tools,^19-22 4 predictive models^3,23-25 (of which 3 present receiver operating characteristic/area under the curve scores),^3,23,24 2 framed as risk factor studies,^26,27 and 1 of each of the following: a scale,²⁸ a score,²⁹ and an estimation of the incidence report rate (Table 1).³⁰ Seven studies had “difficult” or “difficulty” in their title as a term to use to describe insertion failure.^{3,19,24-27,30} One study was titled exclusively for the nursing profession,²⁰ 5 studies were reported in medical journals,^{3,24,26,29,30} and 6 were reported in nursing journals,^19-22,25,27 with the remainder published in a vascular access journal.^23,28

General Characteristics of Included Studies

One TRA which was registered as a clinical trial²⁴ involved a standardized reporting tool as is recommended by the EQUATOR Network.¹⁸

Nine of the 13 papers reported that TRA components were chosen based on identified predictors of successful insertion from observational data^{3,19,23-28,30}, with 5 papers using multivariate logistic regression to identify independent predictors.^3,23,24,26,2 At least 4330 insertion attempts on patients were reported. Seven papers reported FTIS, which ranged from 61%-90%.^3,23-27,30

Two clinical settings accounted for 10 of the 13 included studies. We identified 5 papers from the ED setting^{3,23,26,29,30} and 5 studies specific to cancer settings.^19-22,28 Two ED papers identified clinical predictors of insertion difficulty, with 1 identifying an existing medical diagnosis (such as sickle cell disease, diabetes, or intravenous drug abuse) and the other reporting a pragmatic patient self-report of difficulty.^26,30 Three studies focused on patient-exclusive variables (such as vein characteristics)^19,21,28 and some with a combined clinician and patient focus.^{3,23-25,27,30}Relatively few studies reported interobserver measurements to describe the reliability of clinical assessments made.^3,19,21,28 Webster et al. in Australia assessed interrater reliability of a vein assessment tool (VAT) and found high agreement (kappa 0.83 for medical imaging nurses and 0.93 for oncology nurses).²¹ Wells compared reliability with Altman’s K scores obtained from a different VAT when compared with the Deciding on Intravenous Access tool and found good agreement.²² Vein deterioration was proposed as a variable for inclusion when developing an assessment tool within an oncological context.³¹ In Spain, de la Torre and colleagues²⁸ demonstrated good interrater agreement (with kappa, 0.77) for the Venous International Assessment (VIA) tool. The VIA offers a grading system scale to predict the patient’s declining vessel size while undergoing chemotherapy via peripheral veins with PIVCs. Grade I suggests little or no insertion failure, whereas a Grade V should predict insertion failure.

Patient Variables

Vein characteristics were significant independent factors associated with insertion success in a number of studies.^{3,19,23,24,27,28} These included the number of veins, descriptive quality (eg, small, medium, large), size, location, visible veins, and palpable veins. Other factors appear to be patient specific (such as chronic conditions), including diabetes (OR, 2.1 [adjusted to identify demographic risk factors]; 95% CI, 1.3-3.4), sickle cell disease (OR, 3.5; 95% CI, 1.4-4.8), and intravenous drug abuse (OR, 2.4; 95% CI, 1.1-5.3).²⁶ It is unclear if a consistent relationship between weight classification and insertion outcomes exists. Despite a finding that BMI was not independently associated with insertion difficulty,²⁶ one study reports that BMI was independently associated with insertion failure (BMI <18.5 [OR, 2.24; 95% CI, 1.07-4.67], BMI >30 [OR, 1.98; 95% CI, 1.9-3.60])³ and another reports emaciated patients were associated with greater failure when compared to normal weight patients (OR, 0.07; 95% CI, 0.02-0.34).²³ Consequently, extremes of BMI appear to be associated with insertion outcomes despite 1 study reporting no significant association with BMI as an independent factor of insertion failure.²⁶ A history of difficult intravenous access (DIVA) was reported in 1 study and independently associated with insertion failure (OR, 3.86; 95% CI, 2.39-6.25; see Table 2). DIVA appears to be the motivating factor in the title of 7 studies. When defined, the definitions of DIVA are heterogeneous and varied and include the following: >1 minute to insert a PIVC and requiring >1 attempt²⁷; 2 failed attempts³⁰; 3 or more PIVC attempts.²⁶ In the remaining 4 studies, variables associated with difficulty are identified and, therefore, TRAs to target those in future with predicted difficulty prior to any attempts are proposed.^3,19,24,25

Clinician Variables

Specialist nurse certification, years of experience, and self-report skill level (P < 0.001) appear to be significantly associated with successful insertions.²⁵ This is in part validated in another study reporting greater procedural inserting PIVCs as an independent predictor of success (OR, 4.404; 95% CI, 1.61-12-06; see Table 2).²³ Two studies involved simple pragmatic percentage cut offs for PIVCs: likelihood of use²⁹ and likelihood of insertion success.²³ One paper using a cross-sectional design that surveyed ED clinicians suggested if the clinician’s predicted likelihood of the patient needing a PIVC was >80%, this was a reasonable trigger for PIVC insertion.²⁹ The other, in a self-report cohort study, reported that a clinician’s likelihood estimation of PIVC FTIS prior to insertion is independently associated with FTIS (OR, 1.06; 95% CI, 1.04-1.07).²³

Product Variables

In this review, higher failure rates were identified in smaller sizes (22-24 g).²⁶ One study revealed gauge size was significantly associated with a failed first attempt in a univariate analysis (OR, 0.44; 95% CI, 0.34-0.58), but this was not retained in a multivariate model.²⁴ Matching the PIVC size with vein assessment is considered in the VIA tool.²⁸ It suggests a large PIVC (18 g) can be considered in patients with at least 6 vein options; smaller PIVCs of 22 to 24 g are recommended when 3 or fewer veins are found.²⁸ One paper describes a greater proportion of success between PIVC brands.²⁵

The published evidence for TRAs for PIVCs is limited, with few studies using 2 or more reliability, validity, responsiveness, clinical feasibility, or utility measurements in their development. There is a clear need to assess the clinical utility and clinical feasibility of these approaches so they can be externally validated prior to clinical adoption.¹⁶ For this reason, a validated TRA is likely required but must be appropriate for the capability of the healthcare services to use it. We suggest the consistent absence of all of these phases is owing to the variety of healthcare practitioners who are responsible for the insertion, the care and surveillance of peripheral cannulae, and the fragmentation of clinical approaches that exist.³²

Previously, a comprehensive systematic review on the subject of PIVCs found that the presence of a visible and/or palpable vein is usually associated with FTIS.³³ This current review found evidence of simple scores or cutoff percentage estimates in 2 TRA reports to predict either appropriate PIVC insertion or FTIS.^23,29 If such methods are supported by future experimental trials, then such simple approaches could initiate huge clinical return, particularly given that idle or unused PIVCs are of substantial clinical concern.^34-36 PIVCs transcend a variety of clinical environments with excessive use identified in the ED, where it may be performed for blood sampling alone and, hence, are labeled as “just in case” PIVCs and contribute to the term “idle PIVC.”^23,34 Therefore, a clinical indication to perform PIVC insertion in the first instance must be embedded into any TRA; for example, clinical deterioration is likely and the risks are outweighed by benefit, intravenous fluids and/or medicines are required, and/or diagnostic or clinical procedures are requested (such as contrast scans or procedural sedation).

In the majority of papers reviewed, researchers described how to categorize patients into levels of anticipated and predicted difficulty, but none offered corresponding detailed recommendations for strategies to increase insertion success, such as insertion with ultrasound or vascular access expert. Hypothetically, adopting a TRA may assist with the early identification of difficult to cannulate patients who may require a more expert vascular access clinician. However, in this review, we identify that a uniform definition for DIVA is lacking. Both Webster et al.²¹ and Wells²² suggest that an expert inserter is required if difficult access is identified by their tools, but there is no clear description of the qualities of an expert inserter in the literature.³⁷ Recently, consensus recommendations for the definition of vascular access specialist add to discussions about defining vascular access as an interdisciplinary specialist role.³⁸ This is supported by other publications that highlight the association between PIVC procedural experience and increased insertion success.^6,23,39-41With regards to products, PIVC gauge size may or may not be significantly associated with insertion success. For identifying a relationship of PIVC gauge with vein quality, both the vein diameter and description will help with the clinical interpretation of results. For example, it may be the case that bigger veins are easier to insert a PIVC and, thus, larger PIVCs are inserted. The opposite can occur when the veins are small and poorly visualized; hence, one may select a small gauge catheter. This argument is supported by Prottengeier et al.⁴² in a prehospital study that excluded PIVC size in a multivariate analysis because of confounding. However, gauge size is very likely to influence postinsertion complications. Prospective studies are contradictory and suggest 16 to 18 g PIVCs are more likely to contribute to superficial thrombus,⁴³ phlebitis, and, thus, device failure, in contrast to others reporting more frequent dislodgement with smaller 22 g PIVCs.^6,44Finally, the studies included did not assess survival times of the inserted PIVCs, given postinsertion failure in the hospitalized patient is prevalent⁴⁵ and, importantly, modifiable.⁴⁶ A TRA may yield initial insertion success, but if postinsertion the PIVC fails because of a modifiable reason that the TRA has not acknowledged, then it may be of negligible overall benefit. Therefore, TRAs for PIVC insertion need calibration, further development, and ongoing refinement prior to external validation testing.²⁴ Future research should also examine the role of TRAs in settings where ultrasound or other insertion technology is routinely used.

This review identifies a clinically significant gap in vascular access science. The findings of this review support recent work on vessel health and preservation^47-49 and appropriate device insertion.⁵⁰ It also points to the need for further research on the development and testing of an appropriate clinical TRA to improve vascular access outcomes in clinical practice.

Acknowledgments

The authors thank Ms. Kylie Black and Mr. Simon Lewis, who are medical research librarians at The University of Western Australia.

Disclosure

 Mr. Carr has received “speakers bureau” payment form CareFusion in 2013 and Becton Dickinson (BD) in 2014 for lectures on the subject of vascular access. He received a grant from CareFusion (facilitated by his institution at the time) to attend a scientific meeting on vascular access in the USA in 2012. Griffith University has received unrestricted investigator initiated research or educational grants on Marie Cooke’s behalf from product manufacturers: Baxter; Becton, Dickinson and Company; Centurion Medical Products and Entrotech Lifesciences. Griffith University has received unrestricted investigator initiated research or educational grants on Claire M. Rickard’s behalf from product manufacturers: 3M; Adhezion Biomedical, AngioDynamics; Bard, Baxter; B.Braun; Becton, Dickinson and Company; Centurion Medical Products; Cook Medical; Entrotech, Flomedical; ICU Medical; Medtronic; Smiths Medical, Teleflex. Griffith University has received consultancy payments on Claire M. Rickard’s behalf from product manufacturers: 3M, Bard; BBraun, BD, ResQDevices, Smiths Medical. Dr. Higgins and Dr. Rippey have nothing to disclose. All of the aforementioned have not biased or influenced this review.

All authors have made substantial contributions with this review. Each author has contributed to drafting and editing the manuscript and approves the final version for publishing.

Up to a billion peripheral intravenous catheters (PIVCs) are inserted annually; therefore, the importance of this invasive device in modern medicine cannot be argued.¹ The insertion of a PIVC is a clinical procedure undertaken by a range of clinical staff and in a variety of patient populations and settings. In many clinical environments (for example, the emergency department [ED]), PIVCs are the predominant first-choice vascular access device (VAD).^2,3 Researchers in one study estimated over 25 million PIVCs are used in French EDs each year,³ and intravenous therapy is the leading ED treatment in the United States.⁴

First-time insertion success (FTIS) for PIVCs has been reported at 18% to 98% in adult populations.^5,6 The variability of FTIS likely reflects not just a variety of clinician groups and patient populations but also the absence of uniform approaches to PIVC insertion. Terms frequently used to describe or formalize a pattern of care or a clinical procedure include the following: diagnostic and prognostic tools and/or plans, frameworks, predictive assessment tools, prediction models, rules, decision-making rules, scores, scales, risk factors, risk algorithms, and algorithms.^7-12 In this paper, we use the terms tools, clinical prediction rules, and algorithms (TRAs) to review such frameworks that have been reported in the context of promoting FTIS for PIVCs.

The purpose of this systematic scoping review was to investigate what PIVC decision-making approaches exist to facilitate FTIS of PIVCs in adult hospitalized patients. Our intention was to systematically synthesize the research on TRAs, to review significant associations identified with these TRAs, and to critique TRA validity and reliability.

Scoping Review

We selected a scoping review method that, by definition, maps the evidence to identify gaps,^13,14 set research agendas, and identify implications for decision making. This allowed a targeted approach to answering our 3 research questions:

• What published clinical TRAs exist to facilitate PIVC insertion in adults?
• What clinical, patient and/or product variables have been identified using TRAs as having significant associations with FTIS for PIVCs in adult patients?
• What is the reported reliability, validity, responsiveness, clinical feasibility, and utility of existing TRAs for PIVC insertion in adults?

Our aim was to identify the amount, variety and essential qualities of TRA literature rather than to critically appraise and evaluate the effectiveness of TRAs, a process reserved for systematic review and meta-analysis of interventional studies.^13,14 We followed scoping review guidelines published by members and collaborators of the Joanna Briggs Institute, an internationally recognized leader in research synthesis, evidence use, and implementation. The guidance is based on 5 steps: (i) scoping review objective and question, (ii) background of the topic to support scoping review, (iii) study selection, (iv) charting the results, and (v) collating and summarizing results.¹⁵ Clinicometric assessment of a TRA or any clinical prediction rule requires 4 specific phases: (i) development (identification of predictors from data), (ii) validation (testing the rule in a separate population for reliability), (iii) impact analysis or responsiveness (How clinically useful is the rule in the clinical setting? Is it resource heavy or light? Is it cost effective?), and (iv) implementation and adoption (uptake into clinical practice).¹⁶

Search Strategy

We included studies that described the use or development of any TRA regarding PIVC insertion in the adult hospitalized population.

Inclusion Criteria

Studies were included if they were published in the English Language, included TRAs for PIVC insertion in adult hospital patients, and prospectively assessed a clinical category of patient for PIVC insertion using a traditional approach. We defined a traditional PIVC insertion approach as an assessment and/or insertion with touch and feel, therefore, without vessel-locating technology such as ultrasound and/or near infrared technology.

Exclusion Criteria

Exclusion criteria included pediatric studies, authors’ personal (nonresearch) experience of tools, TRAs focused on postinsertion assessment of the cannula (such as phlebitis, infiltration, and/or dressing failure), and papers with a focus on VADs other than PIVCs. We excluded studies using PIVC ultrasound and/or near infrared technology because these are not standard in all insertions and greatly change the information available for pre-insertion assessment as well as the likelihood of insertion success.

In June 2016, a systematic search of the Cochrane library, Ovid Medline® In-process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>, EBSCO CINAHL databases, and Google Scholar with specific keywords to identify publications that identified or defined TRAs was undertaken. Medical subject headings were created with assistance from a research librarian using tailored functions within individual databases. With key search terms, we limited studies to those related to our inclusion criteria. See Appendix 1 for our search strategy for Medline and CINAHL.

We used Covidence, a web-based application specifically designed for systematic reviews to screen and evaluate eligible publications.¹⁷ Two authors (PJC and NSH) screened the initial retrieved searches based upon the predetermined inclusion and exclusion criteria.

Data Extraction

A paper template was developed and used by 2 reviewers (P.J.C. and N.S.H.). Data included the following: study sample, aim(s), design, setting and country in which the study took place, clinical and patient variables, and how the TRAs were developed and tested. Studies were categorized by TRA type. We also sought to identify if clinical trial registration (where appropriate) was evidenced, in addition to evidence of protocol publication and what standardized reporting guidelines were used (such as those outlined by the EQUATOR Network).¹⁸

Data Synthesis

Formal meta-analysis was beyond the scope and intention of this review. However, we provide the FTIS rate and the ranges of odds ratios (ORs) with 95% confidence intervals (CIs) for certain independent predictors.

Thirty-six references were imported for screening against title and abstract content, with 11 studies excluded and 25 studies assessed for full-text eligibility (see Figure, PRISMA Flowchart). We then excluded a further 12 studies (6 did not meet inclusion criteria, 2 were focused on the prehospital setting, 2 were personal correspondence and focused on another type of VAD, 1 was a protocol to establish a TRA, and 1 was a framework for all device types), leaving 13 studies included in the final review (see Figure). These studies presented data on 4 tools,^19-22 4 predictive models^3,23-25 (of which 3 present receiver operating characteristic/area under the curve scores),^3,23,24 2 framed as risk factor studies,^26,27 and 1 of each of the following: a scale,²⁸ a score,²⁹ and an estimation of the incidence report rate (Table 1).³⁰ Seven studies had “difficult” or “difficulty” in their title as a term to use to describe insertion failure.^{3,19,24-27,30} One study was titled exclusively for the nursing profession,²⁰ 5 studies were reported in medical journals,^{3,24,26,29,30} and 6 were reported in nursing journals,^19-22,25,27 with the remainder published in a vascular access journal.^23,28

General Characteristics of Included Studies

One TRA which was registered as a clinical trial²⁴ involved a standardized reporting tool as is recommended by the EQUATOR Network.¹⁸

Nine of the 13 papers reported that TRA components were chosen based on identified predictors of successful insertion from observational data^{3,19,23-28,30}, with 5 papers using multivariate logistic regression to identify independent predictors.^3,23,24,26,2 At least 4330 insertion attempts on patients were reported. Seven papers reported FTIS, which ranged from 61%-90%.^3,23-27,30

Two clinical settings accounted for 10 of the 13 included studies. We identified 5 papers from the ED setting^{3,23,26,29,30} and 5 studies specific to cancer settings.^19-22,28 Two ED papers identified clinical predictors of insertion difficulty, with 1 identifying an existing medical diagnosis (such as sickle cell disease, diabetes, or intravenous drug abuse) and the other reporting a pragmatic patient self-report of difficulty.^26,30 Three studies focused on patient-exclusive variables (such as vein characteristics)^19,21,28 and some with a combined clinician and patient focus.^{3,23-25,27,30}Relatively few studies reported interobserver measurements to describe the reliability of clinical assessments made.^3,19,21,28 Webster et al. in Australia assessed interrater reliability of a vein assessment tool (VAT) and found high agreement (kappa 0.83 for medical imaging nurses and 0.93 for oncology nurses).²¹ Wells compared reliability with Altman’s K scores obtained from a different VAT when compared with the Deciding on Intravenous Access tool and found good agreement.²² Vein deterioration was proposed as a variable for inclusion when developing an assessment tool within an oncological context.³¹ In Spain, de la Torre and colleagues²⁸ demonstrated good interrater agreement (with kappa, 0.77) for the Venous International Assessment (VIA) tool. The VIA offers a grading system scale to predict the patient’s declining vessel size while undergoing chemotherapy via peripheral veins with PIVCs. Grade I suggests little or no insertion failure, whereas a Grade V should predict insertion failure.

Patient Variables

Vein characteristics were significant independent factors associated with insertion success in a number of studies.^{3,19,23,24,27,28} These included the number of veins, descriptive quality (eg, small, medium, large), size, location, visible veins, and palpable veins. Other factors appear to be patient specific (such as chronic conditions), including diabetes (OR, 2.1 [adjusted to identify demographic risk factors]; 95% CI, 1.3-3.4), sickle cell disease (OR, 3.5; 95% CI, 1.4-4.8), and intravenous drug abuse (OR, 2.4; 95% CI, 1.1-5.3).²⁶ It is unclear if a consistent relationship between weight classification and insertion outcomes exists. Despite a finding that BMI was not independently associated with insertion difficulty,²⁶ one study reports that BMI was independently associated with insertion failure (BMI <18.5 [OR, 2.24; 95% CI, 1.07-4.67], BMI >30 [OR, 1.98; 95% CI, 1.9-3.60])³ and another reports emaciated patients were associated with greater failure when compared to normal weight patients (OR, 0.07; 95% CI, 0.02-0.34).²³ Consequently, extremes of BMI appear to be associated with insertion outcomes despite 1 study reporting no significant association with BMI as an independent factor of insertion failure.²⁶ A history of difficult intravenous access (DIVA) was reported in 1 study and independently associated with insertion failure (OR, 3.86; 95% CI, 2.39-6.25; see Table 2). DIVA appears to be the motivating factor in the title of 7 studies. When defined, the definitions of DIVA are heterogeneous and varied and include the following: >1 minute to insert a PIVC and requiring >1 attempt²⁷; 2 failed attempts³⁰; 3 or more PIVC attempts.²⁶ In the remaining 4 studies, variables associated with difficulty are identified and, therefore, TRAs to target those in future with predicted difficulty prior to any attempts are proposed.^3,19,24,25

Clinician Variables

Specialist nurse certification, years of experience, and self-report skill level (P < 0.001) appear to be significantly associated with successful insertions.²⁵ This is in part validated in another study reporting greater procedural inserting PIVCs as an independent predictor of success (OR, 4.404; 95% CI, 1.61-12-06; see Table 2).²³ Two studies involved simple pragmatic percentage cut offs for PIVCs: likelihood of use²⁹ and likelihood of insertion success.²³ One paper using a cross-sectional design that surveyed ED clinicians suggested if the clinician’s predicted likelihood of the patient needing a PIVC was >80%, this was a reasonable trigger for PIVC insertion.²⁹ The other, in a self-report cohort study, reported that a clinician’s likelihood estimation of PIVC FTIS prior to insertion is independently associated with FTIS (OR, 1.06; 95% CI, 1.04-1.07).²³

Product Variables

In this review, higher failure rates were identified in smaller sizes (22-24 g).²⁶ One study revealed gauge size was significantly associated with a failed first attempt in a univariate analysis (OR, 0.44; 95% CI, 0.34-0.58), but this was not retained in a multivariate model.²⁴ Matching the PIVC size with vein assessment is considered in the VIA tool.²⁸ It suggests a large PIVC (18 g) can be considered in patients with at least 6 vein options; smaller PIVCs of 22 to 24 g are recommended when 3 or fewer veins are found.²⁸ One paper describes a greater proportion of success between PIVC brands.²⁵

The published evidence for TRAs for PIVCs is limited, with few studies using 2 or more reliability, validity, responsiveness, clinical feasibility, or utility measurements in their development. There is a clear need to assess the clinical utility and clinical feasibility of these approaches so they can be externally validated prior to clinical adoption.¹⁶ For this reason, a validated TRA is likely required but must be appropriate for the capability of the healthcare services to use it. We suggest the consistent absence of all of these phases is owing to the variety of healthcare practitioners who are responsible for the insertion, the care and surveillance of peripheral cannulae, and the fragmentation of clinical approaches that exist.³²

Previously, a comprehensive systematic review on the subject of PIVCs found that the presence of a visible and/or palpable vein is usually associated with FTIS.³³ This current review found evidence of simple scores or cutoff percentage estimates in 2 TRA reports to predict either appropriate PIVC insertion or FTIS.^23,29 If such methods are supported by future experimental trials, then such simple approaches could initiate huge clinical return, particularly given that idle or unused PIVCs are of substantial clinical concern.^34-36 PIVCs transcend a variety of clinical environments with excessive use identified in the ED, where it may be performed for blood sampling alone and, hence, are labeled as “just in case” PIVCs and contribute to the term “idle PIVC.”^23,34 Therefore, a clinical indication to perform PIVC insertion in the first instance must be embedded into any TRA; for example, clinical deterioration is likely and the risks are outweighed by benefit, intravenous fluids and/or medicines are required, and/or diagnostic or clinical procedures are requested (such as contrast scans or procedural sedation).

In the majority of papers reviewed, researchers described how to categorize patients into levels of anticipated and predicted difficulty, but none offered corresponding detailed recommendations for strategies to increase insertion success, such as insertion with ultrasound or vascular access expert. Hypothetically, adopting a TRA may assist with the early identification of difficult to cannulate patients who may require a more expert vascular access clinician. However, in this review, we identify that a uniform definition for DIVA is lacking. Both Webster et al.²¹ and Wells²² suggest that an expert inserter is required if difficult access is identified by their tools, but there is no clear description of the qualities of an expert inserter in the literature.³⁷ Recently, consensus recommendations for the definition of vascular access specialist add to discussions about defining vascular access as an interdisciplinary specialist role.³⁸ This is supported by other publications that highlight the association between PIVC procedural experience and increased insertion success.^6,23,39-41With regards to products, PIVC gauge size may or may not be significantly associated with insertion success. For identifying a relationship of PIVC gauge with vein quality, both the vein diameter and description will help with the clinical interpretation of results. For example, it may be the case that bigger veins are easier to insert a PIVC and, thus, larger PIVCs are inserted. The opposite can occur when the veins are small and poorly visualized; hence, one may select a small gauge catheter. This argument is supported by Prottengeier et al.⁴² in a prehospital study that excluded PIVC size in a multivariate analysis because of confounding. However, gauge size is very likely to influence postinsertion complications. Prospective studies are contradictory and suggest 16 to 18 g PIVCs are more likely to contribute to superficial thrombus,⁴³ phlebitis, and, thus, device failure, in contrast to others reporting more frequent dislodgement with smaller 22 g PIVCs.^6,44Finally, the studies included did not assess survival times of the inserted PIVCs, given postinsertion failure in the hospitalized patient is prevalent⁴⁵ and, importantly, modifiable.⁴⁶ A TRA may yield initial insertion success, but if postinsertion the PIVC fails because of a modifiable reason that the TRA has not acknowledged, then it may be of negligible overall benefit. Therefore, TRAs for PIVC insertion need calibration, further development, and ongoing refinement prior to external validation testing.²⁴ Future research should also examine the role of TRAs in settings where ultrasound or other insertion technology is routinely used.

This review identifies a clinically significant gap in vascular access science. The findings of this review support recent work on vessel health and preservation^47-49 and appropriate device insertion.⁵⁰ It also points to the need for further research on the development and testing of an appropriate clinical TRA to improve vascular access outcomes in clinical practice.

Acknowledgments

The authors thank Ms. Kylie Black and Mr. Simon Lewis, who are medical research librarians at The University of Western Australia.

Disclosure

 Mr. Carr has received “speakers bureau” payment form CareFusion in 2013 and Becton Dickinson (BD) in 2014 for lectures on the subject of vascular access. He received a grant from CareFusion (facilitated by his institution at the time) to attend a scientific meeting on vascular access in the USA in 2012. Griffith University has received unrestricted investigator initiated research or educational grants on Marie Cooke’s behalf from product manufacturers: Baxter; Becton, Dickinson and Company; Centurion Medical Products and Entrotech Lifesciences. Griffith University has received unrestricted investigator initiated research or educational grants on Claire M. Rickard’s behalf from product manufacturers: 3M; Adhezion Biomedical, AngioDynamics; Bard, Baxter; B.Braun; Becton, Dickinson and Company; Centurion Medical Products; Cook Medical; Entrotech, Flomedical; ICU Medical; Medtronic; Smiths Medical, Teleflex. Griffith University has received consultancy payments on Claire M. Rickard’s behalf from product manufacturers: 3M, Bard; BBraun, BD, ResQDevices, Smiths Medical. Dr. Higgins and Dr. Rippey have nothing to disclose. All of the aforementioned have not biased or influenced this review.

All authors have made substantial contributions with this review. Each author has contributed to drafting and editing the manuscript and approves the final version for publishing.

Up to a billion peripheral intravenous catheters (PIVCs) are inserted annually; therefore, the importance of this invasive device in modern medicine cannot be argued.¹ The insertion of a PIVC is a clinical procedure undertaken by a range of clinical staff and in a variety of patient populations and settings. In many clinical environments (for example, the emergency department [ED]), PIVCs are the predominant first-choice vascular access device (VAD).^2,3 Researchers in one study estimated over 25 million PIVCs are used in French EDs each year,³ and intravenous therapy is the leading ED treatment in the United States.⁴

First-time insertion success (FTIS) for PIVCs has been reported at 18% to 98% in adult populations.^5,6 The variability of FTIS likely reflects not just a variety of clinician groups and patient populations but also the absence of uniform approaches to PIVC insertion. Terms frequently used to describe or formalize a pattern of care or a clinical procedure include the following: diagnostic and prognostic tools and/or plans, frameworks, predictive assessment tools, prediction models, rules, decision-making rules, scores, scales, risk factors, risk algorithms, and algorithms.^7-12 In this paper, we use the terms tools, clinical prediction rules, and algorithms (TRAs) to review such frameworks that have been reported in the context of promoting FTIS for PIVCs.

The purpose of this systematic scoping review was to investigate what PIVC decision-making approaches exist to facilitate FTIS of PIVCs in adult hospitalized patients. Our intention was to systematically synthesize the research on TRAs, to review significant associations identified with these TRAs, and to critique TRA validity and reliability.

Scoping Review

We selected a scoping review method that, by definition, maps the evidence to identify gaps,^13,14 set research agendas, and identify implications for decision making. This allowed a targeted approach to answering our 3 research questions:

• What published clinical TRAs exist to facilitate PIVC insertion in adults?
• What clinical, patient and/or product variables have been identified using TRAs as having significant associations with FTIS for PIVCs in adult patients?
• What is the reported reliability, validity, responsiveness, clinical feasibility, and utility of existing TRAs for PIVC insertion in adults?

Our aim was to identify the amount, variety and essential qualities of TRA literature rather than to critically appraise and evaluate the effectiveness of TRAs, a process reserved for systematic review and meta-analysis of interventional studies.^13,14 We followed scoping review guidelines published by members and collaborators of the Joanna Briggs Institute, an internationally recognized leader in research synthesis, evidence use, and implementation. The guidance is based on 5 steps: (i) scoping review objective and question, (ii) background of the topic to support scoping review, (iii) study selection, (iv) charting the results, and (v) collating and summarizing results.¹⁵ Clinicometric assessment of a TRA or any clinical prediction rule requires 4 specific phases: (i) development (identification of predictors from data), (ii) validation (testing the rule in a separate population for reliability), (iii) impact analysis or responsiveness (How clinically useful is the rule in the clinical setting? Is it resource heavy or light? Is it cost effective?), and (iv) implementation and adoption (uptake into clinical practice).¹⁶

Search Strategy

We included studies that described the use or development of any TRA regarding PIVC insertion in the adult hospitalized population.

Inclusion Criteria

Studies were included if they were published in the English Language, included TRAs for PIVC insertion in adult hospital patients, and prospectively assessed a clinical category of patient for PIVC insertion using a traditional approach. We defined a traditional PIVC insertion approach as an assessment and/or insertion with touch and feel, therefore, without vessel-locating technology such as ultrasound and/or near infrared technology.

Exclusion Criteria

Exclusion criteria included pediatric studies, authors’ personal (nonresearch) experience of tools, TRAs focused on postinsertion assessment of the cannula (such as phlebitis, infiltration, and/or dressing failure), and papers with a focus on VADs other than PIVCs. We excluded studies using PIVC ultrasound and/or near infrared technology because these are not standard in all insertions and greatly change the information available for pre-insertion assessment as well as the likelihood of insertion success.

In June 2016, a systematic search of the Cochrane library, Ovid Medline® In-process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>, EBSCO CINAHL databases, and Google Scholar with specific keywords to identify publications that identified or defined TRAs was undertaken. Medical subject headings were created with assistance from a research librarian using tailored functions within individual databases. With key search terms, we limited studies to those related to our inclusion criteria. See Appendix 1 for our search strategy for Medline and CINAHL.

We used Covidence, a web-based application specifically designed for systematic reviews to screen and evaluate eligible publications.¹⁷ Two authors (PJC and NSH) screened the initial retrieved searches based upon the predetermined inclusion and exclusion criteria.

Data Extraction

A paper template was developed and used by 2 reviewers (P.J.C. and N.S.H.). Data included the following: study sample, aim(s), design, setting and country in which the study took place, clinical and patient variables, and how the TRAs were developed and tested. Studies were categorized by TRA type. We also sought to identify if clinical trial registration (where appropriate) was evidenced, in addition to evidence of protocol publication and what standardized reporting guidelines were used (such as those outlined by the EQUATOR Network).¹⁸

Data Synthesis

Formal meta-analysis was beyond the scope and intention of this review. However, we provide the FTIS rate and the ranges of odds ratios (ORs) with 95% confidence intervals (CIs) for certain independent predictors.

Thirty-six references were imported for screening against title and abstract content, with 11 studies excluded and 25 studies assessed for full-text eligibility (see Figure, PRISMA Flowchart). We then excluded a further 12 studies (6 did not meet inclusion criteria, 2 were focused on the prehospital setting, 2 were personal correspondence and focused on another type of VAD, 1 was a protocol to establish a TRA, and 1 was a framework for all device types), leaving 13 studies included in the final review (see Figure). These studies presented data on 4 tools,^19-22 4 predictive models^3,23-25 (of which 3 present receiver operating characteristic/area under the curve scores),^3,23,24 2 framed as risk factor studies,^26,27 and 1 of each of the following: a scale,²⁸ a score,²⁹ and an estimation of the incidence report rate (Table 1).³⁰ Seven studies had “difficult” or “difficulty” in their title as a term to use to describe insertion failure.^{3,19,24-27,30} One study was titled exclusively for the nursing profession,²⁰ 5 studies were reported in medical journals,^{3,24,26,29,30} and 6 were reported in nursing journals,^19-22,25,27 with the remainder published in a vascular access journal.^23,28

General Characteristics of Included Studies

One TRA which was registered as a clinical trial²⁴ involved a standardized reporting tool as is recommended by the EQUATOR Network.¹⁸

Nine of the 13 papers reported that TRA components were chosen based on identified predictors of successful insertion from observational data^{3,19,23-28,30}, with 5 papers using multivariate logistic regression to identify independent predictors.^3,23,24,26,2 At least 4330 insertion attempts on patients were reported. Seven papers reported FTIS, which ranged from 61%-90%.^3,23-27,30

Two clinical settings accounted for 10 of the 13 included studies. We identified 5 papers from the ED setting^{3,23,26,29,30} and 5 studies specific to cancer settings.^19-22,28 Two ED papers identified clinical predictors of insertion difficulty, with 1 identifying an existing medical diagnosis (such as sickle cell disease, diabetes, or intravenous drug abuse) and the other reporting a pragmatic patient self-report of difficulty.^26,30 Three studies focused on patient-exclusive variables (such as vein characteristics)^19,21,28 and some with a combined clinician and patient focus.^{3,23-25,27,30}Relatively few studies reported interobserver measurements to describe the reliability of clinical assessments made.^3,19,21,28 Webster et al. in Australia assessed interrater reliability of a vein assessment tool (VAT) and found high agreement (kappa 0.83 for medical imaging nurses and 0.93 for oncology nurses).²¹ Wells compared reliability with Altman’s K scores obtained from a different VAT when compared with the Deciding on Intravenous Access tool and found good agreement.²² Vein deterioration was proposed as a variable for inclusion when developing an assessment tool within an oncological context.³¹ In Spain, de la Torre and colleagues²⁸ demonstrated good interrater agreement (with kappa, 0.77) for the Venous International Assessment (VIA) tool. The VIA offers a grading system scale to predict the patient’s declining vessel size while undergoing chemotherapy via peripheral veins with PIVCs. Grade I suggests little or no insertion failure, whereas a Grade V should predict insertion failure.

Patient Variables

Vein characteristics were significant independent factors associated with insertion success in a number of studies.^{3,19,23,24,27,28} These included the number of veins, descriptive quality (eg, small, medium, large), size, location, visible veins, and palpable veins. Other factors appear to be patient specific (such as chronic conditions), including diabetes (OR, 2.1 [adjusted to identify demographic risk factors]; 95% CI, 1.3-3.4), sickle cell disease (OR, 3.5; 95% CI, 1.4-4.8), and intravenous drug abuse (OR, 2.4; 95% CI, 1.1-5.3).²⁶ It is unclear if a consistent relationship between weight classification and insertion outcomes exists. Despite a finding that BMI was not independently associated with insertion difficulty,²⁶ one study reports that BMI was independently associated with insertion failure (BMI <18.5 [OR, 2.24; 95% CI, 1.07-4.67], BMI >30 [OR, 1.98; 95% CI, 1.9-3.60])³ and another reports emaciated patients were associated with greater failure when compared to normal weight patients (OR, 0.07; 95% CI, 0.02-0.34).²³ Consequently, extremes of BMI appear to be associated with insertion outcomes despite 1 study reporting no significant association with BMI as an independent factor of insertion failure.²⁶ A history of difficult intravenous access (DIVA) was reported in 1 study and independently associated with insertion failure (OR, 3.86; 95% CI, 2.39-6.25; see Table 2). DIVA appears to be the motivating factor in the title of 7 studies. When defined, the definitions of DIVA are heterogeneous and varied and include the following: >1 minute to insert a PIVC and requiring >1 attempt²⁷; 2 failed attempts³⁰; 3 or more PIVC attempts.²⁶ In the remaining 4 studies, variables associated with difficulty are identified and, therefore, TRAs to target those in future with predicted difficulty prior to any attempts are proposed.^3,19,24,25

Clinician Variables

Specialist nurse certification, years of experience, and self-report skill level (P < 0.001) appear to be significantly associated with successful insertions.²⁵ This is in part validated in another study reporting greater procedural inserting PIVCs as an independent predictor of success (OR, 4.404; 95% CI, 1.61-12-06; see Table 2).²³ Two studies involved simple pragmatic percentage cut offs for PIVCs: likelihood of use²⁹ and likelihood of insertion success.²³ One paper using a cross-sectional design that surveyed ED clinicians suggested if the clinician’s predicted likelihood of the patient needing a PIVC was >80%, this was a reasonable trigger for PIVC insertion.²⁹ The other, in a self-report cohort study, reported that a clinician’s likelihood estimation of PIVC FTIS prior to insertion is independently associated with FTIS (OR, 1.06; 95% CI, 1.04-1.07).²³

Product Variables

In this review, higher failure rates were identified in smaller sizes (22-24 g).²⁶ One study revealed gauge size was significantly associated with a failed first attempt in a univariate analysis (OR, 0.44; 95% CI, 0.34-0.58), but this was not retained in a multivariate model.²⁴ Matching the PIVC size with vein assessment is considered in the VIA tool.²⁸ It suggests a large PIVC (18 g) can be considered in patients with at least 6 vein options; smaller PIVCs of 22 to 24 g are recommended when 3 or fewer veins are found.²⁸ One paper describes a greater proportion of success between PIVC brands.²⁵

The published evidence for TRAs for PIVCs is limited, with few studies using 2 or more reliability, validity, responsiveness, clinical feasibility, or utility measurements in their development. There is a clear need to assess the clinical utility and clinical feasibility of these approaches so they can be externally validated prior to clinical adoption.¹⁶ For this reason, a validated TRA is likely required but must be appropriate for the capability of the healthcare services to use it. We suggest the consistent absence of all of these phases is owing to the variety of healthcare practitioners who are responsible for the insertion, the care and surveillance of peripheral cannulae, and the fragmentation of clinical approaches that exist.³²

Previously, a comprehensive systematic review on the subject of PIVCs found that the presence of a visible and/or palpable vein is usually associated with FTIS.³³ This current review found evidence of simple scores or cutoff percentage estimates in 2 TRA reports to predict either appropriate PIVC insertion or FTIS.^23,29 If such methods are supported by future experimental trials, then such simple approaches could initiate huge clinical return, particularly given that idle or unused PIVCs are of substantial clinical concern.^34-36 PIVCs transcend a variety of clinical environments with excessive use identified in the ED, where it may be performed for blood sampling alone and, hence, are labeled as “just in case” PIVCs and contribute to the term “idle PIVC.”^23,34 Therefore, a clinical indication to perform PIVC insertion in the first instance must be embedded into any TRA; for example, clinical deterioration is likely and the risks are outweighed by benefit, intravenous fluids and/or medicines are required, and/or diagnostic or clinical procedures are requested (such as contrast scans or procedural sedation).

In the majority of papers reviewed, researchers described how to categorize patients into levels of anticipated and predicted difficulty, but none offered corresponding detailed recommendations for strategies to increase insertion success, such as insertion with ultrasound or vascular access expert. Hypothetically, adopting a TRA may assist with the early identification of difficult to cannulate patients who may require a more expert vascular access clinician. However, in this review, we identify that a uniform definition for DIVA is lacking. Both Webster et al.²¹ and Wells²² suggest that an expert inserter is required if difficult access is identified by their tools, but there is no clear description of the qualities of an expert inserter in the literature.³⁷ Recently, consensus recommendations for the definition of vascular access specialist add to discussions about defining vascular access as an interdisciplinary specialist role.³⁸ This is supported by other publications that highlight the association between PIVC procedural experience and increased insertion success.^6,23,39-41With regards to products, PIVC gauge size may or may not be significantly associated with insertion success. For identifying a relationship of PIVC gauge with vein quality, both the vein diameter and description will help with the clinical interpretation of results. For example, it may be the case that bigger veins are easier to insert a PIVC and, thus, larger PIVCs are inserted. The opposite can occur when the veins are small and poorly visualized; hence, one may select a small gauge catheter. This argument is supported by Prottengeier et al.⁴² in a prehospital study that excluded PIVC size in a multivariate analysis because of confounding. However, gauge size is very likely to influence postinsertion complications. Prospective studies are contradictory and suggest 16 to 18 g PIVCs are more likely to contribute to superficial thrombus,⁴³ phlebitis, and, thus, device failure, in contrast to others reporting more frequent dislodgement with smaller 22 g PIVCs.^6,44Finally, the studies included did not assess survival times of the inserted PIVCs, given postinsertion failure in the hospitalized patient is prevalent⁴⁵ and, importantly, modifiable.⁴⁶ A TRA may yield initial insertion success, but if postinsertion the PIVC fails because of a modifiable reason that the TRA has not acknowledged, then it may be of negligible overall benefit. Therefore, TRAs for PIVC insertion need calibration, further development, and ongoing refinement prior to external validation testing.²⁴ Future research should also examine the role of TRAs in settings where ultrasound or other insertion technology is routinely used.

This review identifies a clinically significant gap in vascular access science. The findings of this review support recent work on vessel health and preservation^47-49 and appropriate device insertion.⁵⁰ It also points to the need for further research on the development and testing of an appropriate clinical TRA to improve vascular access outcomes in clinical practice.

Acknowledgments

The authors thank Ms. Kylie Black and Mr. Simon Lewis, who are medical research librarians at The University of Western Australia.

Disclosure

 Mr. Carr has received “speakers bureau” payment form CareFusion in 2013 and Becton Dickinson (BD) in 2014 for lectures on the subject of vascular access. He received a grant from CareFusion (facilitated by his institution at the time) to attend a scientific meeting on vascular access in the USA in 2012. Griffith University has received unrestricted investigator initiated research or educational grants on Marie Cooke’s behalf from product manufacturers: Baxter; Becton, Dickinson and Company; Centurion Medical Products and Entrotech Lifesciences. Griffith University has received unrestricted investigator initiated research or educational grants on Claire M. Rickard’s behalf from product manufacturers: 3M; Adhezion Biomedical, AngioDynamics; Bard, Baxter; B.Braun; Becton, Dickinson and Company; Centurion Medical Products; Cook Medical; Entrotech, Flomedical; ICU Medical; Medtronic; Smiths Medical, Teleflex. Griffith University has received consultancy payments on Claire M. Rickard’s behalf from product manufacturers: 3M, Bard; BBraun, BD, ResQDevices, Smiths Medical. Dr. Higgins and Dr. Rippey have nothing to disclose. All of the aforementioned have not biased or influenced this review.

All authors have made substantial contributions with this review. Each author has contributed to drafting and editing the manuscript and approves the final version for publishing.

A 52-year-old woman presented with a 4-day history of progressive dyspnea, nonproductive cough, pleuritic chest pain, and subjective fevers. She described dyspnea at rest, which worsened with exertion. She reported no chills, night sweats, weight change, wheezing, hemoptysis, orthopnea, lower extremity edema, or nasal congestion. She also denied myalgia, arthralgia, or joint swelling. She reported no rash, itching, or peripheral lymphadenopathy. She had no seasonal allergies. She was treated for presumed bronchitis with azithromycin by her primary care provider 4 days prior to presentation but experienced progressive dyspnea.

The constellation of dry cough, fever, and dyspnea is often infectious in origin, with the nonproductive, dry cough more suggestive of a viral than bacterial syndrome. Atypical organisms such as Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae may also present with these symptoms. Noninfectious etiologies should also be considered, including pulmonary embolism, systemic lupus erythematosus, asbestosis, hypersensitivity pneumonitis, sarcoidosis, and lung cancer. The dyspnea at rest stands out as a worrisome feature, as it implies hypoxia; therefore, an oxygen saturation is necessary to quickly determine her peripheral oxygen saturation.

Her past medical history was notable for lung adenocarcinoma, for which she had undergone right upper lobectomy, without chemotherapy or radiation, 13 years ago without recurrence. She had no history of chronic obstructive pulmonary disease, asthma, or pneumonia, nor a family history of chronic obstructive pulmonary disease, asthma, pneumonia, or lung cancer. Her only medication was azithromycin. She drank alcohol on occasion and denied illicit drug use. Three weeks prior to admission, she began smoking 4 to 5 cigarettes per day after 13 years of abstinence. Her smoking history prior to abstinence was 1 pack per day for 20 years. She worked as a department store remodeler; she had no exposure to asbestos, mold, or water-damaged wood. She reported no recent travel, sick contacts, or exposure to animals.

A primary lung neoplasm with a pleural effusion could cause her shortness of breath and pleuritic chest pain. Her history of lung cancer at age 39 raises the possibility of recurrence. For cigarette smokers, a second lung cancer may occur many years after the first diagnosis and treatment, even if they have quit smoking. A review of her original cancer records is essential to confirm the diagnosis of pulmonary adenocarcinoma. What is now being described as pulmonary adenocarcinoma may have been a metastatic lesion arising from outside the lung. Although unlikely, a primary adenocarcinoma may remain active.

Infectious etiologies continue to merit consideration. A parapneumonic effusion from a pneumonia or an empyema are consistent with her symptoms. Systemic lupus erythematosus can cause lung disease with pleural effusions. She does exhibit dyspnea and pleurisy, which are consistent with autoimmune disease, but does not exhibit some of the more typical autoimmune symptoms such as arthralgias, joint swelling, and rash. Pneumothorax could also produce her symptoms; however, pneumothorax usually occurs spontaneously in younger patients or after trauma or a procedure. Remote right upper lobectomy would not be a cause of pneumothorax now. Her reported history makes lung disease or pneumoconiosis due to occupational exposure to mold or aspergillosis a possibility. Legionellosis, histoplasmosis, or coccidioidomycosis should be considered if she lives in or has visited a high-risk area. Pulmonary embolism remains a concern for all patients with new-onset shortness of breath. Decision support tools, such as the Wells criteria, are valuable, but the gestalt of the physician does not lag far behind in accuracy.

Cardiac disease is also in the differential. Bibasilar crackles, third heart sound gallop, and jugular vein distension would suggest heart failure. A pericardial friction rub would be highly suggestive of pericarditis. A paradoxical pulse would raise concern for pericardial tamponade. Pleurisy may be associated with a pericardial effusion, making viral pericarditis and myocarditis possibilities.

She was in moderate distress with tachypnea and increased work of breathing. Her temperature was 36.7°C, heart rate 104 beats per minute, respiratory rate 24 breaths per minute, oxygen saturation was 88% on room air, 94% on 3 liters of oxygen, and blood pressure was 147/61 mmHg. Auscultation of the lungs revealed bibasilar crackles and decreased breath sounds at the bases. She was tachycardic, with a regular rhythm and no appreciable murmurs, rubs, or gallops. There was no jugular venous distention or lower extremity edema. Her thyroid was palpable, without appreciation of nodules. Skin and musculoskeletal examinations were normal.

Unless she is immunocompromised, infection has become lower in the differential, as she is afebrile. Decreased breath sounds at the bases and bibasilar crackles may be due to pleural effusions. Congestive heart failure is a possibility, especially given her dyspnea and bibasilar crackles. Volume overload from renal failure is possible, but she does not have other signs of volume overload such as lower extremity edema or jugular venous distension. It is important to note that crackles may be due to other etiologies, including atelectasis, fibrosis, or pneumonia. Pulmonary embolism may cause hypoxia, tachycardia, and pleural effusions. Additional diseases may present similarly, including human immunodeficiency virus with Pneumocystis jirovecii, causing dyspnea, tachypnea, and tachycardia; hematologic malignancy with anemia, causing dyspnea and tachycardia; and thyrotoxic states with thyromegaly, causing dyspnea and tachycardia. Thyroid storm patients appear in distress, are tachycardic, and may have thyromegaly.

Moderate distress, increased work of breathing, tachycardia, tachypnea, and hypoxia are all worrisome signs. Her temperature is subnormal, although this may not be accurate, as oral temperatures may register lower in patients with increased respiratory rates because of increased air flow across the thermometer. Bibasilar crackles with decreased bibasilar sounds require further investigation. A complete blood count, complete metabolic profile, troponin, arterial blood gas (ABG), electrocardiogram (ECG), and chest radiograph are warranted.

Laboratory studies revealed a white blood cell count of 8600 per mm³ with 11% bands and 7.3% eosinophils, and a hemoglobin count of 15 gm/dL. Basic metabolic panel, liver function tests, coagulation panel, and urinalysis were within normal limits, including serum creatinine 0.7 mg/dL, sodium 143 mmoL/L, chloride 104 mmoL/L, bicarbonate 30 mEq/L, anion gap 9 mmoL/L, and blood urea nitrogen 12 mg/dL. Chest radiograph disclosed diffusely increased interstitial markings and a small left pleural effusion (Figure 1).

Eosinophilia may be seen in drug reactions, allergies, pulmonary emboli, pleural effusions, and occasionally in malignancy. Eosinophilic pneumonia typically has the “reverse pulmonary edema” picture, with infiltrates in the periphery and not centrally, as in congestive heart failure.

A serum bicarbonate of 30 mEq/L suggests a metabolic compensation for a chronic respiratory acidosis as renal compensation, and rise in bicarbonate generally takes 3 days. She may have been hypoxic longer than her symptoms suggest.

An ABG should be ordered to determine the degree of hypoxia and whether a higher level of care is indicated. The abnormal chest radiograph, along with her hypoxia, merits a closer look at her lung parenchyma with chest computed tomography (CT). A D-dimer would be beneficial to rule out pulmonary embolism. If the D-dimer is positive, chest CT with contrast is indicated to determine if a pulmonary embolism is present. A brain natriuretic peptide would assist in the diagnosis of congestive heart failure. A sputum culture and Gram stain and respiratory viral panel may establish a pathogen for pneumonia. An ECG and troponin to rule out myocardial infarction should be performed as well.

Eosinophilic infiltration may lead to fibrosis, as was found on the lung biopsy. She should be counseled to avoid “fine dust exposure” in the future. Follow-up lung imaging and pulmonary function tests (PFTs) should be performed once her acute illness resolves. She should be strongly urged not to smoke tobacco. Interestingly, there are reports that ex-smokers who restart smoking have an increased risk of eosinophilic pneumonia, but in this case dust exposure is the more likely etiology.

She was diagnosed with acute eosinophilic pneumonia (AEP). Antibiotics were discontinued, and oral prednisone was initiated at 40 mg daily, with a brisk response and resolution of her dyspnea. She was discharged with a 6-week prednisone taper. She had no cough, dyspnea, chest pain, or fevers at her follow-up 14 days after discharge. On a 6-week, postdischarge phone call, she continued to report no symptoms, and she maintained abstinence from cigarette smoking.

This case highlights that the very best test in any medical situation is a thorough, detailed history and physical examination. A comprehensive history with physical examination is noninvasive, safe, and cheap. Had the history of fine-dust exposure been known, it is likely that a great deal of testing and money would have been saved. The patient would have been diagnosed and treated earlier, and suffered less.

First described in 1989,^1,2 AEP is an uncommon cause of acute respiratory failure. Cases have been reported throughout the world, including in the United States, Belgium, Japan, and Iraq.^2,3 AEP is an acute febrile illness with cough, chest pain, and dyspnea for fewer than 7 days, diffuse pulmonary infiltrates on chest radiograph, hypoxemia, no history of asthma or atopic disease, no infection, and greater than 25% eosinophils on a BAL.^1,3 Physical examination typically reveals fever, tachypnea, and crackles on auscultation.¹ Peripheral blood eosinophilia is inconsistently seen at presentation but generally observed as the disease progresses.¹ Peripheral eosinophilia at presentation is positively correlated with a milder course of AEP, including higher oxygen saturation and fewer intensive care admissions.⁴ Acute respiratory failure in AEP progresses rapidly, often within hours.¹ Delayed recognition of AEP may lead to respiratory failure, requiring intubation, and even to death.¹

Reticular markings with Kerley-B lines, mixed reticular and alveolar infiltrates, and pleural effusions are usually found on chest radiography.¹ Bilateral areas of ground-glass attenuation, interlobular septal thickening, bronchovascular bundle thickening, and pleural effusions are seen on chest CT.⁵ Marked eosinophilic infiltration of the interstitium and alveolar spaces, as well as diffuse alveolar damage with hyaline membrane fibroblast proliferation and inflammatory cells, are present on lung biopsy.¹ Restriction with impaired diffusion capacity is found on PFTs. However, PFTs return to normal after recovery.¹

AEP is distinguished from other pulmonary diseases by BAL, lung biopsy, symptoms, symptom course, and/or radiographically. AEP is often misdiagnosed as severe community-acquired pneumonia and/or acute respiratory distress syndrome, as AEP tends to occur in previously healthy individuals who have diffuse infiltrates on chest radiograph, fevers, and acute, often severe, respiratory symptoms.^1-3 Other eosinophilic lung diseases to rule out include simple pulmonary eosinophilia, chronic eosinophilic pneumonia, eosinophilic granulomatosis with polyangitis (Churg-Strauss), idiopathic hypereosinophilic syndrome, infection, and drug reactions.^1,3,5 Simple eosinophilic pneumonia is characterized by no symptoms or very mild pulmonary symptoms and transient patchy infiltrates on radiography.^3,5 Patients with simple pulmonary eosinophilia do not have interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions radiographically, as seen with AEP.⁵ Chronic eosinophilic pneumonia is subacute, with respiratory symptoms of more than 3 months in duration, in contrast with the 7 days of respiratory symptoms for AEP, and is also not associated with interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions on radiography.^3,5 Unlike AEP, chronic eosinophilic pneumonia often recurs after the course of steroids has ended.³ In contrast with AEP, eosinophilic granulomatosis with polyangitis is associated with concomitant asthma and the involvement of nonpulmonary organs.³ Idiopathic hypereosinophilic syndrome is characterized by extremely high peripheral eosinophilia and by eosinophilic involvement of multiple organs, and it requires chronic steroid use.³ Patients with allergic bronchopulmonary aspergillosis (ABPA), in contrast with AEP, typically have steroid-dependent asthma and chronic respiratory symptoms.³ ABPA also differs from AEP in that radiographic infiltrates are localized and transient, and the syndrome may relapse after steroid treatment.³ Other infectious etiologies that may present similarly to AEP include invasive pulmonary aspergillosis, pulmonary coccidiodomycosis, Pneumocystis jioveri pneumonia, pulmonary toxocariasis, pulmonary filariasis, paragonimiasis, and Loeffler syndrome (pneumonia due to Strongyloides, Ascaris, or hookworms), highlighting the importance of a thorough travel and exposure history.^1,3 Several drugs may cause eosinophilic lung disease, including nitrofurantoin, tetracyclines, phenytoin, L-tryptophan, acetaminophen, ampicillin, heroin, and cocaine, which necessitates a thorough review of medication and illegal drug use.³

Steroids and supportive care are the treatment of choice for AEP, although spontaneous resolution has been seen.^1,3 Significant clinical improvement occurs within 24 to 48 hours of steroid initiation.^1,3 Optimal dose and duration of therapy have not been determined; however, methylprednisolone 125 mg intravenously every 6 hours until improvement is an often-used option.¹ Tapers vary from 2 to 12 weeks with no difference in outcome.^1-3 AEP does not recur after appropriate treatment with steroids.^1,3

Little is known about the etiology of AEP. It usually occurs in young, healthy individuals and is presumed to be an unusual, acute hypersensitivity reaction to an inhaled allergen.¹ A report of 18 US soldiers deployed in or near Iraq proposed dust exposure and cigarette or cigar smoking as a cause of AEP.² Similar to our patient’s fine-dust exposure and recent onset of cigarette smoking, the soldiers were exposed to the dusty, arid environment for at least 1 day and had been smoking for at least 1 month.² The authors proposed that small dust particles irritate alveoli, stimulating eosinophils, which are exacerbated by the onset of smoking. Alternatively, cigarette smoke may prime the lung such that dust triggers an inflammatory cascade, resulting in AEP.² Because of the potential for the rapid progression of respiratory failure, it is critical that clinicians recognize that AEP may be caused by relatively new cigarette smoking and dust in the wind.

• With the potential for the rapid progression of respiratory failure, it is imperative that the diagnosis of AEP be considered for a patient with diffuse infiltrates on a chest radiograph and acute respiratory failure of unknown cause.
• A thorough history of exposure is key to including AEP in the differential of acute pulmonary disease, with recent-onset cigarette smoking and dust exposure.
• The rapid initiation of steroids leads to a full recovery without recurrence and may be life-saving in AEP.

Disclosure 

The authors report no conflicts of interest.

A 52-year-old woman presented with a 4-day history of progressive dyspnea, nonproductive cough, pleuritic chest pain, and subjective fevers. She described dyspnea at rest, which worsened with exertion. She reported no chills, night sweats, weight change, wheezing, hemoptysis, orthopnea, lower extremity edema, or nasal congestion. She also denied myalgia, arthralgia, or joint swelling. She reported no rash, itching, or peripheral lymphadenopathy. She had no seasonal allergies. She was treated for presumed bronchitis with azithromycin by her primary care provider 4 days prior to presentation but experienced progressive dyspnea.

The constellation of dry cough, fever, and dyspnea is often infectious in origin, with the nonproductive, dry cough more suggestive of a viral than bacterial syndrome. Atypical organisms such as Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae may also present with these symptoms. Noninfectious etiologies should also be considered, including pulmonary embolism, systemic lupus erythematosus, asbestosis, hypersensitivity pneumonitis, sarcoidosis, and lung cancer. The dyspnea at rest stands out as a worrisome feature, as it implies hypoxia; therefore, an oxygen saturation is necessary to quickly determine her peripheral oxygen saturation.

Her past medical history was notable for lung adenocarcinoma, for which she had undergone right upper lobectomy, without chemotherapy or radiation, 13 years ago without recurrence. She had no history of chronic obstructive pulmonary disease, asthma, or pneumonia, nor a family history of chronic obstructive pulmonary disease, asthma, pneumonia, or lung cancer. Her only medication was azithromycin. She drank alcohol on occasion and denied illicit drug use. Three weeks prior to admission, she began smoking 4 to 5 cigarettes per day after 13 years of abstinence. Her smoking history prior to abstinence was 1 pack per day for 20 years. She worked as a department store remodeler; she had no exposure to asbestos, mold, or water-damaged wood. She reported no recent travel, sick contacts, or exposure to animals.

A primary lung neoplasm with a pleural effusion could cause her shortness of breath and pleuritic chest pain. Her history of lung cancer at age 39 raises the possibility of recurrence. For cigarette smokers, a second lung cancer may occur many years after the first diagnosis and treatment, even if they have quit smoking. A review of her original cancer records is essential to confirm the diagnosis of pulmonary adenocarcinoma. What is now being described as pulmonary adenocarcinoma may have been a metastatic lesion arising from outside the lung. Although unlikely, a primary adenocarcinoma may remain active.

Infectious etiologies continue to merit consideration. A parapneumonic effusion from a pneumonia or an empyema are consistent with her symptoms. Systemic lupus erythematosus can cause lung disease with pleural effusions. She does exhibit dyspnea and pleurisy, which are consistent with autoimmune disease, but does not exhibit some of the more typical autoimmune symptoms such as arthralgias, joint swelling, and rash. Pneumothorax could also produce her symptoms; however, pneumothorax usually occurs spontaneously in younger patients or after trauma or a procedure. Remote right upper lobectomy would not be a cause of pneumothorax now. Her reported history makes lung disease or pneumoconiosis due to occupational exposure to mold or aspergillosis a possibility. Legionellosis, histoplasmosis, or coccidioidomycosis should be considered if she lives in or has visited a high-risk area. Pulmonary embolism remains a concern for all patients with new-onset shortness of breath. Decision support tools, such as the Wells criteria, are valuable, but the gestalt of the physician does not lag far behind in accuracy.

Cardiac disease is also in the differential. Bibasilar crackles, third heart sound gallop, and jugular vein distension would suggest heart failure. A pericardial friction rub would be highly suggestive of pericarditis. A paradoxical pulse would raise concern for pericardial tamponade. Pleurisy may be associated with a pericardial effusion, making viral pericarditis and myocarditis possibilities.

She was in moderate distress with tachypnea and increased work of breathing. Her temperature was 36.7°C, heart rate 104 beats per minute, respiratory rate 24 breaths per minute, oxygen saturation was 88% on room air, 94% on 3 liters of oxygen, and blood pressure was 147/61 mmHg. Auscultation of the lungs revealed bibasilar crackles and decreased breath sounds at the bases. She was tachycardic, with a regular rhythm and no appreciable murmurs, rubs, or gallops. There was no jugular venous distention or lower extremity edema. Her thyroid was palpable, without appreciation of nodules. Skin and musculoskeletal examinations were normal.

Unless she is immunocompromised, infection has become lower in the differential, as she is afebrile. Decreased breath sounds at the bases and bibasilar crackles may be due to pleural effusions. Congestive heart failure is a possibility, especially given her dyspnea and bibasilar crackles. Volume overload from renal failure is possible, but she does not have other signs of volume overload such as lower extremity edema or jugular venous distension. It is important to note that crackles may be due to other etiologies, including atelectasis, fibrosis, or pneumonia. Pulmonary embolism may cause hypoxia, tachycardia, and pleural effusions. Additional diseases may present similarly, including human immunodeficiency virus with Pneumocystis jirovecii, causing dyspnea, tachypnea, and tachycardia; hematologic malignancy with anemia, causing dyspnea and tachycardia; and thyrotoxic states with thyromegaly, causing dyspnea and tachycardia. Thyroid storm patients appear in distress, are tachycardic, and may have thyromegaly.

Moderate distress, increased work of breathing, tachycardia, tachypnea, and hypoxia are all worrisome signs. Her temperature is subnormal, although this may not be accurate, as oral temperatures may register lower in patients with increased respiratory rates because of increased air flow across the thermometer. Bibasilar crackles with decreased bibasilar sounds require further investigation. A complete blood count, complete metabolic profile, troponin, arterial blood gas (ABG), electrocardiogram (ECG), and chest radiograph are warranted.

Laboratory studies revealed a white blood cell count of 8600 per mm³ with 11% bands and 7.3% eosinophils, and a hemoglobin count of 15 gm/dL. Basic metabolic panel, liver function tests, coagulation panel, and urinalysis were within normal limits, including serum creatinine 0.7 mg/dL, sodium 143 mmoL/L, chloride 104 mmoL/L, bicarbonate 30 mEq/L, anion gap 9 mmoL/L, and blood urea nitrogen 12 mg/dL. Chest radiograph disclosed diffusely increased interstitial markings and a small left pleural effusion (Figure 1).

Eosinophilia may be seen in drug reactions, allergies, pulmonary emboli, pleural effusions, and occasionally in malignancy. Eosinophilic pneumonia typically has the “reverse pulmonary edema” picture, with infiltrates in the periphery and not centrally, as in congestive heart failure.

A serum bicarbonate of 30 mEq/L suggests a metabolic compensation for a chronic respiratory acidosis as renal compensation, and rise in bicarbonate generally takes 3 days. She may have been hypoxic longer than her symptoms suggest.

An ABG should be ordered to determine the degree of hypoxia and whether a higher level of care is indicated. The abnormal chest radiograph, along with her hypoxia, merits a closer look at her lung parenchyma with chest computed tomography (CT). A D-dimer would be beneficial to rule out pulmonary embolism. If the D-dimer is positive, chest CT with contrast is indicated to determine if a pulmonary embolism is present. A brain natriuretic peptide would assist in the diagnosis of congestive heart failure. A sputum culture and Gram stain and respiratory viral panel may establish a pathogen for pneumonia. An ECG and troponin to rule out myocardial infarction should be performed as well.

Eosinophilic infiltration may lead to fibrosis, as was found on the lung biopsy. She should be counseled to avoid “fine dust exposure” in the future. Follow-up lung imaging and pulmonary function tests (PFTs) should be performed once her acute illness resolves. She should be strongly urged not to smoke tobacco. Interestingly, there are reports that ex-smokers who restart smoking have an increased risk of eosinophilic pneumonia, but in this case dust exposure is the more likely etiology.

She was diagnosed with acute eosinophilic pneumonia (AEP). Antibiotics were discontinued, and oral prednisone was initiated at 40 mg daily, with a brisk response and resolution of her dyspnea. She was discharged with a 6-week prednisone taper. She had no cough, dyspnea, chest pain, or fevers at her follow-up 14 days after discharge. On a 6-week, postdischarge phone call, she continued to report no symptoms, and she maintained abstinence from cigarette smoking.

This case highlights that the very best test in any medical situation is a thorough, detailed history and physical examination. A comprehensive history with physical examination is noninvasive, safe, and cheap. Had the history of fine-dust exposure been known, it is likely that a great deal of testing and money would have been saved. The patient would have been diagnosed and treated earlier, and suffered less.

First described in 1989,^1,2 AEP is an uncommon cause of acute respiratory failure. Cases have been reported throughout the world, including in the United States, Belgium, Japan, and Iraq.^2,3 AEP is an acute febrile illness with cough, chest pain, and dyspnea for fewer than 7 days, diffuse pulmonary infiltrates on chest radiograph, hypoxemia, no history of asthma or atopic disease, no infection, and greater than 25% eosinophils on a BAL.^1,3 Physical examination typically reveals fever, tachypnea, and crackles on auscultation.¹ Peripheral blood eosinophilia is inconsistently seen at presentation but generally observed as the disease progresses.¹ Peripheral eosinophilia at presentation is positively correlated with a milder course of AEP, including higher oxygen saturation and fewer intensive care admissions.⁴ Acute respiratory failure in AEP progresses rapidly, often within hours.¹ Delayed recognition of AEP may lead to respiratory failure, requiring intubation, and even to death.¹

Reticular markings with Kerley-B lines, mixed reticular and alveolar infiltrates, and pleural effusions are usually found on chest radiography.¹ Bilateral areas of ground-glass attenuation, interlobular septal thickening, bronchovascular bundle thickening, and pleural effusions are seen on chest CT.⁵ Marked eosinophilic infiltration of the interstitium and alveolar spaces, as well as diffuse alveolar damage with hyaline membrane fibroblast proliferation and inflammatory cells, are present on lung biopsy.¹ Restriction with impaired diffusion capacity is found on PFTs. However, PFTs return to normal after recovery.¹

AEP is distinguished from other pulmonary diseases by BAL, lung biopsy, symptoms, symptom course, and/or radiographically. AEP is often misdiagnosed as severe community-acquired pneumonia and/or acute respiratory distress syndrome, as AEP tends to occur in previously healthy individuals who have diffuse infiltrates on chest radiograph, fevers, and acute, often severe, respiratory symptoms.^1-3 Other eosinophilic lung diseases to rule out include simple pulmonary eosinophilia, chronic eosinophilic pneumonia, eosinophilic granulomatosis with polyangitis (Churg-Strauss), idiopathic hypereosinophilic syndrome, infection, and drug reactions.^1,3,5 Simple eosinophilic pneumonia is characterized by no symptoms or very mild pulmonary symptoms and transient patchy infiltrates on radiography.^3,5 Patients with simple pulmonary eosinophilia do not have interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions radiographically, as seen with AEP.⁵ Chronic eosinophilic pneumonia is subacute, with respiratory symptoms of more than 3 months in duration, in contrast with the 7 days of respiratory symptoms for AEP, and is also not associated with interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions on radiography.^3,5 Unlike AEP, chronic eosinophilic pneumonia often recurs after the course of steroids has ended.³ In contrast with AEP, eosinophilic granulomatosis with polyangitis is associated with concomitant asthma and the involvement of nonpulmonary organs.³ Idiopathic hypereosinophilic syndrome is characterized by extremely high peripheral eosinophilia and by eosinophilic involvement of multiple organs, and it requires chronic steroid use.³ Patients with allergic bronchopulmonary aspergillosis (ABPA), in contrast with AEP, typically have steroid-dependent asthma and chronic respiratory symptoms.³ ABPA also differs from AEP in that radiographic infiltrates are localized and transient, and the syndrome may relapse after steroid treatment.³ Other infectious etiologies that may present similarly to AEP include invasive pulmonary aspergillosis, pulmonary coccidiodomycosis, Pneumocystis jioveri pneumonia, pulmonary toxocariasis, pulmonary filariasis, paragonimiasis, and Loeffler syndrome (pneumonia due to Strongyloides, Ascaris, or hookworms), highlighting the importance of a thorough travel and exposure history.^1,3 Several drugs may cause eosinophilic lung disease, including nitrofurantoin, tetracyclines, phenytoin, L-tryptophan, acetaminophen, ampicillin, heroin, and cocaine, which necessitates a thorough review of medication and illegal drug use.³

Steroids and supportive care are the treatment of choice for AEP, although spontaneous resolution has been seen.^1,3 Significant clinical improvement occurs within 24 to 48 hours of steroid initiation.^1,3 Optimal dose and duration of therapy have not been determined; however, methylprednisolone 125 mg intravenously every 6 hours until improvement is an often-used option.¹ Tapers vary from 2 to 12 weeks with no difference in outcome.^1-3 AEP does not recur after appropriate treatment with steroids.^1,3

Little is known about the etiology of AEP. It usually occurs in young, healthy individuals and is presumed to be an unusual, acute hypersensitivity reaction to an inhaled allergen.¹ A report of 18 US soldiers deployed in or near Iraq proposed dust exposure and cigarette or cigar smoking as a cause of AEP.² Similar to our patient’s fine-dust exposure and recent onset of cigarette smoking, the soldiers were exposed to the dusty, arid environment for at least 1 day and had been smoking for at least 1 month.² The authors proposed that small dust particles irritate alveoli, stimulating eosinophils, which are exacerbated by the onset of smoking. Alternatively, cigarette smoke may prime the lung such that dust triggers an inflammatory cascade, resulting in AEP.² Because of the potential for the rapid progression of respiratory failure, it is critical that clinicians recognize that AEP may be caused by relatively new cigarette smoking and dust in the wind.

• With the potential for the rapid progression of respiratory failure, it is imperative that the diagnosis of AEP be considered for a patient with diffuse infiltrates on a chest radiograph and acute respiratory failure of unknown cause.
• A thorough history of exposure is key to including AEP in the differential of acute pulmonary disease, with recent-onset cigarette smoking and dust exposure.
• The rapid initiation of steroids leads to a full recovery without recurrence and may be life-saving in AEP.

Disclosure 

The authors report no conflicts of interest.

A 52-year-old woman presented with a 4-day history of progressive dyspnea, nonproductive cough, pleuritic chest pain, and subjective fevers. She described dyspnea at rest, which worsened with exertion. She reported no chills, night sweats, weight change, wheezing, hemoptysis, orthopnea, lower extremity edema, or nasal congestion. She also denied myalgia, arthralgia, or joint swelling. She reported no rash, itching, or peripheral lymphadenopathy. She had no seasonal allergies. She was treated for presumed bronchitis with azithromycin by her primary care provider 4 days prior to presentation but experienced progressive dyspnea.

The constellation of dry cough, fever, and dyspnea is often infectious in origin, with the nonproductive, dry cough more suggestive of a viral than bacterial syndrome. Atypical organisms such as Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae may also present with these symptoms. Noninfectious etiologies should also be considered, including pulmonary embolism, systemic lupus erythematosus, asbestosis, hypersensitivity pneumonitis, sarcoidosis, and lung cancer. The dyspnea at rest stands out as a worrisome feature, as it implies hypoxia; therefore, an oxygen saturation is necessary to quickly determine her peripheral oxygen saturation.

Her past medical history was notable for lung adenocarcinoma, for which she had undergone right upper lobectomy, without chemotherapy or radiation, 13 years ago without recurrence. She had no history of chronic obstructive pulmonary disease, asthma, or pneumonia, nor a family history of chronic obstructive pulmonary disease, asthma, pneumonia, or lung cancer. Her only medication was azithromycin. She drank alcohol on occasion and denied illicit drug use. Three weeks prior to admission, she began smoking 4 to 5 cigarettes per day after 13 years of abstinence. Her smoking history prior to abstinence was 1 pack per day for 20 years. She worked as a department store remodeler; she had no exposure to asbestos, mold, or water-damaged wood. She reported no recent travel, sick contacts, or exposure to animals.

A primary lung neoplasm with a pleural effusion could cause her shortness of breath and pleuritic chest pain. Her history of lung cancer at age 39 raises the possibility of recurrence. For cigarette smokers, a second lung cancer may occur many years after the first diagnosis and treatment, even if they have quit smoking. A review of her original cancer records is essential to confirm the diagnosis of pulmonary adenocarcinoma. What is now being described as pulmonary adenocarcinoma may have been a metastatic lesion arising from outside the lung. Although unlikely, a primary adenocarcinoma may remain active.

Infectious etiologies continue to merit consideration. A parapneumonic effusion from a pneumonia or an empyema are consistent with her symptoms. Systemic lupus erythematosus can cause lung disease with pleural effusions. She does exhibit dyspnea and pleurisy, which are consistent with autoimmune disease, but does not exhibit some of the more typical autoimmune symptoms such as arthralgias, joint swelling, and rash. Pneumothorax could also produce her symptoms; however, pneumothorax usually occurs spontaneously in younger patients or after trauma or a procedure. Remote right upper lobectomy would not be a cause of pneumothorax now. Her reported history makes lung disease or pneumoconiosis due to occupational exposure to mold or aspergillosis a possibility. Legionellosis, histoplasmosis, or coccidioidomycosis should be considered if she lives in or has visited a high-risk area. Pulmonary embolism remains a concern for all patients with new-onset shortness of breath. Decision support tools, such as the Wells criteria, are valuable, but the gestalt of the physician does not lag far behind in accuracy.

Cardiac disease is also in the differential. Bibasilar crackles, third heart sound gallop, and jugular vein distension would suggest heart failure. A pericardial friction rub would be highly suggestive of pericarditis. A paradoxical pulse would raise concern for pericardial tamponade. Pleurisy may be associated with a pericardial effusion, making viral pericarditis and myocarditis possibilities.

She was in moderate distress with tachypnea and increased work of breathing. Her temperature was 36.7°C, heart rate 104 beats per minute, respiratory rate 24 breaths per minute, oxygen saturation was 88% on room air, 94% on 3 liters of oxygen, and blood pressure was 147/61 mmHg. Auscultation of the lungs revealed bibasilar crackles and decreased breath sounds at the bases. She was tachycardic, with a regular rhythm and no appreciable murmurs, rubs, or gallops. There was no jugular venous distention or lower extremity edema. Her thyroid was palpable, without appreciation of nodules. Skin and musculoskeletal examinations were normal.

Unless she is immunocompromised, infection has become lower in the differential, as she is afebrile. Decreased breath sounds at the bases and bibasilar crackles may be due to pleural effusions. Congestive heart failure is a possibility, especially given her dyspnea and bibasilar crackles. Volume overload from renal failure is possible, but she does not have other signs of volume overload such as lower extremity edema or jugular venous distension. It is important to note that crackles may be due to other etiologies, including atelectasis, fibrosis, or pneumonia. Pulmonary embolism may cause hypoxia, tachycardia, and pleural effusions. Additional diseases may present similarly, including human immunodeficiency virus with Pneumocystis jirovecii, causing dyspnea, tachypnea, and tachycardia; hematologic malignancy with anemia, causing dyspnea and tachycardia; and thyrotoxic states with thyromegaly, causing dyspnea and tachycardia. Thyroid storm patients appear in distress, are tachycardic, and may have thyromegaly.

Moderate distress, increased work of breathing, tachycardia, tachypnea, and hypoxia are all worrisome signs. Her temperature is subnormal, although this may not be accurate, as oral temperatures may register lower in patients with increased respiratory rates because of increased air flow across the thermometer. Bibasilar crackles with decreased bibasilar sounds require further investigation. A complete blood count, complete metabolic profile, troponin, arterial blood gas (ABG), electrocardiogram (ECG), and chest radiograph are warranted.

Laboratory studies revealed a white blood cell count of 8600 per mm³ with 11% bands and 7.3% eosinophils, and a hemoglobin count of 15 gm/dL. Basic metabolic panel, liver function tests, coagulation panel, and urinalysis were within normal limits, including serum creatinine 0.7 mg/dL, sodium 143 mmoL/L, chloride 104 mmoL/L, bicarbonate 30 mEq/L, anion gap 9 mmoL/L, and blood urea nitrogen 12 mg/dL. Chest radiograph disclosed diffusely increased interstitial markings and a small left pleural effusion (Figure 1).

Eosinophilia may be seen in drug reactions, allergies, pulmonary emboli, pleural effusions, and occasionally in malignancy. Eosinophilic pneumonia typically has the “reverse pulmonary edema” picture, with infiltrates in the periphery and not centrally, as in congestive heart failure.

A serum bicarbonate of 30 mEq/L suggests a metabolic compensation for a chronic respiratory acidosis as renal compensation, and rise in bicarbonate generally takes 3 days. She may have been hypoxic longer than her symptoms suggest.

An ABG should be ordered to determine the degree of hypoxia and whether a higher level of care is indicated. The abnormal chest radiograph, along with her hypoxia, merits a closer look at her lung parenchyma with chest computed tomography (CT). A D-dimer would be beneficial to rule out pulmonary embolism. If the D-dimer is positive, chest CT with contrast is indicated to determine if a pulmonary embolism is present. A brain natriuretic peptide would assist in the diagnosis of congestive heart failure. A sputum culture and Gram stain and respiratory viral panel may establish a pathogen for pneumonia. An ECG and troponin to rule out myocardial infarction should be performed as well.

Eosinophilic infiltration may lead to fibrosis, as was found on the lung biopsy. She should be counseled to avoid “fine dust exposure” in the future. Follow-up lung imaging and pulmonary function tests (PFTs) should be performed once her acute illness resolves. She should be strongly urged not to smoke tobacco. Interestingly, there are reports that ex-smokers who restart smoking have an increased risk of eosinophilic pneumonia, but in this case dust exposure is the more likely etiology.

She was diagnosed with acute eosinophilic pneumonia (AEP). Antibiotics were discontinued, and oral prednisone was initiated at 40 mg daily, with a brisk response and resolution of her dyspnea. She was discharged with a 6-week prednisone taper. She had no cough, dyspnea, chest pain, or fevers at her follow-up 14 days after discharge. On a 6-week, postdischarge phone call, she continued to report no symptoms, and she maintained abstinence from cigarette smoking.

This case highlights that the very best test in any medical situation is a thorough, detailed history and physical examination. A comprehensive history with physical examination is noninvasive, safe, and cheap. Had the history of fine-dust exposure been known, it is likely that a great deal of testing and money would have been saved. The patient would have been diagnosed and treated earlier, and suffered less.

First described in 1989,^1,2 AEP is an uncommon cause of acute respiratory failure. Cases have been reported throughout the world, including in the United States, Belgium, Japan, and Iraq.^2,3 AEP is an acute febrile illness with cough, chest pain, and dyspnea for fewer than 7 days, diffuse pulmonary infiltrates on chest radiograph, hypoxemia, no history of asthma or atopic disease, no infection, and greater than 25% eosinophils on a BAL.^1,3 Physical examination typically reveals fever, tachypnea, and crackles on auscultation.¹ Peripheral blood eosinophilia is inconsistently seen at presentation but generally observed as the disease progresses.¹ Peripheral eosinophilia at presentation is positively correlated with a milder course of AEP, including higher oxygen saturation and fewer intensive care admissions.⁴ Acute respiratory failure in AEP progresses rapidly, often within hours.¹ Delayed recognition of AEP may lead to respiratory failure, requiring intubation, and even to death.¹

Reticular markings with Kerley-B lines, mixed reticular and alveolar infiltrates, and pleural effusions are usually found on chest radiography.¹ Bilateral areas of ground-glass attenuation, interlobular septal thickening, bronchovascular bundle thickening, and pleural effusions are seen on chest CT.⁵ Marked eosinophilic infiltration of the interstitium and alveolar spaces, as well as diffuse alveolar damage with hyaline membrane fibroblast proliferation and inflammatory cells, are present on lung biopsy.¹ Restriction with impaired diffusion capacity is found on PFTs. However, PFTs return to normal after recovery.¹

AEP is distinguished from other pulmonary diseases by BAL, lung biopsy, symptoms, symptom course, and/or radiographically. AEP is often misdiagnosed as severe community-acquired pneumonia and/or acute respiratory distress syndrome, as AEP tends to occur in previously healthy individuals who have diffuse infiltrates on chest radiograph, fevers, and acute, often severe, respiratory symptoms.^1-3 Other eosinophilic lung diseases to rule out include simple pulmonary eosinophilia, chronic eosinophilic pneumonia, eosinophilic granulomatosis with polyangitis (Churg-Strauss), idiopathic hypereosinophilic syndrome, infection, and drug reactions.^1,3,5 Simple eosinophilic pneumonia is characterized by no symptoms or very mild pulmonary symptoms and transient patchy infiltrates on radiography.^3,5 Patients with simple pulmonary eosinophilia do not have interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions radiographically, as seen with AEP.⁵ Chronic eosinophilic pneumonia is subacute, with respiratory symptoms of more than 3 months in duration, in contrast with the 7 days of respiratory symptoms for AEP, and is also not associated with interlobular septal thickening, thickening of the bronchovascular bundles, or pleural effusions on radiography.^3,5 Unlike AEP, chronic eosinophilic pneumonia often recurs after the course of steroids has ended.³ In contrast with AEP, eosinophilic granulomatosis with polyangitis is associated with concomitant asthma and the involvement of nonpulmonary organs.³ Idiopathic hypereosinophilic syndrome is characterized by extremely high peripheral eosinophilia and by eosinophilic involvement of multiple organs, and it requires chronic steroid use.³ Patients with allergic bronchopulmonary aspergillosis (ABPA), in contrast with AEP, typically have steroid-dependent asthma and chronic respiratory symptoms.³ ABPA also differs from AEP in that radiographic infiltrates are localized and transient, and the syndrome may relapse after steroid treatment.³ Other infectious etiologies that may present similarly to AEP include invasive pulmonary aspergillosis, pulmonary coccidiodomycosis, Pneumocystis jioveri pneumonia, pulmonary toxocariasis, pulmonary filariasis, paragonimiasis, and Loeffler syndrome (pneumonia due to Strongyloides, Ascaris, or hookworms), highlighting the importance of a thorough travel and exposure history.^1,3 Several drugs may cause eosinophilic lung disease, including nitrofurantoin, tetracyclines, phenytoin, L-tryptophan, acetaminophen, ampicillin, heroin, and cocaine, which necessitates a thorough review of medication and illegal drug use.³

Steroids and supportive care are the treatment of choice for AEP, although spontaneous resolution has been seen.^1,3 Significant clinical improvement occurs within 24 to 48 hours of steroid initiation.^1,3 Optimal dose and duration of therapy have not been determined; however, methylprednisolone 125 mg intravenously every 6 hours until improvement is an often-used option.¹ Tapers vary from 2 to 12 weeks with no difference in outcome.^1-3 AEP does not recur after appropriate treatment with steroids.^1,3

Little is known about the etiology of AEP. It usually occurs in young, healthy individuals and is presumed to be an unusual, acute hypersensitivity reaction to an inhaled allergen.¹ A report of 18 US soldiers deployed in or near Iraq proposed dust exposure and cigarette or cigar smoking as a cause of AEP.² Similar to our patient’s fine-dust exposure and recent onset of cigarette smoking, the soldiers were exposed to the dusty, arid environment for at least 1 day and had been smoking for at least 1 month.² The authors proposed that small dust particles irritate alveoli, stimulating eosinophils, which are exacerbated by the onset of smoking. Alternatively, cigarette smoke may prime the lung such that dust triggers an inflammatory cascade, resulting in AEP.² Because of the potential for the rapid progression of respiratory failure, it is critical that clinicians recognize that AEP may be caused by relatively new cigarette smoking and dust in the wind.

• With the potential for the rapid progression of respiratory failure, it is imperative that the diagnosis of AEP be considered for a patient with diffuse infiltrates on a chest radiograph and acute respiratory failure of unknown cause.
• A thorough history of exposure is key to including AEP in the differential of acute pulmonary disease, with recent-onset cigarette smoking and dust exposure.
• The rapid initiation of steroids leads to a full recovery without recurrence and may be life-saving in AEP.

Disclosure 

The authors report no conflicts of interest.

The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Against medical advice (AMA) discharges, which account for up to 2% of all inpatient discharges, are associated with worse health and health services outcomes and disproportionately affect vulnerable patient populations. This paper will review the background data on AMA discharges as well as the reasons physicians may choose to discharge patients AMA. From a healthcare quality perspective, the designation of a discharge as AMA is low-value care in that it is a routine hospital practice without demonstrated benefit and is not supported by a strong evidence base. We argue that designating discharges as AMA has never been shown to advance patient care and that it has the potential to harm patients by reducing access to care and promoting stigma. We believe that greater attention to both shared decision-making as well as harm reduction principles in discharge planning can serve as effective, patient-centered alternatives when patients choose not to follow a healthcare professional’s recommended advice.

A 54-year-old man with active intravenous (IV) drug use and hepatitis C was admitted with lower extremity cellulitis. On hospital day 2, the patient insisted that he wanted to go home. The treatment team informed the patient that an additional 2-3 days of IV antibiotics would produce a more reliable cure and reduce the risk of readmission. Should the team inform the patient that he will be discharged against medical advice (AMA) if he chooses to leave the hospital prematurely?

In the United States, patients are discharged AMA approximately 500,000 times per year (1%-2% of all discharges).¹ These discharges represent a wide array of clinical scenarios that all culminate in the formal recognition and documentation of a competent patient’s choice to decline further inpatient medical care and leave the hospital prior to a recommended clinical endpoint. Compared with standard discharges, AMA discharges are associated with an increased adjusted relative risk of 30-day mortality as high as 10% and 30-day readmission rates that are 20%-40% higher than readmission rates following standard discharges.² AMA discharges are more likely among patients with substance use disorders, psychiatric illness, and HIV.³

Although there are little empirical data to inform how and why physicians choose to designate a discharge as AMA when patients decline recommended care, the existing evidence suggests that fears of legal liability are strongly driving the practice.⁴ Physicians may believe that they must discharge patients AMA in order to fulfill their legal and ethical responsibilities, or to demonstrate in writing the physician’s concern and the significant risk of leaving.^5,6 Clinicians may have been acculturated during training to believe that an AMA discharge may also be seen as a way of formally distancing themselves from the patient’s request for a nonstandard or unsafe discharge plan, thus deflecting any potential blame for worse patient outcomes.

Finally, clinicians and administrators may also believe that an AMA discharge is the appropriate designation for a hospital stay that ended because the patient chose to prematurely discontinue the treatment relationship or to decline the postdischarge placement recommendations. This reasoning may explain why the hospital penalties authorized by Medicare’s Hospital Readmission Reduction Program generally exclude initial admissions ending in an AMA discharge⁷ and may provide the rationale (and perhaps a financial incentive) to discharge patients AMA in order to limit CMS readmission penalties.

The AMA discharge is a routine hospital practice without demonstrated patient benefit and which disproportionately affects vulnerable populations. There is also a growing literature that demonstrates that AMA discharges stigmatize patients, reduce their access to care, and can reduce the quality of informed consent discussions in discharge planning.^8-10 Although there are no conclusive data that AMA discharges are more likely among underrepresented racial minorities, the disproportionate burden of AMA discharges and their worse health outcomes are borne by the homeless, those with substance use disorders, and the uninsured.^3,11

Compared to patients discharged conventionally from an emergency department, 25% of patients discharged AMA reported not wanting to return for follow-up care.⁸ This reluctance to return for care is in part mediated by provider-generated stigma and blame^9,12 and may be exacerbated when patients believe that their decision to leave AMA was based upon extenuating circumstance or competing necessity (eg, limited care options for their dependents, poor quality hospital care, etc.).

To persuade patients to remain hospitalized, 85% of trainees and 67% of attending physicians in one study incorrectly informed their patients that insurance will not reimburse a hospitalization if they leave AMA.¹³ Because this study demonstrated that there is no empirical evidence that payment after AMA discharges is denied by private or government payers, physicians sharing this misinformation can breed distrust and coercively undermine patients’ ability to make a voluntary choice.

When clinicians assert they are bound by duty to discharge a patient AMA, they may be conflating a presumed legal obligation to formally designate the discharge as AMA in the medical record with their actual obligation to obtain the patient’s informed consent for the discharge. In other words, there is no identifiable medico-legal requirement to specifically designate a discharge as AMA.

Although clinicians may presume that the AMA designation provides protection from liability, the claim is not supported by the available literature.^14,15 In these studies, which reviewed relevant case law, defendants prevailed not because of the physician’s AMA designation, but because the plaintiff was not able to prove negligence. The proper execution of the discharge process, not the specific designation of AMA, is what conferred liability protection.⁵ Indeed, malpractice claims, which are associated with patient perceptions of feeling deserted or devalued,¹⁶ might be more likely with AMA discharges when they result from flawed and stigmatizing communication processes.¹⁷

Finally, there are no clinical, regulatory, or professional standards that specify the designation of an AMA discharge. Neither the Joint Commission nor any other professional organization specify under what conditions a clinician should discharge a patient AMA, thus promoting wide variability in its use and further limiting it as a valid and reliable healthcare metric.

Because all competent patients have the right to decline recommended inpatient treatment, the ethical and legal standard is that the physician obtain the patient’s informed consent to leave by communicating the risks, benefits, and alternatives to leaving and fully documenting the conversation in the medical record.² The additional steps of formalizing the discharge as AMA and providing AMA forms for the patient to sign have never been demonstrated to improve quality (and add needless clerical work). When declining any treatment, even life-sustaining treatment, the request for a patient signature to decline such treatment has not been demonstrated to improve risk communication and is not considered a best practice for informed consent.¹⁸ When the physician’s motives for this behavior are punitive or directed primarily at reducing liability, it may distract the physician from their fiduciary duty to put patients first.

The solution to improve quality is straightforward—avoid designating discharges as AMA. Instead, clinicians should maintain a single discharge process with clear, objective documentation including providing appropriate prescriptions and follow-up appointments regardless of whether the patient’s choice is consistent with a physician’s recommendation. In its place, the physician should use shared decision-making (SDM) and harm reduction principles to enhance the patient’s well-being within the identified constraints. SDM involves physicians and patients making healthcare decisions together by combining the patients’ values and preferences for care with the physicians’ expertise and knowledge of medical evidence. Harm reduction practices seek to reduce the adverse health consequences that may come from unhealthy behaviors while assuming that patients will likely continue such behaviors. Evidence-based and widely accepted examples of harm reduction strategies include nicotine replacement therapy and needle exchange programs.¹⁹

SDM in discharge planning provides a range of discharge and transitional care options that are within prevailing medical standards, not simply a single recommendation that prioritizes health promotion to the exclusion of other identified patient goals. Quality discharge planning should provide the “right care for the right patient at the right time”²⁰ that moves beyond the false choice of either remaining in the hospital under the conditions specified by the physician or leaving AMA. Although physicians are understandably concerned about patients making choices that do not prioritize their health, physicians can consider the evidence for harm reduction programs’ effectiveness in improving health outcomes²¹ and accommodate patients by providing harm-reducing discharge options that, while suboptimal, may not be substandard.²²

Physicians who wish to promote stronger patient-centered discharge practices may find that avoiding or limiting AMA discharges may conflict with their institution’s policy. In those cases, physicians should work closely with their leadership and legal counsel to ensure that any proposed practice changes are legally compliant but also improve SDM and reduce stigma for this population.

Although ending the clinical practice of designating discharges as AMA is unlikely to completely ameliorate the morbidity and costs associated with patients declining episodes of inpatient care, there is reasonable face validity to conclude that replacing the AMA practice with greater attention to harm reduction and SDM can reduce some of the preventable harms like stigmatization and reduced access to care. Together, these practices demonstrate the profession’s continued commitment to the public to practice patient-centered care.

• Treat all discharges similarly. Avoid designating an inpatient discharge as AMA.
• Ensure there is objective documentation of the patient’s informed choice to leave the hospital.
• When patients wish to leave the hospital prior to a physician-recommended clinical endpoint, engage in SDM with a focus on providing all medically reasonable treatment options that promote harm reduction.
• If you choose to designate a discharge as AMA, approach the discharge planning process consistently and with patient-centered principles by optimizing SDM and harm reduction.

The physician informed the patient of the risks, benefits, and alternatives to leaving the hospital prior to the completion of IV antibiotics and confirmed the patient’s decision-making capacity. Next, the physician elicited the patient’s preferences for care and identified competing priorities. The patient wanted treatment for his cellulitis, but he was experiencing pain and opioid withdrawal. The physician then expanded the range of potential treatment options, including evaluation for medication-assisted treatment for the patient’s opioid use disorder (OUD) and harm reduction measures such as safer injection practices, needle exchange, housing assistance, and overdose prevention and treatment education.²³ An alternative harm-reducing option included discharge with oral antibiotics and follow-up with his primary physician in 48-72 hours. After the patient indicated that he wanted to leave because he was not yet ready for OUD treatment, he was discharged with the standard discharge paperwork and antibiotics, and the physician documented the informed consent discussion.

Disclosure

The authors report no conflicts of interest, financial or otherwise. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs, the VA National Center for Ethics in Health Care or the US Government.

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason?” Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected] 

The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Against medical advice (AMA) discharges, which account for up to 2% of all inpatient discharges, are associated with worse health and health services outcomes and disproportionately affect vulnerable patient populations. This paper will review the background data on AMA discharges as well as the reasons physicians may choose to discharge patients AMA. From a healthcare quality perspective, the designation of a discharge as AMA is low-value care in that it is a routine hospital practice without demonstrated benefit and is not supported by a strong evidence base. We argue that designating discharges as AMA has never been shown to advance patient care and that it has the potential to harm patients by reducing access to care and promoting stigma. We believe that greater attention to both shared decision-making as well as harm reduction principles in discharge planning can serve as effective, patient-centered alternatives when patients choose not to follow a healthcare professional’s recommended advice.

A 54-year-old man with active intravenous (IV) drug use and hepatitis C was admitted with lower extremity cellulitis. On hospital day 2, the patient insisted that he wanted to go home. The treatment team informed the patient that an additional 2-3 days of IV antibiotics would produce a more reliable cure and reduce the risk of readmission. Should the team inform the patient that he will be discharged against medical advice (AMA) if he chooses to leave the hospital prematurely?

In the United States, patients are discharged AMA approximately 500,000 times per year (1%-2% of all discharges).¹ These discharges represent a wide array of clinical scenarios that all culminate in the formal recognition and documentation of a competent patient’s choice to decline further inpatient medical care and leave the hospital prior to a recommended clinical endpoint. Compared with standard discharges, AMA discharges are associated with an increased adjusted relative risk of 30-day mortality as high as 10% and 30-day readmission rates that are 20%-40% higher than readmission rates following standard discharges.² AMA discharges are more likely among patients with substance use disorders, psychiatric illness, and HIV.³

Although there are little empirical data to inform how and why physicians choose to designate a discharge as AMA when patients decline recommended care, the existing evidence suggests that fears of legal liability are strongly driving the practice.⁴ Physicians may believe that they must discharge patients AMA in order to fulfill their legal and ethical responsibilities, or to demonstrate in writing the physician’s concern and the significant risk of leaving.^5,6 Clinicians may have been acculturated during training to believe that an AMA discharge may also be seen as a way of formally distancing themselves from the patient’s request for a nonstandard or unsafe discharge plan, thus deflecting any potential blame for worse patient outcomes.

Finally, clinicians and administrators may also believe that an AMA discharge is the appropriate designation for a hospital stay that ended because the patient chose to prematurely discontinue the treatment relationship or to decline the postdischarge placement recommendations. This reasoning may explain why the hospital penalties authorized by Medicare’s Hospital Readmission Reduction Program generally exclude initial admissions ending in an AMA discharge⁷ and may provide the rationale (and perhaps a financial incentive) to discharge patients AMA in order to limit CMS readmission penalties.

The AMA discharge is a routine hospital practice without demonstrated patient benefit and which disproportionately affects vulnerable populations. There is also a growing literature that demonstrates that AMA discharges stigmatize patients, reduce their access to care, and can reduce the quality of informed consent discussions in discharge planning.^8-10 Although there are no conclusive data that AMA discharges are more likely among underrepresented racial minorities, the disproportionate burden of AMA discharges and their worse health outcomes are borne by the homeless, those with substance use disorders, and the uninsured.^3,11

Compared to patients discharged conventionally from an emergency department, 25% of patients discharged AMA reported not wanting to return for follow-up care.⁸ This reluctance to return for care is in part mediated by provider-generated stigma and blame^9,12 and may be exacerbated when patients believe that their decision to leave AMA was based upon extenuating circumstance or competing necessity (eg, limited care options for their dependents, poor quality hospital care, etc.).

To persuade patients to remain hospitalized, 85% of trainees and 67% of attending physicians in one study incorrectly informed their patients that insurance will not reimburse a hospitalization if they leave AMA.¹³ Because this study demonstrated that there is no empirical evidence that payment after AMA discharges is denied by private or government payers, physicians sharing this misinformation can breed distrust and coercively undermine patients’ ability to make a voluntary choice.

When clinicians assert they are bound by duty to discharge a patient AMA, they may be conflating a presumed legal obligation to formally designate the discharge as AMA in the medical record with their actual obligation to obtain the patient’s informed consent for the discharge. In other words, there is no identifiable medico-legal requirement to specifically designate a discharge as AMA.

Although clinicians may presume that the AMA designation provides protection from liability, the claim is not supported by the available literature.^14,15 In these studies, which reviewed relevant case law, defendants prevailed not because of the physician’s AMA designation, but because the plaintiff was not able to prove negligence. The proper execution of the discharge process, not the specific designation of AMA, is what conferred liability protection.⁵ Indeed, malpractice claims, which are associated with patient perceptions of feeling deserted or devalued,¹⁶ might be more likely with AMA discharges when they result from flawed and stigmatizing communication processes.¹⁷

Finally, there are no clinical, regulatory, or professional standards that specify the designation of an AMA discharge. Neither the Joint Commission nor any other professional organization specify under what conditions a clinician should discharge a patient AMA, thus promoting wide variability in its use and further limiting it as a valid and reliable healthcare metric.

Because all competent patients have the right to decline recommended inpatient treatment, the ethical and legal standard is that the physician obtain the patient’s informed consent to leave by communicating the risks, benefits, and alternatives to leaving and fully documenting the conversation in the medical record.² The additional steps of formalizing the discharge as AMA and providing AMA forms for the patient to sign have never been demonstrated to improve quality (and add needless clerical work). When declining any treatment, even life-sustaining treatment, the request for a patient signature to decline such treatment has not been demonstrated to improve risk communication and is not considered a best practice for informed consent.¹⁸ When the physician’s motives for this behavior are punitive or directed primarily at reducing liability, it may distract the physician from their fiduciary duty to put patients first.

The solution to improve quality is straightforward—avoid designating discharges as AMA. Instead, clinicians should maintain a single discharge process with clear, objective documentation including providing appropriate prescriptions and follow-up appointments regardless of whether the patient’s choice is consistent with a physician’s recommendation. In its place, the physician should use shared decision-making (SDM) and harm reduction principles to enhance the patient’s well-being within the identified constraints. SDM involves physicians and patients making healthcare decisions together by combining the patients’ values and preferences for care with the physicians’ expertise and knowledge of medical evidence. Harm reduction practices seek to reduce the adverse health consequences that may come from unhealthy behaviors while assuming that patients will likely continue such behaviors. Evidence-based and widely accepted examples of harm reduction strategies include nicotine replacement therapy and needle exchange programs.¹⁹

SDM in discharge planning provides a range of discharge and transitional care options that are within prevailing medical standards, not simply a single recommendation that prioritizes health promotion to the exclusion of other identified patient goals. Quality discharge planning should provide the “right care for the right patient at the right time”²⁰ that moves beyond the false choice of either remaining in the hospital under the conditions specified by the physician or leaving AMA. Although physicians are understandably concerned about patients making choices that do not prioritize their health, physicians can consider the evidence for harm reduction programs’ effectiveness in improving health outcomes²¹ and accommodate patients by providing harm-reducing discharge options that, while suboptimal, may not be substandard.²²

Physicians who wish to promote stronger patient-centered discharge practices may find that avoiding or limiting AMA discharges may conflict with their institution’s policy. In those cases, physicians should work closely with their leadership and legal counsel to ensure that any proposed practice changes are legally compliant but also improve SDM and reduce stigma for this population.

Although ending the clinical practice of designating discharges as AMA is unlikely to completely ameliorate the morbidity and costs associated with patients declining episodes of inpatient care, there is reasonable face validity to conclude that replacing the AMA practice with greater attention to harm reduction and SDM can reduce some of the preventable harms like stigmatization and reduced access to care. Together, these practices demonstrate the profession’s continued commitment to the public to practice patient-centered care.

• Treat all discharges similarly. Avoid designating an inpatient discharge as AMA.
• Ensure there is objective documentation of the patient’s informed choice to leave the hospital.
• When patients wish to leave the hospital prior to a physician-recommended clinical endpoint, engage in SDM with a focus on providing all medically reasonable treatment options that promote harm reduction.
• If you choose to designate a discharge as AMA, approach the discharge planning process consistently and with patient-centered principles by optimizing SDM and harm reduction.

The physician informed the patient of the risks, benefits, and alternatives to leaving the hospital prior to the completion of IV antibiotics and confirmed the patient’s decision-making capacity. Next, the physician elicited the patient’s preferences for care and identified competing priorities. The patient wanted treatment for his cellulitis, but he was experiencing pain and opioid withdrawal. The physician then expanded the range of potential treatment options, including evaluation for medication-assisted treatment for the patient’s opioid use disorder (OUD) and harm reduction measures such as safer injection practices, needle exchange, housing assistance, and overdose prevention and treatment education.²³ An alternative harm-reducing option included discharge with oral antibiotics and follow-up with his primary physician in 48-72 hours. After the patient indicated that he wanted to leave because he was not yet ready for OUD treatment, he was discharged with the standard discharge paperwork and antibiotics, and the physician documented the informed consent discussion.

Disclosure

The authors report no conflicts of interest, financial or otherwise. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs, the VA National Center for Ethics in Health Care or the US Government.

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason?” Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected] 

The “Things We Do for No Reason” (TWDFNR) series reviews practices which have become common parts of hospital care but which may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent “black and white” conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion. https://www.choosingwisely.org/

Against medical advice (AMA) discharges, which account for up to 2% of all inpatient discharges, are associated with worse health and health services outcomes and disproportionately affect vulnerable patient populations. This paper will review the background data on AMA discharges as well as the reasons physicians may choose to discharge patients AMA. From a healthcare quality perspective, the designation of a discharge as AMA is low-value care in that it is a routine hospital practice without demonstrated benefit and is not supported by a strong evidence base. We argue that designating discharges as AMA has never been shown to advance patient care and that it has the potential to harm patients by reducing access to care and promoting stigma. We believe that greater attention to both shared decision-making as well as harm reduction principles in discharge planning can serve as effective, patient-centered alternatives when patients choose not to follow a healthcare professional’s recommended advice.

A 54-year-old man with active intravenous (IV) drug use and hepatitis C was admitted with lower extremity cellulitis. On hospital day 2, the patient insisted that he wanted to go home. The treatment team informed the patient that an additional 2-3 days of IV antibiotics would produce a more reliable cure and reduce the risk of readmission. Should the team inform the patient that he will be discharged against medical advice (AMA) if he chooses to leave the hospital prematurely?

In the United States, patients are discharged AMA approximately 500,000 times per year (1%-2% of all discharges).¹ These discharges represent a wide array of clinical scenarios that all culminate in the formal recognition and documentation of a competent patient’s choice to decline further inpatient medical care and leave the hospital prior to a recommended clinical endpoint. Compared with standard discharges, AMA discharges are associated with an increased adjusted relative risk of 30-day mortality as high as 10% and 30-day readmission rates that are 20%-40% higher than readmission rates following standard discharges.² AMA discharges are more likely among patients with substance use disorders, psychiatric illness, and HIV.³

Although there are little empirical data to inform how and why physicians choose to designate a discharge as AMA when patients decline recommended care, the existing evidence suggests that fears of legal liability are strongly driving the practice.⁴ Physicians may believe that they must discharge patients AMA in order to fulfill their legal and ethical responsibilities, or to demonstrate in writing the physician’s concern and the significant risk of leaving.^5,6 Clinicians may have been acculturated during training to believe that an AMA discharge may also be seen as a way of formally distancing themselves from the patient’s request for a nonstandard or unsafe discharge plan, thus deflecting any potential blame for worse patient outcomes.

Finally, clinicians and administrators may also believe that an AMA discharge is the appropriate designation for a hospital stay that ended because the patient chose to prematurely discontinue the treatment relationship or to decline the postdischarge placement recommendations. This reasoning may explain why the hospital penalties authorized by Medicare’s Hospital Readmission Reduction Program generally exclude initial admissions ending in an AMA discharge⁷ and may provide the rationale (and perhaps a financial incentive) to discharge patients AMA in order to limit CMS readmission penalties.

The AMA discharge is a routine hospital practice without demonstrated patient benefit and which disproportionately affects vulnerable populations. There is also a growing literature that demonstrates that AMA discharges stigmatize patients, reduce their access to care, and can reduce the quality of informed consent discussions in discharge planning.^8-10 Although there are no conclusive data that AMA discharges are more likely among underrepresented racial minorities, the disproportionate burden of AMA discharges and their worse health outcomes are borne by the homeless, those with substance use disorders, and the uninsured.^3,11

Compared to patients discharged conventionally from an emergency department, 25% of patients discharged AMA reported not wanting to return for follow-up care.⁸ This reluctance to return for care is in part mediated by provider-generated stigma and blame^9,12 and may be exacerbated when patients believe that their decision to leave AMA was based upon extenuating circumstance or competing necessity (eg, limited care options for their dependents, poor quality hospital care, etc.).

To persuade patients to remain hospitalized, 85% of trainees and 67% of attending physicians in one study incorrectly informed their patients that insurance will not reimburse a hospitalization if they leave AMA.¹³ Because this study demonstrated that there is no empirical evidence that payment after AMA discharges is denied by private or government payers, physicians sharing this misinformation can breed distrust and coercively undermine patients’ ability to make a voluntary choice.

When clinicians assert they are bound by duty to discharge a patient AMA, they may be conflating a presumed legal obligation to formally designate the discharge as AMA in the medical record with their actual obligation to obtain the patient’s informed consent for the discharge. In other words, there is no identifiable medico-legal requirement to specifically designate a discharge as AMA.

Although clinicians may presume that the AMA designation provides protection from liability, the claim is not supported by the available literature.^14,15 In these studies, which reviewed relevant case law, defendants prevailed not because of the physician’s AMA designation, but because the plaintiff was not able to prove negligence. The proper execution of the discharge process, not the specific designation of AMA, is what conferred liability protection.⁵ Indeed, malpractice claims, which are associated with patient perceptions of feeling deserted or devalued,¹⁶ might be more likely with AMA discharges when they result from flawed and stigmatizing communication processes.¹⁷

Finally, there are no clinical, regulatory, or professional standards that specify the designation of an AMA discharge. Neither the Joint Commission nor any other professional organization specify under what conditions a clinician should discharge a patient AMA, thus promoting wide variability in its use and further limiting it as a valid and reliable healthcare metric.

Because all competent patients have the right to decline recommended inpatient treatment, the ethical and legal standard is that the physician obtain the patient’s informed consent to leave by communicating the risks, benefits, and alternatives to leaving and fully documenting the conversation in the medical record.² The additional steps of formalizing the discharge as AMA and providing AMA forms for the patient to sign have never been demonstrated to improve quality (and add needless clerical work). When declining any treatment, even life-sustaining treatment, the request for a patient signature to decline such treatment has not been demonstrated to improve risk communication and is not considered a best practice for informed consent.¹⁸ When the physician’s motives for this behavior are punitive or directed primarily at reducing liability, it may distract the physician from their fiduciary duty to put patients first.

The solution to improve quality is straightforward—avoid designating discharges as AMA. Instead, clinicians should maintain a single discharge process with clear, objective documentation including providing appropriate prescriptions and follow-up appointments regardless of whether the patient’s choice is consistent with a physician’s recommendation. In its place, the physician should use shared decision-making (SDM) and harm reduction principles to enhance the patient’s well-being within the identified constraints. SDM involves physicians and patients making healthcare decisions together by combining the patients’ values and preferences for care with the physicians’ expertise and knowledge of medical evidence. Harm reduction practices seek to reduce the adverse health consequences that may come from unhealthy behaviors while assuming that patients will likely continue such behaviors. Evidence-based and widely accepted examples of harm reduction strategies include nicotine replacement therapy and needle exchange programs.¹⁹

SDM in discharge planning provides a range of discharge and transitional care options that are within prevailing medical standards, not simply a single recommendation that prioritizes health promotion to the exclusion of other identified patient goals. Quality discharge planning should provide the “right care for the right patient at the right time”²⁰ that moves beyond the false choice of either remaining in the hospital under the conditions specified by the physician or leaving AMA. Although physicians are understandably concerned about patients making choices that do not prioritize their health, physicians can consider the evidence for harm reduction programs’ effectiveness in improving health outcomes²¹ and accommodate patients by providing harm-reducing discharge options that, while suboptimal, may not be substandard.²²

Physicians who wish to promote stronger patient-centered discharge practices may find that avoiding or limiting AMA discharges may conflict with their institution’s policy. In those cases, physicians should work closely with their leadership and legal counsel to ensure that any proposed practice changes are legally compliant but also improve SDM and reduce stigma for this population.

Although ending the clinical practice of designating discharges as AMA is unlikely to completely ameliorate the morbidity and costs associated with patients declining episodes of inpatient care, there is reasonable face validity to conclude that replacing the AMA practice with greater attention to harm reduction and SDM can reduce some of the preventable harms like stigmatization and reduced access to care. Together, these practices demonstrate the profession’s continued commitment to the public to practice patient-centered care.

• Treat all discharges similarly. Avoid designating an inpatient discharge as AMA.
• Ensure there is objective documentation of the patient’s informed choice to leave the hospital.
• When patients wish to leave the hospital prior to a physician-recommended clinical endpoint, engage in SDM with a focus on providing all medically reasonable treatment options that promote harm reduction.
• If you choose to designate a discharge as AMA, approach the discharge planning process consistently and with patient-centered principles by optimizing SDM and harm reduction.

The physician informed the patient of the risks, benefits, and alternatives to leaving the hospital prior to the completion of IV antibiotics and confirmed the patient’s decision-making capacity. Next, the physician elicited the patient’s preferences for care and identified competing priorities. The patient wanted treatment for his cellulitis, but he was experiencing pain and opioid withdrawal. The physician then expanded the range of potential treatment options, including evaluation for medication-assisted treatment for the patient’s opioid use disorder (OUD) and harm reduction measures such as safer injection practices, needle exchange, housing assistance, and overdose prevention and treatment education.²³ An alternative harm-reducing option included discharge with oral antibiotics and follow-up with his primary physician in 48-72 hours. After the patient indicated that he wanted to leave because he was not yet ready for OUD treatment, he was discharged with the standard discharge paperwork and antibiotics, and the physician documented the informed consent discussion.

Disclosure

The authors report no conflicts of interest, financial or otherwise. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the US Department of Veterans Affairs, the VA National Center for Ethics in Health Care or the US Government.

Do you think this is a low-value practice? Is this truly a “Thing We Do for No Reason?” Share what you do in your practice and join in the conversation online by retweeting it on Twitter (#TWDFNR) and liking it on Facebook. We invite you to propose ideas for other “Things We Do for No Reason” topics by emailing [email protected] 

Readmissions result in $41.3 billion in annual healthcare expenses.¹ As a result of the Affordable Care Act, Centers for Medicare & Medicaid Services (CMS) implemented the Hospital Readmission Reduction Program (HRRP) to reduce expenditures and improve quality associated with hospital care.^2-5 The HRRP monitors readmission rates for pneumonia, congestive heart failure (CHF), acute myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD), coronary artery bypass graft (CABG), and joint replacement. Hospitals are penalized for excess readmissions that occur following any of these index admissions. However, some readmissions within 30 days of an index admission are planned. For example, patients may have scheduled admissions for chemotherapy visits or may have prescheduled elective surgeries that happen to fall within a 30-day postdischarge window. Furthermore, even unplanned readmissions may not be a marker of suboptimal care.⁶ To prevent penalization for planned readmissions, CMS developed an algorithm to exclude planned readmissions from the HRRP.⁷

Few studies have investigated the planned readmissions in the HRRP since Horwitz and colleagues⁷ developed the algorithm with the assistance of a technical expert panel and validated it by reviewing charts in 2 healthcare systems comprising 7 hospitals. Most studies focus on unplanned readmissions.^8,9 We build on this work by studying readmissions for 131 hospitals and using administrative claims to determine whether the algorithm could be improved. Specifically, we examined planned readmissions after the conditions included in the HRRP and determine whether they occurred under elective, urgent, or emergent circumstances. The goal is to assess whether the algorithm may misclassify some readmissions as planned even though the readmission is unanticipated. We hypothesize that some readmissions considered planned by the HRRP will occur under emergent circumstances. Our findings will provide more nuanced insights regarding planned readmissions and potentially provide a mechanism to identify potentially misclassified readmissions without administrative burden.

We analyzed Medicare claims from 2011 to 2015 for beneficiaries in Michigan who had index admissions for pneumonia, CHF, AMI, COPD, CABG, and joint replacement. Exclusion criteria were as follows: patients who were not continuously enrolled in Medicare Part A and B, had health maintenance organization coverage, were transferred to another hospital during the index admission, or received Medicare because of end-stage renal disease or disability. Patients with hip fractures were excluded because the HRRP readmission algorithm only includes elective, unilateral, total hip arthroplasties. Transfer patients were excluded because these patients are excluded from the HRRP readmission algorithm. We also excluded patients who died within 90 days of their index admission because these patients are often outliers in regards to healthcare utilization. The institutional review board at our health system deemed this study exempt from review.

For each hospital and each condition, we calculated 30-day readmission rates by identifying inpatient claims that occurred following discharge from the index admission. For patients who had multiple readmissions, we only considered the first readmission, as this follows the HRRP method. All readmissions were credited to the hospital where the index admission occurred.

To calculate 30-day planned readmission rates, we examined all readmissions and identified those deemed planned by version 3.0 of the CMS readmissions algorithm.¹⁰ We characterized these planned readmissions by examining the admission type variable and the presence or absence of emergency department (ED) charges. Planned readmissions that had an admission type of “emergent” or “urgent” and/or ED charges may have been unplanned. Because we cannot unequivocally determine whether or not the readmissions were misclassified, we refer to these readmissions as “potentially misclassified” in this manuscript. We also calculated the potential misclassification rate by hospital type.

For 131 Michigan hospitals, we identified 143,054 index admissions, 16,116 (11.3%) 30-day readmissions, and 1252 (7.8%) planned readmissions (Table 1).

Of the unplanned readmissions, 97.0% had either an admission type that was “urgent” or “emergent” and/or ED charges, 96.2% were associated with an “emergent” or “urgent” admission type, and 84.3% had emergency room charges on the claim line.

In this study, we found that planned readmissions are generally infrequent. However, the majority are coded with an emergent or urgent admission type and many have ED charges reported on the claim. These findings suggest that the CMS readmission algorithm examined in this study may potentially misclassify many planned readmissions and that CMS should explore the use of admission type and presence of ED charges in the unplanned/planned readmission algorithm.

Our primary finding that planned readmissions are infrequent is supported by several observations.^7-9,11 In the initial article describing the CMS algorithm,⁷ 7.8% of readmissions were considered planned; upon review of the discharge medical records from the index admissions, 41.3% of these planned readmissions were found to be unplanned. These findings closely correlate with our own findings that 7.8% of readmissions were considered planned by the CMS criteria, and 57.8% of planned readmissions were urgent or emergent. From a clinical perspective, there are few circumstances where a patient undergoing an elective procedure will transit electively through the ED.

The CMS algorithm was intentionally designed to have a high specificity for unplanned readmissions to ensure that truly planned readmissions would not be characterized as unplanned.⁷ There is a potential tradeoff to increasing the sensitivity for unplanned readmissions, in that more planned readmissions might be inadvertently characterized as unplanned. Additional validation work (ie, medical chart review) will be required to explore potentially misclassified planned readmissions in greater detail.

Our study has several limitations. First, we rely solely on information in administrative claims to determine whether an admission is planned. The full clinical story is obviously limited by this method. However, the CMS readmission algorithm is only based on information from administrative claims,⁷ and our goal was to explore a method of improving the algorithm that could be applied by CMS in a pragmatic manner. Second, the validity of the admission type variable for the purpose of identifying “emergent” and “urgent” admissions is not entirely clear. However, based on personal communication with the Research Data Assistance Center, the variable is known to be reliable, although no specific validity testing has been performed. Third, it is possible that some truly planned readmissions began in the ED. This situation may arise at small hospitals. However, we found that most of the planned readmissions that started in the ED had secondary diagnosis codes associated with acute conditions. In addition, we did not find a disproportionate number of potentially misclassified planned readmissions at small hospitals. Fourth, the association between high readmission rates and poor quality of care has been called into question recently. However, the purpose of this study is not to assess the quality of healthcare provided by these hospitals; our intent is to explore opportunities to improve the HRRP planned readmission algorithm. Fifth, our analysis only included the state of Michigan. However, Michigan is 1 of the 10 largest states by population, and we do not expect significant differences between our data and the rest of the country. Sixth, we conducted this analysis with version 3.0 of the CMS readmission algorithm. The latest version (4.0) has made several substantial changes to reduce the number of potentially misclassified planned readmissions. However, neither admission type nor presence of ED charges are considered in the updated version. Therefore, our study provides another potential target for further improvement.

These limitations notwithstanding, these findings have important implications for key stakeholders. Relevant to policymakers, the finding that a large percentage of the planned readmissions had ED charges and/or emergent/urgent admission claim type suggests that CMS should explore the use of these variables in their readmission algorithm. Relevant to hospitals and physicians, the potential misclassification of some planned readmissions suggests that close evaluation of the sources and causes of readmission is imperative during the local development of readmission reduction initiatives.

Collectively, these findings suggest that although planned readmissions are infrequent, many of these planned readmissions may actually be nonelective or unplanned in nature. Furthermore, our findings suggest that the CMS readmission algorithm might improve its accuracy by considering the admission type and the presence of ED charges. Future research in this area should focus on validating the use of ED charges and admission type to identify unplanned readmissions through medical chart review. The aim of the HRRP is to identify signals of poor quality in a fair and equitable manner. Misclassification of readmissions will limit CMS’ ability to achieve this important goal.

Disclosure

None of the authors have any conflicts of interest to disclose.

Readmissions result in $41.3 billion in annual healthcare expenses.¹ As a result of the Affordable Care Act, Centers for Medicare & Medicaid Services (CMS) implemented the Hospital Readmission Reduction Program (HRRP) to reduce expenditures and improve quality associated with hospital care.^2-5 The HRRP monitors readmission rates for pneumonia, congestive heart failure (CHF), acute myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD), coronary artery bypass graft (CABG), and joint replacement. Hospitals are penalized for excess readmissions that occur following any of these index admissions. However, some readmissions within 30 days of an index admission are planned. For example, patients may have scheduled admissions for chemotherapy visits or may have prescheduled elective surgeries that happen to fall within a 30-day postdischarge window. Furthermore, even unplanned readmissions may not be a marker of suboptimal care.⁶ To prevent penalization for planned readmissions, CMS developed an algorithm to exclude planned readmissions from the HRRP.⁷

Few studies have investigated the planned readmissions in the HRRP since Horwitz and colleagues⁷ developed the algorithm with the assistance of a technical expert panel and validated it by reviewing charts in 2 healthcare systems comprising 7 hospitals. Most studies focus on unplanned readmissions.^8,9 We build on this work by studying readmissions for 131 hospitals and using administrative claims to determine whether the algorithm could be improved. Specifically, we examined planned readmissions after the conditions included in the HRRP and determine whether they occurred under elective, urgent, or emergent circumstances. The goal is to assess whether the algorithm may misclassify some readmissions as planned even though the readmission is unanticipated. We hypothesize that some readmissions considered planned by the HRRP will occur under emergent circumstances. Our findings will provide more nuanced insights regarding planned readmissions and potentially provide a mechanism to identify potentially misclassified readmissions without administrative burden.

We analyzed Medicare claims from 2011 to 2015 for beneficiaries in Michigan who had index admissions for pneumonia, CHF, AMI, COPD, CABG, and joint replacement. Exclusion criteria were as follows: patients who were not continuously enrolled in Medicare Part A and B, had health maintenance organization coverage, were transferred to another hospital during the index admission, or received Medicare because of end-stage renal disease or disability. Patients with hip fractures were excluded because the HRRP readmission algorithm only includes elective, unilateral, total hip arthroplasties. Transfer patients were excluded because these patients are excluded from the HRRP readmission algorithm. We also excluded patients who died within 90 days of their index admission because these patients are often outliers in regards to healthcare utilization. The institutional review board at our health system deemed this study exempt from review.

For each hospital and each condition, we calculated 30-day readmission rates by identifying inpatient claims that occurred following discharge from the index admission. For patients who had multiple readmissions, we only considered the first readmission, as this follows the HRRP method. All readmissions were credited to the hospital where the index admission occurred.

To calculate 30-day planned readmission rates, we examined all readmissions and identified those deemed planned by version 3.0 of the CMS readmissions algorithm.¹⁰ We characterized these planned readmissions by examining the admission type variable and the presence or absence of emergency department (ED) charges. Planned readmissions that had an admission type of “emergent” or “urgent” and/or ED charges may have been unplanned. Because we cannot unequivocally determine whether or not the readmissions were misclassified, we refer to these readmissions as “potentially misclassified” in this manuscript. We also calculated the potential misclassification rate by hospital type.

For 131 Michigan hospitals, we identified 143,054 index admissions, 16,116 (11.3%) 30-day readmissions, and 1252 (7.8%) planned readmissions (Table 1).

Of the unplanned readmissions, 97.0% had either an admission type that was “urgent” or “emergent” and/or ED charges, 96.2% were associated with an “emergent” or “urgent” admission type, and 84.3% had emergency room charges on the claim line.

In this study, we found that planned readmissions are generally infrequent. However, the majority are coded with an emergent or urgent admission type and many have ED charges reported on the claim. These findings suggest that the CMS readmission algorithm examined in this study may potentially misclassify many planned readmissions and that CMS should explore the use of admission type and presence of ED charges in the unplanned/planned readmission algorithm.

Our primary finding that planned readmissions are infrequent is supported by several observations.^7-9,11 In the initial article describing the CMS algorithm,⁷ 7.8% of readmissions were considered planned; upon review of the discharge medical records from the index admissions, 41.3% of these planned readmissions were found to be unplanned. These findings closely correlate with our own findings that 7.8% of readmissions were considered planned by the CMS criteria, and 57.8% of planned readmissions were urgent or emergent. From a clinical perspective, there are few circumstances where a patient undergoing an elective procedure will transit electively through the ED.

The CMS algorithm was intentionally designed to have a high specificity for unplanned readmissions to ensure that truly planned readmissions would not be characterized as unplanned.⁷ There is a potential tradeoff to increasing the sensitivity for unplanned readmissions, in that more planned readmissions might be inadvertently characterized as unplanned. Additional validation work (ie, medical chart review) will be required to explore potentially misclassified planned readmissions in greater detail.

Our study has several limitations. First, we rely solely on information in administrative claims to determine whether an admission is planned. The full clinical story is obviously limited by this method. However, the CMS readmission algorithm is only based on information from administrative claims,⁷ and our goal was to explore a method of improving the algorithm that could be applied by CMS in a pragmatic manner. Second, the validity of the admission type variable for the purpose of identifying “emergent” and “urgent” admissions is not entirely clear. However, based on personal communication with the Research Data Assistance Center, the variable is known to be reliable, although no specific validity testing has been performed. Third, it is possible that some truly planned readmissions began in the ED. This situation may arise at small hospitals. However, we found that most of the planned readmissions that started in the ED had secondary diagnosis codes associated with acute conditions. In addition, we did not find a disproportionate number of potentially misclassified planned readmissions at small hospitals. Fourth, the association between high readmission rates and poor quality of care has been called into question recently. However, the purpose of this study is not to assess the quality of healthcare provided by these hospitals; our intent is to explore opportunities to improve the HRRP planned readmission algorithm. Fifth, our analysis only included the state of Michigan. However, Michigan is 1 of the 10 largest states by population, and we do not expect significant differences between our data and the rest of the country. Sixth, we conducted this analysis with version 3.0 of the CMS readmission algorithm. The latest version (4.0) has made several substantial changes to reduce the number of potentially misclassified planned readmissions. However, neither admission type nor presence of ED charges are considered in the updated version. Therefore, our study provides another potential target for further improvement.

These limitations notwithstanding, these findings have important implications for key stakeholders. Relevant to policymakers, the finding that a large percentage of the planned readmissions had ED charges and/or emergent/urgent admission claim type suggests that CMS should explore the use of these variables in their readmission algorithm. Relevant to hospitals and physicians, the potential misclassification of some planned readmissions suggests that close evaluation of the sources and causes of readmission is imperative during the local development of readmission reduction initiatives.

Collectively, these findings suggest that although planned readmissions are infrequent, many of these planned readmissions may actually be nonelective or unplanned in nature. Furthermore, our findings suggest that the CMS readmission algorithm might improve its accuracy by considering the admission type and the presence of ED charges. Future research in this area should focus on validating the use of ED charges and admission type to identify unplanned readmissions through medical chart review. The aim of the HRRP is to identify signals of poor quality in a fair and equitable manner. Misclassification of readmissions will limit CMS’ ability to achieve this important goal.

Disclosure

None of the authors have any conflicts of interest to disclose.

Readmissions result in $41.3 billion in annual healthcare expenses.¹ As a result of the Affordable Care Act, Centers for Medicare & Medicaid Services (CMS) implemented the Hospital Readmission Reduction Program (HRRP) to reduce expenditures and improve quality associated with hospital care.^2-5 The HRRP monitors readmission rates for pneumonia, congestive heart failure (CHF), acute myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD), coronary artery bypass graft (CABG), and joint replacement. Hospitals are penalized for excess readmissions that occur following any of these index admissions. However, some readmissions within 30 days of an index admission are planned. For example, patients may have scheduled admissions for chemotherapy visits or may have prescheduled elective surgeries that happen to fall within a 30-day postdischarge window. Furthermore, even unplanned readmissions may not be a marker of suboptimal care.⁶ To prevent penalization for planned readmissions, CMS developed an algorithm to exclude planned readmissions from the HRRP.⁷

Few studies have investigated the planned readmissions in the HRRP since Horwitz and colleagues⁷ developed the algorithm with the assistance of a technical expert panel and validated it by reviewing charts in 2 healthcare systems comprising 7 hospitals. Most studies focus on unplanned readmissions.^8,9 We build on this work by studying readmissions for 131 hospitals and using administrative claims to determine whether the algorithm could be improved. Specifically, we examined planned readmissions after the conditions included in the HRRP and determine whether they occurred under elective, urgent, or emergent circumstances. The goal is to assess whether the algorithm may misclassify some readmissions as planned even though the readmission is unanticipated. We hypothesize that some readmissions considered planned by the HRRP will occur under emergent circumstances. Our findings will provide more nuanced insights regarding planned readmissions and potentially provide a mechanism to identify potentially misclassified readmissions without administrative burden.

We analyzed Medicare claims from 2011 to 2015 for beneficiaries in Michigan who had index admissions for pneumonia, CHF, AMI, COPD, CABG, and joint replacement. Exclusion criteria were as follows: patients who were not continuously enrolled in Medicare Part A and B, had health maintenance organization coverage, were transferred to another hospital during the index admission, or received Medicare because of end-stage renal disease or disability. Patients with hip fractures were excluded because the HRRP readmission algorithm only includes elective, unilateral, total hip arthroplasties. Transfer patients were excluded because these patients are excluded from the HRRP readmission algorithm. We also excluded patients who died within 90 days of their index admission because these patients are often outliers in regards to healthcare utilization. The institutional review board at our health system deemed this study exempt from review.

For each hospital and each condition, we calculated 30-day readmission rates by identifying inpatient claims that occurred following discharge from the index admission. For patients who had multiple readmissions, we only considered the first readmission, as this follows the HRRP method. All readmissions were credited to the hospital where the index admission occurred.

To calculate 30-day planned readmission rates, we examined all readmissions and identified those deemed planned by version 3.0 of the CMS readmissions algorithm.¹⁰ We characterized these planned readmissions by examining the admission type variable and the presence or absence of emergency department (ED) charges. Planned readmissions that had an admission type of “emergent” or “urgent” and/or ED charges may have been unplanned. Because we cannot unequivocally determine whether or not the readmissions were misclassified, we refer to these readmissions as “potentially misclassified” in this manuscript. We also calculated the potential misclassification rate by hospital type.

For 131 Michigan hospitals, we identified 143,054 index admissions, 16,116 (11.3%) 30-day readmissions, and 1252 (7.8%) planned readmissions (Table 1).

Of the unplanned readmissions, 97.0% had either an admission type that was “urgent” or “emergent” and/or ED charges, 96.2% were associated with an “emergent” or “urgent” admission type, and 84.3% had emergency room charges on the claim line.

In this study, we found that planned readmissions are generally infrequent. However, the majority are coded with an emergent or urgent admission type and many have ED charges reported on the claim. These findings suggest that the CMS readmission algorithm examined in this study may potentially misclassify many planned readmissions and that CMS should explore the use of admission type and presence of ED charges in the unplanned/planned readmission algorithm.

Our primary finding that planned readmissions are infrequent is supported by several observations.^7-9,11 In the initial article describing the CMS algorithm,⁷ 7.8% of readmissions were considered planned; upon review of the discharge medical records from the index admissions, 41.3% of these planned readmissions were found to be unplanned. These findings closely correlate with our own findings that 7.8% of readmissions were considered planned by the CMS criteria, and 57.8% of planned readmissions were urgent or emergent. From a clinical perspective, there are few circumstances where a patient undergoing an elective procedure will transit electively through the ED.

The CMS algorithm was intentionally designed to have a high specificity for unplanned readmissions to ensure that truly planned readmissions would not be characterized as unplanned.⁷ There is a potential tradeoff to increasing the sensitivity for unplanned readmissions, in that more planned readmissions might be inadvertently characterized as unplanned. Additional validation work (ie, medical chart review) will be required to explore potentially misclassified planned readmissions in greater detail.

Our study has several limitations. First, we rely solely on information in administrative claims to determine whether an admission is planned. The full clinical story is obviously limited by this method. However, the CMS readmission algorithm is only based on information from administrative claims,⁷ and our goal was to explore a method of improving the algorithm that could be applied by CMS in a pragmatic manner. Second, the validity of the admission type variable for the purpose of identifying “emergent” and “urgent” admissions is not entirely clear. However, based on personal communication with the Research Data Assistance Center, the variable is known to be reliable, although no specific validity testing has been performed. Third, it is possible that some truly planned readmissions began in the ED. This situation may arise at small hospitals. However, we found that most of the planned readmissions that started in the ED had secondary diagnosis codes associated with acute conditions. In addition, we did not find a disproportionate number of potentially misclassified planned readmissions at small hospitals. Fourth, the association between high readmission rates and poor quality of care has been called into question recently. However, the purpose of this study is not to assess the quality of healthcare provided by these hospitals; our intent is to explore opportunities to improve the HRRP planned readmission algorithm. Fifth, our analysis only included the state of Michigan. However, Michigan is 1 of the 10 largest states by population, and we do not expect significant differences between our data and the rest of the country. Sixth, we conducted this analysis with version 3.0 of the CMS readmission algorithm. The latest version (4.0) has made several substantial changes to reduce the number of potentially misclassified planned readmissions. However, neither admission type nor presence of ED charges are considered in the updated version. Therefore, our study provides another potential target for further improvement.

These limitations notwithstanding, these findings have important implications for key stakeholders. Relevant to policymakers, the finding that a large percentage of the planned readmissions had ED charges and/or emergent/urgent admission claim type suggests that CMS should explore the use of these variables in their readmission algorithm. Relevant to hospitals and physicians, the potential misclassification of some planned readmissions suggests that close evaluation of the sources and causes of readmission is imperative during the local development of readmission reduction initiatives.

Collectively, these findings suggest that although planned readmissions are infrequent, many of these planned readmissions may actually be nonelective or unplanned in nature. Furthermore, our findings suggest that the CMS readmission algorithm might improve its accuracy by considering the admission type and the presence of ED charges. Future research in this area should focus on validating the use of ED charges and admission type to identify unplanned readmissions through medical chart review. The aim of the HRRP is to identify signals of poor quality in a fair and equitable manner. Misclassification of readmissions will limit CMS’ ability to achieve this important goal.

Disclosure

None of the authors have any conflicts of interest to disclose.

The prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms in intensive care unit (ICU) survivors ranges from 17% to 44%.^1-4 Psychiatric comorbidity, the presence of 2 or more psychiatric disorders, is highly prevalent in survivors of acute respiratory distress syndrome and is associated with higher mortality in postsurgical ICU survivors.^5-7 While long-term cognitive impairment in patients with ICU delirium has been associated with poor quality of life (QoL),¹ the effects of psychiatric comorbidity on QoL among similar patients are not as well understood. In this study, we examined whether psychiatric comorbidity was associated with poorer QoL in survivors of ICU delirium.

We examined subjects who participated in the Pharmacologic Management of Delirium (PMD) clinical trial. This trial examined the efficacy of a pharmacological intervention for patients who developed ICU delirium at a local tertiary-care academic hospital.⁸ Out of 62 patients who participated in the follow-up of the PMD study, 58 completed QoL interviews and validated psychiatric screens (Patient Health Questionnaire-9 [PHQ-9] for depression, the Generalized Anxiety Disorder-7 [GAD-7] questionnaire for anxiety, and the Post-Traumatic Stress Syndrome [PTSS-10] questionnaire for PTSD) at 3 months after hospital discharge. High psychiatric comorbidity was defined as having significant symptoms for all 3 conditions (depression: PHQ-9 score ≥ 10; anxiety: GAD-7 ≥ 10; and PTSD: PTSS-10 > 35). No psychiatric morbidity was defined as having no significant symptoms for all 3 conditions. Low to moderate (low-moderate) psychiatric morbidity was defined as having symptoms for 1 to 2 conditions.

Participants also completed 2 complementary QoL measures: the EuroQol 5 dimensions questionnaire 3-level (EQ-5D-3L) Index and the EuroQol 5 dimensions Visual Analog Scale (EQ-5D-VAS).⁹ The EQ-5D-3L Index asks participants to rate themselves as having (1) no problems, (2) some problems, or (3) extreme problems on the following 5 scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scores are then indexed against the US population to create a continuous index scale ranging from −0.11 to 1.00. A score of 1 represents perfect health, 0 represents death, and negative values indicate a health state worse than death. The EQ-5D-VAS asks participants to draw a line on a visual scale from an anchor box to the point that represents their health state. The score ranges from 0 being the worst imaginable health state to 100 being the best imaginable health state. Demographic information, clinical characteristics, and prior history of depression, anxiety, and PTSD were obtained through PMD study records and clinical records. The Charlson Comorbidity Index, which measures chronic comorbidities, and Acute Physiology and Chronic Health Evaluation II, which estimates acute severity of illness within 24 hours of ICU admission, were calculated from patients’ available clinical information.

Fisher’s exact tests were used to compare dichotomous outcomes. Analysis of variance (ANOVA) was used to compare continuous outcomes across the 3 psychiatric groups. Analysis of covariance (ANCOVA) was used to determine whether psychiatric comorbidity in survivors of ICU delirium was associated with QoL measures. Models were adjusted for the following covariates: age, gender, Charlson Comorbidity Index, discharged to home, prior history of depression, and prior history of anxiety. To assess the relationship of psychiatric comorbidity with QoL, we chose the 2 continuous QoL measures as the outcome. Because we were interested in the effect of psychiatric burden on QoL, we used ANCOVA with QoL as the dependent variable and psychiatric burden as an independent variable. Pairwise comparisons were then performed when overall differences were significant (P < 0.05). We performed 2 separate sensitivity analyses. The first analysis looked solely at the subgroup of patients from the medical intensive care unit. We also recalculated the EQ-5D-3L index excluding the anxiety/depression item.

Nearly one-third of patients (18/58) had high psychiatric burden. The table looks at the demographic and clinical characteristics of patients with high psychiatric comorbidity versus those of low-moderate psychiatric comorbidity and those with no psychiatric morbidity. Patient groups did not differ significantly in terms of demographics. For clinical characteristics, patients with high psychiatric comorbidity were more likely than patients with low-moderate psychiatric comorbidity to have a prior history of depression (P < 0.05).

Patients with high psychiatric comorbidity were more likely to have a poorer QoL when compared with patients with low-moderate psychiatric comorbidity and to those with no morbidity as measured by a lower EQ-5D-3L Index (no, 0.69 ± 0.25; low-moderate, 0.70 ± 0.19; high, 0.48 ± 0.24; P = 0.006) and EQ-5D-VAS (no, 67.0 ± 20.7; low-moderate, 76.6 ± 20.0; high, 50.8 ± 22.4; P = 0.004). After adjusting for covariates, patients with high psychiatric comorbidity had a poorer QoL compared with those with no morbidity or low-moderate comorbidity on the EQ-5D-3L Index (P = 0.017 for overall differences), whereas patients who had high psychiatric comorbidity had a poorer QoL compared to those with low-moderate comorbidity on the EQ-5D-VAS (P = 0.039 for overall differences; Figure). Subgroup analysis of MICU patients yielded similar results. Patients with high psychiatric burden had significantly poorer QoL as measured by the EQ-5D-3L (unadjusted P = 0.044, adjusted P = 0.003) and the EQ-5D-VAS (unadjusted P = 0.007, adjusted P = 0.021). After excluding the anxiety/depression item from the EQ-5D-3L, we observed similar differences (no, 0.71 ± 0.24; low-moderate, 0.75 ± 0.15; high, 0.58 ± 0.22; unadjusted P = 0.062; adjusted P = 0.040).

Psychiatric comorbidities in ICU survivors are common and pose a significant clinical issue. Patients with multiple psychiatric comorbidities can be more complicated to identify from a diagnostic standpoint and often require more prolonged, intensive mental health treatment when compared with patients with a single psychiatric disorder.^10,11 Our study showed that high psychiatric comorbidity in survivors of ICU delirium is associated with a decreased QoL compared with those with no psychiatric comorbidity or with low-moderate psychiatric comorbidity. This finding is consistent with previous studies in the general population that patients with multiple psychiatric comorbidities are associated with a poorer QoL compared with patients with a single psychiatric comorbidity.^10,11

There is a pressing need to better characterize psychiatric comorbidities in ICU survivors because our current evidence suggests that the prevalence of psychiatric comorbidities of ICU survivors is substantially higher than that of the general population. We found that nearly one-third of survivors of ICU delirium had comorbid depression, anxiety, and PTSD symptoms at 3 months. This is consistent with the few other studies of ICU survivors, which showed a prevalence of psychiatric comorbidity of 25% to 33%.^5,12 These rates are substantially higher than the prevalence in the general population of 6%.¹³

The high rate of psychiatric comorbidities may render it difficult to effectively treat the mental health symptoms in ICU survivors.¹⁴ Treating multiple psychiatric comorbidities may also be especially challenging in survivors of ICU delirium because they have a high prevalence of cognitive impairment. Mental health treatments for patients with psychiatric disorders and comorbid cognitive impairment are limited. Better characterization of psychiatric comorbidity in ICU survivors, particularly those with ICU delirium, is vital to the development of more effective, bundled treatments for this population with multiple comorbidities.

Standardized screenings of ICU survivors at a high risk for psychiatric disorders, such as survivors of ICU delirium, may help to identify patients with comorbid psychiatric disorder symptoms and have them referred to appropriate treatment earlier with the hope of improving their QoL sooner. Although opportunities to deliver integrated outpatient collaborative mental health and medical care for a subspecialty population are limited, one potential model of care would be to utilize a collaborative-care model in an ICU survivor clinic.¹⁵

Strengths of our study include the examination of psychiatric comorbidities in survivors of ICU delirium, who often have a poor QoL. A deeper understanding of psychiatric comorbidity and its relationship with QoL is needed to better understand how to deliver more effective treatments for these survivors. Limitations include the small sample size, a one-time measurement of psychiatric comorbidities at the 3-month follow-up based on screenings tools, and a lack of objective measures of physical functioning to determine the effects of psychiatric comorbidities on physical functioning. There may also have been differences in how patients with no psychiatric comorbidity responded to the EQ-5D-VAS as a result of premorbid differences (eg, they were healthier prior to their ICU stay and perceived their survivor status more negatively). This may explain why we did not see a statistically significant difference between no psychiatric comorbidity and high psychiatric comorbidity groups on the EQ-5D-VAS. Nevertheless, we did see a difference between the low-moderate psychiatric comorbidity group on EQ-5D-VAS and differences between the no comorbidity and low-moderate comorbidity groups versus the high comorbidity group on the EQ-5D-3L. Finally, data about psychiatric history and QoL prior to ICU hospitalization were limited. Therefore, truly determining incidence versus prevalence of post-ICU comorbidities and whether psychiatric symptoms and its effects on QoL were due to ICU hospitalization or to premorbid psychiatric symptoms is difficult.

Our study demonstrated that in survivors of ICU delirium, higher comorbidity of psychiatric symptoms was associated with poorer QoL. Future studies will need to confirm these findings. We will also need to identify potentially reversible risk factors for psychiatric comorbidity and poorer QoL and develop treatments to effectively target the mental health symptoms of survivors of ICU delirium.

Disclosure

Grant support: The PMD trial is funded through the National Institutes of Health grant R01AG054205-02. SW is supported by NIA 2P30AG010133. AP is supported by CMS 1 L1 CMS331444-02-00, Indiana CTSI, and NIA R01AG054205-02. SG is supported by NIA 2P30AG010133, NIA 5R01AG045350, and NIA R01AG054205-02. SK is supported by NHBLI 5T32HL091816-07. MB is supported by NIA R01 AG040220-05, AHRQ P30 HS024384-02, CMS 1 L1 CMS331444-02-00, NIA R01 AG030618-05A1 and NIA R01AG054205-02. BK is supported by NIA K23-AG043476 and NHLBI R01HL131730. The funding agency had no role in the development of the study design, collection, analysis, interpretation of data, manuscript development, or the decision to submit the manuscript for publication. Conflicts of interest include MB, SG, and AP being funded by NIA R01AG054205-02 for the PMD study.

The prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms in intensive care unit (ICU) survivors ranges from 17% to 44%.^1-4 Psychiatric comorbidity, the presence of 2 or more psychiatric disorders, is highly prevalent in survivors of acute respiratory distress syndrome and is associated with higher mortality in postsurgical ICU survivors.^5-7 While long-term cognitive impairment in patients with ICU delirium has been associated with poor quality of life (QoL),¹ the effects of psychiatric comorbidity on QoL among similar patients are not as well understood. In this study, we examined whether psychiatric comorbidity was associated with poorer QoL in survivors of ICU delirium.

We examined subjects who participated in the Pharmacologic Management of Delirium (PMD) clinical trial. This trial examined the efficacy of a pharmacological intervention for patients who developed ICU delirium at a local tertiary-care academic hospital.⁸ Out of 62 patients who participated in the follow-up of the PMD study, 58 completed QoL interviews and validated psychiatric screens (Patient Health Questionnaire-9 [PHQ-9] for depression, the Generalized Anxiety Disorder-7 [GAD-7] questionnaire for anxiety, and the Post-Traumatic Stress Syndrome [PTSS-10] questionnaire for PTSD) at 3 months after hospital discharge. High psychiatric comorbidity was defined as having significant symptoms for all 3 conditions (depression: PHQ-9 score ≥ 10; anxiety: GAD-7 ≥ 10; and PTSD: PTSS-10 > 35). No psychiatric morbidity was defined as having no significant symptoms for all 3 conditions. Low to moderate (low-moderate) psychiatric morbidity was defined as having symptoms for 1 to 2 conditions.

Participants also completed 2 complementary QoL measures: the EuroQol 5 dimensions questionnaire 3-level (EQ-5D-3L) Index and the EuroQol 5 dimensions Visual Analog Scale (EQ-5D-VAS).⁹ The EQ-5D-3L Index asks participants to rate themselves as having (1) no problems, (2) some problems, or (3) extreme problems on the following 5 scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scores are then indexed against the US population to create a continuous index scale ranging from −0.11 to 1.00. A score of 1 represents perfect health, 0 represents death, and negative values indicate a health state worse than death. The EQ-5D-VAS asks participants to draw a line on a visual scale from an anchor box to the point that represents their health state. The score ranges from 0 being the worst imaginable health state to 100 being the best imaginable health state. Demographic information, clinical characteristics, and prior history of depression, anxiety, and PTSD were obtained through PMD study records and clinical records. The Charlson Comorbidity Index, which measures chronic comorbidities, and Acute Physiology and Chronic Health Evaluation II, which estimates acute severity of illness within 24 hours of ICU admission, were calculated from patients’ available clinical information.

Fisher’s exact tests were used to compare dichotomous outcomes. Analysis of variance (ANOVA) was used to compare continuous outcomes across the 3 psychiatric groups. Analysis of covariance (ANCOVA) was used to determine whether psychiatric comorbidity in survivors of ICU delirium was associated with QoL measures. Models were adjusted for the following covariates: age, gender, Charlson Comorbidity Index, discharged to home, prior history of depression, and prior history of anxiety. To assess the relationship of psychiatric comorbidity with QoL, we chose the 2 continuous QoL measures as the outcome. Because we were interested in the effect of psychiatric burden on QoL, we used ANCOVA with QoL as the dependent variable and psychiatric burden as an independent variable. Pairwise comparisons were then performed when overall differences were significant (P < 0.05). We performed 2 separate sensitivity analyses. The first analysis looked solely at the subgroup of patients from the medical intensive care unit. We also recalculated the EQ-5D-3L index excluding the anxiety/depression item.

Nearly one-third of patients (18/58) had high psychiatric burden. The table looks at the demographic and clinical characteristics of patients with high psychiatric comorbidity versus those of low-moderate psychiatric comorbidity and those with no psychiatric morbidity. Patient groups did not differ significantly in terms of demographics. For clinical characteristics, patients with high psychiatric comorbidity were more likely than patients with low-moderate psychiatric comorbidity to have a prior history of depression (P < 0.05).

Patients with high psychiatric comorbidity were more likely to have a poorer QoL when compared with patients with low-moderate psychiatric comorbidity and to those with no morbidity as measured by a lower EQ-5D-3L Index (no, 0.69 ± 0.25; low-moderate, 0.70 ± 0.19; high, 0.48 ± 0.24; P = 0.006) and EQ-5D-VAS (no, 67.0 ± 20.7; low-moderate, 76.6 ± 20.0; high, 50.8 ± 22.4; P = 0.004). After adjusting for covariates, patients with high psychiatric comorbidity had a poorer QoL compared with those with no morbidity or low-moderate comorbidity on the EQ-5D-3L Index (P = 0.017 for overall differences), whereas patients who had high psychiatric comorbidity had a poorer QoL compared to those with low-moderate comorbidity on the EQ-5D-VAS (P = 0.039 for overall differences; Figure). Subgroup analysis of MICU patients yielded similar results. Patients with high psychiatric burden had significantly poorer QoL as measured by the EQ-5D-3L (unadjusted P = 0.044, adjusted P = 0.003) and the EQ-5D-VAS (unadjusted P = 0.007, adjusted P = 0.021). After excluding the anxiety/depression item from the EQ-5D-3L, we observed similar differences (no, 0.71 ± 0.24; low-moderate, 0.75 ± 0.15; high, 0.58 ± 0.22; unadjusted P = 0.062; adjusted P = 0.040).

Psychiatric comorbidities in ICU survivors are common and pose a significant clinical issue. Patients with multiple psychiatric comorbidities can be more complicated to identify from a diagnostic standpoint and often require more prolonged, intensive mental health treatment when compared with patients with a single psychiatric disorder.^10,11 Our study showed that high psychiatric comorbidity in survivors of ICU delirium is associated with a decreased QoL compared with those with no psychiatric comorbidity or with low-moderate psychiatric comorbidity. This finding is consistent with previous studies in the general population that patients with multiple psychiatric comorbidities are associated with a poorer QoL compared with patients with a single psychiatric comorbidity.^10,11

There is a pressing need to better characterize psychiatric comorbidities in ICU survivors because our current evidence suggests that the prevalence of psychiatric comorbidities of ICU survivors is substantially higher than that of the general population. We found that nearly one-third of survivors of ICU delirium had comorbid depression, anxiety, and PTSD symptoms at 3 months. This is consistent with the few other studies of ICU survivors, which showed a prevalence of psychiatric comorbidity of 25% to 33%.^5,12 These rates are substantially higher than the prevalence in the general population of 6%.¹³

The high rate of psychiatric comorbidities may render it difficult to effectively treat the mental health symptoms in ICU survivors.¹⁴ Treating multiple psychiatric comorbidities may also be especially challenging in survivors of ICU delirium because they have a high prevalence of cognitive impairment. Mental health treatments for patients with psychiatric disorders and comorbid cognitive impairment are limited. Better characterization of psychiatric comorbidity in ICU survivors, particularly those with ICU delirium, is vital to the development of more effective, bundled treatments for this population with multiple comorbidities.

Standardized screenings of ICU survivors at a high risk for psychiatric disorders, such as survivors of ICU delirium, may help to identify patients with comorbid psychiatric disorder symptoms and have them referred to appropriate treatment earlier with the hope of improving their QoL sooner. Although opportunities to deliver integrated outpatient collaborative mental health and medical care for a subspecialty population are limited, one potential model of care would be to utilize a collaborative-care model in an ICU survivor clinic.¹⁵

Strengths of our study include the examination of psychiatric comorbidities in survivors of ICU delirium, who often have a poor QoL. A deeper understanding of psychiatric comorbidity and its relationship with QoL is needed to better understand how to deliver more effective treatments for these survivors. Limitations include the small sample size, a one-time measurement of psychiatric comorbidities at the 3-month follow-up based on screenings tools, and a lack of objective measures of physical functioning to determine the effects of psychiatric comorbidities on physical functioning. There may also have been differences in how patients with no psychiatric comorbidity responded to the EQ-5D-VAS as a result of premorbid differences (eg, they were healthier prior to their ICU stay and perceived their survivor status more negatively). This may explain why we did not see a statistically significant difference between no psychiatric comorbidity and high psychiatric comorbidity groups on the EQ-5D-VAS. Nevertheless, we did see a difference between the low-moderate psychiatric comorbidity group on EQ-5D-VAS and differences between the no comorbidity and low-moderate comorbidity groups versus the high comorbidity group on the EQ-5D-3L. Finally, data about psychiatric history and QoL prior to ICU hospitalization were limited. Therefore, truly determining incidence versus prevalence of post-ICU comorbidities and whether psychiatric symptoms and its effects on QoL were due to ICU hospitalization or to premorbid psychiatric symptoms is difficult.

Our study demonstrated that in survivors of ICU delirium, higher comorbidity of psychiatric symptoms was associated with poorer QoL. Future studies will need to confirm these findings. We will also need to identify potentially reversible risk factors for psychiatric comorbidity and poorer QoL and develop treatments to effectively target the mental health symptoms of survivors of ICU delirium.

Disclosure

Grant support: The PMD trial is funded through the National Institutes of Health grant R01AG054205-02. SW is supported by NIA 2P30AG010133. AP is supported by CMS 1 L1 CMS331444-02-00, Indiana CTSI, and NIA R01AG054205-02. SG is supported by NIA 2P30AG010133, NIA 5R01AG045350, and NIA R01AG054205-02. SK is supported by NHBLI 5T32HL091816-07. MB is supported by NIA R01 AG040220-05, AHRQ P30 HS024384-02, CMS 1 L1 CMS331444-02-00, NIA R01 AG030618-05A1 and NIA R01AG054205-02. BK is supported by NIA K23-AG043476 and NHLBI R01HL131730. The funding agency had no role in the development of the study design, collection, analysis, interpretation of data, manuscript development, or the decision to submit the manuscript for publication. Conflicts of interest include MB, SG, and AP being funded by NIA R01AG054205-02 for the PMD study.

The prevalence of depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms in intensive care unit (ICU) survivors ranges from 17% to 44%.^1-4 Psychiatric comorbidity, the presence of 2 or more psychiatric disorders, is highly prevalent in survivors of acute respiratory distress syndrome and is associated with higher mortality in postsurgical ICU survivors.^5-7 While long-term cognitive impairment in patients with ICU delirium has been associated with poor quality of life (QoL),¹ the effects of psychiatric comorbidity on QoL among similar patients are not as well understood. In this study, we examined whether psychiatric comorbidity was associated with poorer QoL in survivors of ICU delirium.

We examined subjects who participated in the Pharmacologic Management of Delirium (PMD) clinical trial. This trial examined the efficacy of a pharmacological intervention for patients who developed ICU delirium at a local tertiary-care academic hospital.⁸ Out of 62 patients who participated in the follow-up of the PMD study, 58 completed QoL interviews and validated psychiatric screens (Patient Health Questionnaire-9 [PHQ-9] for depression, the Generalized Anxiety Disorder-7 [GAD-7] questionnaire for anxiety, and the Post-Traumatic Stress Syndrome [PTSS-10] questionnaire for PTSD) at 3 months after hospital discharge. High psychiatric comorbidity was defined as having significant symptoms for all 3 conditions (depression: PHQ-9 score ≥ 10; anxiety: GAD-7 ≥ 10; and PTSD: PTSS-10 > 35). No psychiatric morbidity was defined as having no significant symptoms for all 3 conditions. Low to moderate (low-moderate) psychiatric morbidity was defined as having symptoms for 1 to 2 conditions.

Participants also completed 2 complementary QoL measures: the EuroQol 5 dimensions questionnaire 3-level (EQ-5D-3L) Index and the EuroQol 5 dimensions Visual Analog Scale (EQ-5D-VAS).⁹ The EQ-5D-3L Index asks participants to rate themselves as having (1) no problems, (2) some problems, or (3) extreme problems on the following 5 scales: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scores are then indexed against the US population to create a continuous index scale ranging from −0.11 to 1.00. A score of 1 represents perfect health, 0 represents death, and negative values indicate a health state worse than death. The EQ-5D-VAS asks participants to draw a line on a visual scale from an anchor box to the point that represents their health state. The score ranges from 0 being the worst imaginable health state to 100 being the best imaginable health state. Demographic information, clinical characteristics, and prior history of depression, anxiety, and PTSD were obtained through PMD study records and clinical records. The Charlson Comorbidity Index, which measures chronic comorbidities, and Acute Physiology and Chronic Health Evaluation II, which estimates acute severity of illness within 24 hours of ICU admission, were calculated from patients’ available clinical information.

Fisher’s exact tests were used to compare dichotomous outcomes. Analysis of variance (ANOVA) was used to compare continuous outcomes across the 3 psychiatric groups. Analysis of covariance (ANCOVA) was used to determine whether psychiatric comorbidity in survivors of ICU delirium was associated with QoL measures. Models were adjusted for the following covariates: age, gender, Charlson Comorbidity Index, discharged to home, prior history of depression, and prior history of anxiety. To assess the relationship of psychiatric comorbidity with QoL, we chose the 2 continuous QoL measures as the outcome. Because we were interested in the effect of psychiatric burden on QoL, we used ANCOVA with QoL as the dependent variable and psychiatric burden as an independent variable. Pairwise comparisons were then performed when overall differences were significant (P < 0.05). We performed 2 separate sensitivity analyses. The first analysis looked solely at the subgroup of patients from the medical intensive care unit. We also recalculated the EQ-5D-3L index excluding the anxiety/depression item.

Nearly one-third of patients (18/58) had high psychiatric burden. The table looks at the demographic and clinical characteristics of patients with high psychiatric comorbidity versus those of low-moderate psychiatric comorbidity and those with no psychiatric morbidity. Patient groups did not differ significantly in terms of demographics. For clinical characteristics, patients with high psychiatric comorbidity were more likely than patients with low-moderate psychiatric comorbidity to have a prior history of depression (P < 0.05).

Patients with high psychiatric comorbidity were more likely to have a poorer QoL when compared with patients with low-moderate psychiatric comorbidity and to those with no morbidity as measured by a lower EQ-5D-3L Index (no, 0.69 ± 0.25; low-moderate, 0.70 ± 0.19; high, 0.48 ± 0.24; P = 0.006) and EQ-5D-VAS (no, 67.0 ± 20.7; low-moderate, 76.6 ± 20.0; high, 50.8 ± 22.4; P = 0.004). After adjusting for covariates, patients with high psychiatric comorbidity had a poorer QoL compared with those with no morbidity or low-moderate comorbidity on the EQ-5D-3L Index (P = 0.017 for overall differences), whereas patients who had high psychiatric comorbidity had a poorer QoL compared to those with low-moderate comorbidity on the EQ-5D-VAS (P = 0.039 for overall differences; Figure). Subgroup analysis of MICU patients yielded similar results. Patients with high psychiatric burden had significantly poorer QoL as measured by the EQ-5D-3L (unadjusted P = 0.044, adjusted P = 0.003) and the EQ-5D-VAS (unadjusted P = 0.007, adjusted P = 0.021). After excluding the anxiety/depression item from the EQ-5D-3L, we observed similar differences (no, 0.71 ± 0.24; low-moderate, 0.75 ± 0.15; high, 0.58 ± 0.22; unadjusted P = 0.062; adjusted P = 0.040).

Psychiatric comorbidities in ICU survivors are common and pose a significant clinical issue. Patients with multiple psychiatric comorbidities can be more complicated to identify from a diagnostic standpoint and often require more prolonged, intensive mental health treatment when compared with patients with a single psychiatric disorder.^10,11 Our study showed that high psychiatric comorbidity in survivors of ICU delirium is associated with a decreased QoL compared with those with no psychiatric comorbidity or with low-moderate psychiatric comorbidity. This finding is consistent with previous studies in the general population that patients with multiple psychiatric comorbidities are associated with a poorer QoL compared with patients with a single psychiatric comorbidity.^10,11

There is a pressing need to better characterize psychiatric comorbidities in ICU survivors because our current evidence suggests that the prevalence of psychiatric comorbidities of ICU survivors is substantially higher than that of the general population. We found that nearly one-third of survivors of ICU delirium had comorbid depression, anxiety, and PTSD symptoms at 3 months. This is consistent with the few other studies of ICU survivors, which showed a prevalence of psychiatric comorbidity of 25% to 33%.^5,12 These rates are substantially higher than the prevalence in the general population of 6%.¹³

The high rate of psychiatric comorbidities may render it difficult to effectively treat the mental health symptoms in ICU survivors.¹⁴ Treating multiple psychiatric comorbidities may also be especially challenging in survivors of ICU delirium because they have a high prevalence of cognitive impairment. Mental health treatments for patients with psychiatric disorders and comorbid cognitive impairment are limited. Better characterization of psychiatric comorbidity in ICU survivors, particularly those with ICU delirium, is vital to the development of more effective, bundled treatments for this population with multiple comorbidities.

Standardized screenings of ICU survivors at a high risk for psychiatric disorders, such as survivors of ICU delirium, may help to identify patients with comorbid psychiatric disorder symptoms and have them referred to appropriate treatment earlier with the hope of improving their QoL sooner. Although opportunities to deliver integrated outpatient collaborative mental health and medical care for a subspecialty population are limited, one potential model of care would be to utilize a collaborative-care model in an ICU survivor clinic.¹⁵

Strengths of our study include the examination of psychiatric comorbidities in survivors of ICU delirium, who often have a poor QoL. A deeper understanding of psychiatric comorbidity and its relationship with QoL is needed to better understand how to deliver more effective treatments for these survivors. Limitations include the small sample size, a one-time measurement of psychiatric comorbidities at the 3-month follow-up based on screenings tools, and a lack of objective measures of physical functioning to determine the effects of psychiatric comorbidities on physical functioning. There may also have been differences in how patients with no psychiatric comorbidity responded to the EQ-5D-VAS as a result of premorbid differences (eg, they were healthier prior to their ICU stay and perceived their survivor status more negatively). This may explain why we did not see a statistically significant difference between no psychiatric comorbidity and high psychiatric comorbidity groups on the EQ-5D-VAS. Nevertheless, we did see a difference between the low-moderate psychiatric comorbidity group on EQ-5D-VAS and differences between the no comorbidity and low-moderate comorbidity groups versus the high comorbidity group on the EQ-5D-3L. Finally, data about psychiatric history and QoL prior to ICU hospitalization were limited. Therefore, truly determining incidence versus prevalence of post-ICU comorbidities and whether psychiatric symptoms and its effects on QoL were due to ICU hospitalization or to premorbid psychiatric symptoms is difficult.

Our study demonstrated that in survivors of ICU delirium, higher comorbidity of psychiatric symptoms was associated with poorer QoL. Future studies will need to confirm these findings. We will also need to identify potentially reversible risk factors for psychiatric comorbidity and poorer QoL and develop treatments to effectively target the mental health symptoms of survivors of ICU delirium.

Disclosure

Grant support: The PMD trial is funded through the National Institutes of Health grant R01AG054205-02. SW is supported by NIA 2P30AG010133. AP is supported by CMS 1 L1 CMS331444-02-00, Indiana CTSI, and NIA R01AG054205-02. SG is supported by NIA 2P30AG010133, NIA 5R01AG045350, and NIA R01AG054205-02. SK is supported by NHBLI 5T32HL091816-07. MB is supported by NIA R01 AG040220-05, AHRQ P30 HS024384-02, CMS 1 L1 CMS331444-02-00, NIA R01 AG030618-05A1 and NIA R01AG054205-02. BK is supported by NIA K23-AG043476 and NHLBI R01HL131730. The funding agency had no role in the development of the study design, collection, analysis, interpretation of data, manuscript development, or the decision to submit the manuscript for publication. Conflicts of interest include MB, SG, and AP being funded by NIA R01AG054205-02 for the PMD study.

Venous thromboembolism (VTE) is a common medical condition comprising deep vein thrombosis (DVT) and pulmonary embolism (PE). Estimates of the incidence of DVT in the United States vary between 0.5 and 1.5 cases per 1000 person-years.¹ Left untreated, roughly 50% of DVT patients progress to a PE, of whom 10% to 25% die within 3 months.²

Since the 1990s, multiple randomized controlled studies^3-5 demonstrated the safety and efficacy of outpatient treatment for selected DVT patients with low molecular weight heparin and warfarin. The United States Food and Drug Administration approved enoxaparin, a low molecular weight heparin for outpatient use in 1998,⁶ and by the end of the decade, multiple treatment guidelines for VTE acknowledged the safety of outpatient treatment of DVT with low molecular weight heparin in selected patients.^7-9 Recently, the approval of direct oral anticoagulants (DOACs) by the Food and Drug Administration allows an all-oral treatment regimen for VTE, which could further facilitate outpatient treatment of DVT.

Costs associated with treatment of VTE are enormous. For outpatient treatment, researchers differ on individual estimates of cost savings associated with outpatient DVT management, but most report a cost savings of several thousand dollars per patient treated as an outpatient compared with as an inpatient.^6,10 Given the incidence of DVT, reducing costs while maintaining a high quality of care in even a small percentage of DVT patients would result in significant healthcare cost savings as well as increased convenience for patients.

Despite high-quality evidence supporting the efficacy and safety of outpatient DVT treatment, little is known about the adoption of outpatient DVT treatment in the United States. Several studies that have been published were limited to single hospitals and were small in size^11,12 or limited to a cohort of patients already diagnosed with DVT.¹³

The purpose of this study was to report the frequency of outpatient treatment of DVT in the United States and describe patient characteristics associated with outpatient treatment. Information was gathered from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a contemporary cohort study of more than 30,000 patients residing in the contiguous United States with racial and geographic diversity. We hypothesized that an individual’s age, sex, race, region of residence, urban or rural residence, education level, and personal income would be associated with outpatient treatment. Results would allow the implementation of interventions to promote the appropriate use of outpatient treatment in order to reduce healthcare costs and increase patient convenience without compromising safety or efficacy of care.

Cohort Characteristics

VTE events were ascertained in the REGARDS cohort, a prospective, longitudinal cohort study investigating the causes of racial and geographic disparities in stroke and cognitive decline.¹⁴ Between 2003 and 2007, there were 30,239 participants in the contiguous United States ≥45 years old enrolled in REGARDS. By design, 55% were female, 41% were black, the mean age was 65 years, and 56% lived in the southeastern United States. Participants were recruited from a commercial list by mail and telephone contact followed by verbal consent. A telephone interview was followed by an in-home examination, including obtaining written informed consent. On study entry, many participants had comorbid conditions, including 8% with reported atrial fibrillation, 56% receiving treatment for hypertension, 22% receiving treatment for diabetes, 3.7% taking warfarin, and 14% who were actively smoking.^15,16 Participants were only excluded if they had active cancer, stated a self-reported race other than white or black, were unable to converse in English, had cognitive impairment as judged by the telephone interviewer, or were residing in or on the waiting list for a nursing home. Study methods were reviewed and approved by the institutional review boards at each study institution and have been published elsewhere.¹⁴

Event Ascertainment and Definitions

DVT event ascertainment is complete through 2011, with identification by telephone interview, review of reported hospitalizations, and review of deaths.¹⁷ Questionnaires in similar epidemiological studies have 98% specificity and >70% sensitivity for ascertaining VTE events.¹⁸ A research nurse reviewed the text and recorded each reported hospitalization through 2011. Any report of a blood clot in the legs, arms, or lungs was a potential case for physician review. Medical records were retrieved for up to 1 year before and 1 year after potential events. Retrieved records were used to help guide further record retrieval if they did not contain the primary VTE event. Primary inpatient and outpatient records including history and physical examinations, discharge summaries, imaging reports (to include limb ultrasounds, computed tomography scans, and magnetic resonance imaging), autopsies, and outpatient notes were retrieved using up to 3 attempts.¹⁹ Using all available information, characteristics of the VTE event and treatment were systematically recorded. For each potential VTE case, two of three physician reviewers abstracted medical records to validate and classify the event. If the physician reviewers disagreed, the third physician would review the case, and if VTE status remained uncertain, cases were discussed and resolved. Race was determined by participant self-report as black or white. Location of residence was defined by geocoding the addresses, and urban or rural status was defined by United States census tract data using rural-urban commuting area codes (RUCA; with rural areas being RUCA codes 4–10).²⁰ Other risk factors were obtained through surveys, telephone interviews, or in-home visits.¹⁴

Outpatient treatment was defined as receiving a DVT diagnosis in an emergency department or ambulatory clinic but not receiving an overnight hospitalization. Inpatient treatment was defined as at least 1 overnight stay in a hospital (but not in an emergency department). Only participants admitted with a primary diagnosis of DVT were included in the analysis. If someone was noted to have DVT but was admitted to the hospital for another cause, he or she was not included in the analysis and classified as a hospital-associated DVT. A provoked DVT was defined as occurring within 90 days of a major trauma, surgery, or marked immobility or was associated with active cancer or treatment for cancer (ie, chemotherapy, radiotherapy, or surgical therapy), while an unprovoked DVT was defined as having none of the above provoking factors. A distal DVT was defined as a DVT occurring in the posterior tibial, anterior tibial, peroneal, or soleus sinuses. The primary outcome was DVT treated as an outpatient only without concurrent diagnosis of PE or VTE as a complication of hospitalization (as these individuals were not eligible for outpatient treatment at the time).

Statistical Analysis

Age, sex, race, region of residence (inside or outside the southeastern United States), education, income (determined as greater or less than $20,000 per year), and urban or rural status of residence were compared between DVT patients treated as outpatients and inpatients using χ2 analysis by inpatient or outpatient treatment. Univariable and multivariable logistic regression was then used to determine the odds ratio (OR) of receiving outpatient DVT treatment by the same variables with age per 10-year increment. ORs were adjusted for age, sex, race, year of DVT diagnosis, and region of residence as appropriate. Statistical significance was defined as P < 0.05. All statistical analyses were performed by N.A.Z. and conducted with SAS version 9.3 (SAS Institute, Cary, NC). All authors had access to the primary clinical data.

Over a mean of 4.7 years follow-up, 379 VTE events occurred (incident and recurrent); 185 were diagnosed with a PE, and 53 occurred as a complication of hospitalization (and were not eligible for outpatient treatment), leaving 141 DVT events potentially eligible for outpatient treatment out of a population of 29,556 participants with available records and follow-up in the cohort (Figure).

Of 141 DVT events, 39 (28%) were treated as outpatients. Table 1 presents the characteristics of participants treated as inpatients and as outpatients. Factors significantly associated with outpatient DVT treatment were younger age, female sex, white race, residing in an urban area, having a distal DVT only, and having a higher income. In the study, DVT events were recorded between 2003 and 2011; the median year of a diagnosed DVT and treated as an outpatient was 2009, while the median year of inpatient treatment was 2008. Living in the Southeast versus the rest of the country (P = 0.13) and having a high school education or greater (P = 0.07) were marginally associated with receiving outpatient treatment. In absolute terms, 11% of people living in rural areas and 19% of black patients had outpatient DVT treatment while 33% of the urban dwellers and 32% of white patients received outpatient treatment (Table 1). At the time of cohort enrollment, 92% of participants claimed to have insurance; however, this did not differentiate between Medicare, Medicaid, and private insurance. Only 1 participant diagnosed with DVT had an estimated glomerular filtration rate <30, and this individual was admitted for treatment.

In this national, prospective, observational cohort study, only 28% of participants diagnosed with DVT were treated as outpatients versus being hospitalized. Urban area of residence, white race, female sex, and younger age were significantly associated with an increased odds of outpatient treatment. Groups that had particularly low outpatient treatment rates were rural dwellers and black participants, who had outpatient treatment rates of 11% and 19%, respectively. The odds of receiving outpatient treatment did improve over the course of the study, but in the last year of VTE assessment, outpatient treatment remained at 40%, but this was quite variable over the study years (being 8% two years prior).

The feasibility of outpatient treatment of DVTs requires a coordinated healthcare system and patient support to ensure education and appropriate anticoagulation monitoring. While not all DVTs should be treated as outpatients, differences in treatment location by sex, race, and residence point to potential healthcare disparities that increase the burden on patients and increase healthcare costs. Other studies have documented low outpatient treatment rates of DVTs (20% in 1 United States multicenter DVT registry) but have not discussed the associations of outpatient versus inpatient treatment.¹³ Outpatient treatment also appears to be underutilized in other developed countries; in the European Computerized Registry of Patients with Venous Thromboembolism, only 31% of DVT patients were treated on an outpatient basis between 2001 and 2011.²¹ To our knowledge, this is the first study to document the uptake of outpatient DVT treatment in the United States across multiple states, regions, and health systems well after the safety and efficacy of outpatient treatment of DVT was established by randomized controlled trials.^3-5

The strengths of this study are that these data are derived from a contemporary cohort with a large geographic and racial distribution in the United States and are well characterized with a mean of 4.6 years follow-up.¹⁹ We are limited by a relatively small number of DVT events that were eligible for outpatient treatment (n = 141) and so may miss modest associations. Further, while the geographic scope of the cohort is a tremendous strength of our study, we may have missed some events and did not have complete record retrieval of reported events and could not assess access to healthcare in detail. These data were recorded before the use of DOACs became common. DOACs are an effective and safe alternative to conventional anticoagulation treatment for acute DVT.²² Their use might result in increased outpatient treatment, as they are not parenteral; however, cost considerations (~$400.00 per month), especially with high-deductible insurance plans, may limit their impact on VTE treatment location.²³ This study cannot account for why the racial, sex, and urban–rural differences exist, and by extension if hospitalization rates differ due to associated comorbidities or if this represents a healthcare disparity. While it is reasonable from a healthcare perspective that younger individuals would more likely be treated as outpatients, there is no data to suggest that differences in DVT by sex, race, and residential location support decreased outpatient treatment. Due to the age of the cohort, most individuals had some form of insurance and a primary care provider. However, we were unable to assess the quality of insurance and the ease of access to their primary care providers. More research is needed to determine whether patients were hospitalized on medical grounds or because of a lack of coordinated healthcare systems to care for them as outpatients.

In conclusion, only a minority of patients who were potentially eligible for outpatient DVT treatment (28%) were treated as outpatients in this study, and there were significant racial and socioeconomic differences in who received inpatient and outpatient treatment. While outpatient treatment rates were below 40% in all groups, we identified groups with especially low likelihoods of receiving outpatient treatment. While all eligible individuals should be offered outpatient DVT treatment, these data highlight the need for specific efforts to overcome barriers to outpatient treatment in the elderly, rural areas, black patients, and men. Even modest increases in the rate of outpatient DVT treatment could result in substantial cost savings and increased patient convenience without compromising the efficacy or safety of medical care.

Acknowledgements

The authors thank the staff and participants of REGARDS for their important contributions. The executive committee of REGARDS reviewed and approved this manuscript for publication. This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. Additional funding was provided by an investigator-initiated grant in aid from the American Recovery and Reinvestment Act grant RC1HL099460 from the National Heart, Lung, and Blood Institute. Work for the manuscript was supported in part by the Lake Champlain Cancer Research Organization (Burlington, Vermont).

Disclosure

The authors have no conflicts of interest to report.

Venous thromboembolism (VTE) is a common medical condition comprising deep vein thrombosis (DVT) and pulmonary embolism (PE). Estimates of the incidence of DVT in the United States vary between 0.5 and 1.5 cases per 1000 person-years.¹ Left untreated, roughly 50% of DVT patients progress to a PE, of whom 10% to 25% die within 3 months.²

Since the 1990s, multiple randomized controlled studies^3-5 demonstrated the safety and efficacy of outpatient treatment for selected DVT patients with low molecular weight heparin and warfarin. The United States Food and Drug Administration approved enoxaparin, a low molecular weight heparin for outpatient use in 1998,⁶ and by the end of the decade, multiple treatment guidelines for VTE acknowledged the safety of outpatient treatment of DVT with low molecular weight heparin in selected patients.^7-9 Recently, the approval of direct oral anticoagulants (DOACs) by the Food and Drug Administration allows an all-oral treatment regimen for VTE, which could further facilitate outpatient treatment of DVT.

Costs associated with treatment of VTE are enormous. For outpatient treatment, researchers differ on individual estimates of cost savings associated with outpatient DVT management, but most report a cost savings of several thousand dollars per patient treated as an outpatient compared with as an inpatient.^6,10 Given the incidence of DVT, reducing costs while maintaining a high quality of care in even a small percentage of DVT patients would result in significant healthcare cost savings as well as increased convenience for patients.

Despite high-quality evidence supporting the efficacy and safety of outpatient DVT treatment, little is known about the adoption of outpatient DVT treatment in the United States. Several studies that have been published were limited to single hospitals and were small in size^11,12 or limited to a cohort of patients already diagnosed with DVT.¹³

The purpose of this study was to report the frequency of outpatient treatment of DVT in the United States and describe patient characteristics associated with outpatient treatment. Information was gathered from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a contemporary cohort study of more than 30,000 patients residing in the contiguous United States with racial and geographic diversity. We hypothesized that an individual’s age, sex, race, region of residence, urban or rural residence, education level, and personal income would be associated with outpatient treatment. Results would allow the implementation of interventions to promote the appropriate use of outpatient treatment in order to reduce healthcare costs and increase patient convenience without compromising safety or efficacy of care.

Cohort Characteristics

VTE events were ascertained in the REGARDS cohort, a prospective, longitudinal cohort study investigating the causes of racial and geographic disparities in stroke and cognitive decline.¹⁴ Between 2003 and 2007, there were 30,239 participants in the contiguous United States ≥45 years old enrolled in REGARDS. By design, 55% were female, 41% were black, the mean age was 65 years, and 56% lived in the southeastern United States. Participants were recruited from a commercial list by mail and telephone contact followed by verbal consent. A telephone interview was followed by an in-home examination, including obtaining written informed consent. On study entry, many participants had comorbid conditions, including 8% with reported atrial fibrillation, 56% receiving treatment for hypertension, 22% receiving treatment for diabetes, 3.7% taking warfarin, and 14% who were actively smoking.^15,16 Participants were only excluded if they had active cancer, stated a self-reported race other than white or black, were unable to converse in English, had cognitive impairment as judged by the telephone interviewer, or were residing in or on the waiting list for a nursing home. Study methods were reviewed and approved by the institutional review boards at each study institution and have been published elsewhere.¹⁴

Event Ascertainment and Definitions

DVT event ascertainment is complete through 2011, with identification by telephone interview, review of reported hospitalizations, and review of deaths.¹⁷ Questionnaires in similar epidemiological studies have 98% specificity and >70% sensitivity for ascertaining VTE events.¹⁸ A research nurse reviewed the text and recorded each reported hospitalization through 2011. Any report of a blood clot in the legs, arms, or lungs was a potential case for physician review. Medical records were retrieved for up to 1 year before and 1 year after potential events. Retrieved records were used to help guide further record retrieval if they did not contain the primary VTE event. Primary inpatient and outpatient records including history and physical examinations, discharge summaries, imaging reports (to include limb ultrasounds, computed tomography scans, and magnetic resonance imaging), autopsies, and outpatient notes were retrieved using up to 3 attempts.¹⁹ Using all available information, characteristics of the VTE event and treatment were systematically recorded. For each potential VTE case, two of three physician reviewers abstracted medical records to validate and classify the event. If the physician reviewers disagreed, the third physician would review the case, and if VTE status remained uncertain, cases were discussed and resolved. Race was determined by participant self-report as black or white. Location of residence was defined by geocoding the addresses, and urban or rural status was defined by United States census tract data using rural-urban commuting area codes (RUCA; with rural areas being RUCA codes 4–10).²⁰ Other risk factors were obtained through surveys, telephone interviews, or in-home visits.¹⁴

Outpatient treatment was defined as receiving a DVT diagnosis in an emergency department or ambulatory clinic but not receiving an overnight hospitalization. Inpatient treatment was defined as at least 1 overnight stay in a hospital (but not in an emergency department). Only participants admitted with a primary diagnosis of DVT were included in the analysis. If someone was noted to have DVT but was admitted to the hospital for another cause, he or she was not included in the analysis and classified as a hospital-associated DVT. A provoked DVT was defined as occurring within 90 days of a major trauma, surgery, or marked immobility or was associated with active cancer or treatment for cancer (ie, chemotherapy, radiotherapy, or surgical therapy), while an unprovoked DVT was defined as having none of the above provoking factors. A distal DVT was defined as a DVT occurring in the posterior tibial, anterior tibial, peroneal, or soleus sinuses. The primary outcome was DVT treated as an outpatient only without concurrent diagnosis of PE or VTE as a complication of hospitalization (as these individuals were not eligible for outpatient treatment at the time).

Statistical Analysis

Age, sex, race, region of residence (inside or outside the southeastern United States), education, income (determined as greater or less than $20,000 per year), and urban or rural status of residence were compared between DVT patients treated as outpatients and inpatients using χ2 analysis by inpatient or outpatient treatment. Univariable and multivariable logistic regression was then used to determine the odds ratio (OR) of receiving outpatient DVT treatment by the same variables with age per 10-year increment. ORs were adjusted for age, sex, race, year of DVT diagnosis, and region of residence as appropriate. Statistical significance was defined as P < 0.05. All statistical analyses were performed by N.A.Z. and conducted with SAS version 9.3 (SAS Institute, Cary, NC). All authors had access to the primary clinical data.

Over a mean of 4.7 years follow-up, 379 VTE events occurred (incident and recurrent); 185 were diagnosed with a PE, and 53 occurred as a complication of hospitalization (and were not eligible for outpatient treatment), leaving 141 DVT events potentially eligible for outpatient treatment out of a population of 29,556 participants with available records and follow-up in the cohort (Figure).

Of 141 DVT events, 39 (28%) were treated as outpatients. Table 1 presents the characteristics of participants treated as inpatients and as outpatients. Factors significantly associated with outpatient DVT treatment were younger age, female sex, white race, residing in an urban area, having a distal DVT only, and having a higher income. In the study, DVT events were recorded between 2003 and 2011; the median year of a diagnosed DVT and treated as an outpatient was 2009, while the median year of inpatient treatment was 2008. Living in the Southeast versus the rest of the country (P = 0.13) and having a high school education or greater (P = 0.07) were marginally associated with receiving outpatient treatment. In absolute terms, 11% of people living in rural areas and 19% of black patients had outpatient DVT treatment while 33% of the urban dwellers and 32% of white patients received outpatient treatment (Table 1). At the time of cohort enrollment, 92% of participants claimed to have insurance; however, this did not differentiate between Medicare, Medicaid, and private insurance. Only 1 participant diagnosed with DVT had an estimated glomerular filtration rate <30, and this individual was admitted for treatment.

In this national, prospective, observational cohort study, only 28% of participants diagnosed with DVT were treated as outpatients versus being hospitalized. Urban area of residence, white race, female sex, and younger age were significantly associated with an increased odds of outpatient treatment. Groups that had particularly low outpatient treatment rates were rural dwellers and black participants, who had outpatient treatment rates of 11% and 19%, respectively. The odds of receiving outpatient treatment did improve over the course of the study, but in the last year of VTE assessment, outpatient treatment remained at 40%, but this was quite variable over the study years (being 8% two years prior).

The feasibility of outpatient treatment of DVTs requires a coordinated healthcare system and patient support to ensure education and appropriate anticoagulation monitoring. While not all DVTs should be treated as outpatients, differences in treatment location by sex, race, and residence point to potential healthcare disparities that increase the burden on patients and increase healthcare costs. Other studies have documented low outpatient treatment rates of DVTs (20% in 1 United States multicenter DVT registry) but have not discussed the associations of outpatient versus inpatient treatment.¹³ Outpatient treatment also appears to be underutilized in other developed countries; in the European Computerized Registry of Patients with Venous Thromboembolism, only 31% of DVT patients were treated on an outpatient basis between 2001 and 2011.²¹ To our knowledge, this is the first study to document the uptake of outpatient DVT treatment in the United States across multiple states, regions, and health systems well after the safety and efficacy of outpatient treatment of DVT was established by randomized controlled trials.^3-5

The strengths of this study are that these data are derived from a contemporary cohort with a large geographic and racial distribution in the United States and are well characterized with a mean of 4.6 years follow-up.¹⁹ We are limited by a relatively small number of DVT events that were eligible for outpatient treatment (n = 141) and so may miss modest associations. Further, while the geographic scope of the cohort is a tremendous strength of our study, we may have missed some events and did not have complete record retrieval of reported events and could not assess access to healthcare in detail. These data were recorded before the use of DOACs became common. DOACs are an effective and safe alternative to conventional anticoagulation treatment for acute DVT.²² Their use might result in increased outpatient treatment, as they are not parenteral; however, cost considerations (~$400.00 per month), especially with high-deductible insurance plans, may limit their impact on VTE treatment location.²³ This study cannot account for why the racial, sex, and urban–rural differences exist, and by extension if hospitalization rates differ due to associated comorbidities or if this represents a healthcare disparity. While it is reasonable from a healthcare perspective that younger individuals would more likely be treated as outpatients, there is no data to suggest that differences in DVT by sex, race, and residential location support decreased outpatient treatment. Due to the age of the cohort, most individuals had some form of insurance and a primary care provider. However, we were unable to assess the quality of insurance and the ease of access to their primary care providers. More research is needed to determine whether patients were hospitalized on medical grounds or because of a lack of coordinated healthcare systems to care for them as outpatients.

In conclusion, only a minority of patients who were potentially eligible for outpatient DVT treatment (28%) were treated as outpatients in this study, and there were significant racial and socioeconomic differences in who received inpatient and outpatient treatment. While outpatient treatment rates were below 40% in all groups, we identified groups with especially low likelihoods of receiving outpatient treatment. While all eligible individuals should be offered outpatient DVT treatment, these data highlight the need for specific efforts to overcome barriers to outpatient treatment in the elderly, rural areas, black patients, and men. Even modest increases in the rate of outpatient DVT treatment could result in substantial cost savings and increased patient convenience without compromising the efficacy or safety of medical care.

Acknowledgements

The authors thank the staff and participants of REGARDS for their important contributions. The executive committee of REGARDS reviewed and approved this manuscript for publication. This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. Additional funding was provided by an investigator-initiated grant in aid from the American Recovery and Reinvestment Act grant RC1HL099460 from the National Heart, Lung, and Blood Institute. Work for the manuscript was supported in part by the Lake Champlain Cancer Research Organization (Burlington, Vermont).

Disclosure

The authors have no conflicts of interest to report.

Venous thromboembolism (VTE) is a common medical condition comprising deep vein thrombosis (DVT) and pulmonary embolism (PE). Estimates of the incidence of DVT in the United States vary between 0.5 and 1.5 cases per 1000 person-years.¹ Left untreated, roughly 50% of DVT patients progress to a PE, of whom 10% to 25% die within 3 months.²

Since the 1990s, multiple randomized controlled studies^3-5 demonstrated the safety and efficacy of outpatient treatment for selected DVT patients with low molecular weight heparin and warfarin. The United States Food and Drug Administration approved enoxaparin, a low molecular weight heparin for outpatient use in 1998,⁶ and by the end of the decade, multiple treatment guidelines for VTE acknowledged the safety of outpatient treatment of DVT with low molecular weight heparin in selected patients.^7-9 Recently, the approval of direct oral anticoagulants (DOACs) by the Food and Drug Administration allows an all-oral treatment regimen for VTE, which could further facilitate outpatient treatment of DVT.

Costs associated with treatment of VTE are enormous. For outpatient treatment, researchers differ on individual estimates of cost savings associated with outpatient DVT management, but most report a cost savings of several thousand dollars per patient treated as an outpatient compared with as an inpatient.^6,10 Given the incidence of DVT, reducing costs while maintaining a high quality of care in even a small percentage of DVT patients would result in significant healthcare cost savings as well as increased convenience for patients.

Despite high-quality evidence supporting the efficacy and safety of outpatient DVT treatment, little is known about the adoption of outpatient DVT treatment in the United States. Several studies that have been published were limited to single hospitals and were small in size^11,12 or limited to a cohort of patients already diagnosed with DVT.¹³

The purpose of this study was to report the frequency of outpatient treatment of DVT in the United States and describe patient characteristics associated with outpatient treatment. Information was gathered from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a contemporary cohort study of more than 30,000 patients residing in the contiguous United States with racial and geographic diversity. We hypothesized that an individual’s age, sex, race, region of residence, urban or rural residence, education level, and personal income would be associated with outpatient treatment. Results would allow the implementation of interventions to promote the appropriate use of outpatient treatment in order to reduce healthcare costs and increase patient convenience without compromising safety or efficacy of care.

Cohort Characteristics

VTE events were ascertained in the REGARDS cohort, a prospective, longitudinal cohort study investigating the causes of racial and geographic disparities in stroke and cognitive decline.¹⁴ Between 2003 and 2007, there were 30,239 participants in the contiguous United States ≥45 years old enrolled in REGARDS. By design, 55% were female, 41% were black, the mean age was 65 years, and 56% lived in the southeastern United States. Participants were recruited from a commercial list by mail and telephone contact followed by verbal consent. A telephone interview was followed by an in-home examination, including obtaining written informed consent. On study entry, many participants had comorbid conditions, including 8% with reported atrial fibrillation, 56% receiving treatment for hypertension, 22% receiving treatment for diabetes, 3.7% taking warfarin, and 14% who were actively smoking.^15,16 Participants were only excluded if they had active cancer, stated a self-reported race other than white or black, were unable to converse in English, had cognitive impairment as judged by the telephone interviewer, or were residing in or on the waiting list for a nursing home. Study methods were reviewed and approved by the institutional review boards at each study institution and have been published elsewhere.¹⁴

Event Ascertainment and Definitions

DVT event ascertainment is complete through 2011, with identification by telephone interview, review of reported hospitalizations, and review of deaths.¹⁷ Questionnaires in similar epidemiological studies have 98% specificity and >70% sensitivity for ascertaining VTE events.¹⁸ A research nurse reviewed the text and recorded each reported hospitalization through 2011. Any report of a blood clot in the legs, arms, or lungs was a potential case for physician review. Medical records were retrieved for up to 1 year before and 1 year after potential events. Retrieved records were used to help guide further record retrieval if they did not contain the primary VTE event. Primary inpatient and outpatient records including history and physical examinations, discharge summaries, imaging reports (to include limb ultrasounds, computed tomography scans, and magnetic resonance imaging), autopsies, and outpatient notes were retrieved using up to 3 attempts.¹⁹ Using all available information, characteristics of the VTE event and treatment were systematically recorded. For each potential VTE case, two of three physician reviewers abstracted medical records to validate and classify the event. If the physician reviewers disagreed, the third physician would review the case, and if VTE status remained uncertain, cases were discussed and resolved. Race was determined by participant self-report as black or white. Location of residence was defined by geocoding the addresses, and urban or rural status was defined by United States census tract data using rural-urban commuting area codes (RUCA; with rural areas being RUCA codes 4–10).²⁰ Other risk factors were obtained through surveys, telephone interviews, or in-home visits.¹⁴

Outpatient treatment was defined as receiving a DVT diagnosis in an emergency department or ambulatory clinic but not receiving an overnight hospitalization. Inpatient treatment was defined as at least 1 overnight stay in a hospital (but not in an emergency department). Only participants admitted with a primary diagnosis of DVT were included in the analysis. If someone was noted to have DVT but was admitted to the hospital for another cause, he or she was not included in the analysis and classified as a hospital-associated DVT. A provoked DVT was defined as occurring within 90 days of a major trauma, surgery, or marked immobility or was associated with active cancer or treatment for cancer (ie, chemotherapy, radiotherapy, or surgical therapy), while an unprovoked DVT was defined as having none of the above provoking factors. A distal DVT was defined as a DVT occurring in the posterior tibial, anterior tibial, peroneal, or soleus sinuses. The primary outcome was DVT treated as an outpatient only without concurrent diagnosis of PE or VTE as a complication of hospitalization (as these individuals were not eligible for outpatient treatment at the time).

Statistical Analysis

Age, sex, race, region of residence (inside or outside the southeastern United States), education, income (determined as greater or less than $20,000 per year), and urban or rural status of residence were compared between DVT patients treated as outpatients and inpatients using χ2 analysis by inpatient or outpatient treatment. Univariable and multivariable logistic regression was then used to determine the odds ratio (OR) of receiving outpatient DVT treatment by the same variables with age per 10-year increment. ORs were adjusted for age, sex, race, year of DVT diagnosis, and region of residence as appropriate. Statistical significance was defined as P < 0.05. All statistical analyses were performed by N.A.Z. and conducted with SAS version 9.3 (SAS Institute, Cary, NC). All authors had access to the primary clinical data.

Over a mean of 4.7 years follow-up, 379 VTE events occurred (incident and recurrent); 185 were diagnosed with a PE, and 53 occurred as a complication of hospitalization (and were not eligible for outpatient treatment), leaving 141 DVT events potentially eligible for outpatient treatment out of a population of 29,556 participants with available records and follow-up in the cohort (Figure).

Of 141 DVT events, 39 (28%) were treated as outpatients. Table 1 presents the characteristics of participants treated as inpatients and as outpatients. Factors significantly associated with outpatient DVT treatment were younger age, female sex, white race, residing in an urban area, having a distal DVT only, and having a higher income. In the study, DVT events were recorded between 2003 and 2011; the median year of a diagnosed DVT and treated as an outpatient was 2009, while the median year of inpatient treatment was 2008. Living in the Southeast versus the rest of the country (P = 0.13) and having a high school education or greater (P = 0.07) were marginally associated with receiving outpatient treatment. In absolute terms, 11% of people living in rural areas and 19% of black patients had outpatient DVT treatment while 33% of the urban dwellers and 32% of white patients received outpatient treatment (Table 1). At the time of cohort enrollment, 92% of participants claimed to have insurance; however, this did not differentiate between Medicare, Medicaid, and private insurance. Only 1 participant diagnosed with DVT had an estimated glomerular filtration rate <30, and this individual was admitted for treatment.

In this national, prospective, observational cohort study, only 28% of participants diagnosed with DVT were treated as outpatients versus being hospitalized. Urban area of residence, white race, female sex, and younger age were significantly associated with an increased odds of outpatient treatment. Groups that had particularly low outpatient treatment rates were rural dwellers and black participants, who had outpatient treatment rates of 11% and 19%, respectively. The odds of receiving outpatient treatment did improve over the course of the study, but in the last year of VTE assessment, outpatient treatment remained at 40%, but this was quite variable over the study years (being 8% two years prior).

The feasibility of outpatient treatment of DVTs requires a coordinated healthcare system and patient support to ensure education and appropriate anticoagulation monitoring. While not all DVTs should be treated as outpatients, differences in treatment location by sex, race, and residence point to potential healthcare disparities that increase the burden on patients and increase healthcare costs. Other studies have documented low outpatient treatment rates of DVTs (20% in 1 United States multicenter DVT registry) but have not discussed the associations of outpatient versus inpatient treatment.¹³ Outpatient treatment also appears to be underutilized in other developed countries; in the European Computerized Registry of Patients with Venous Thromboembolism, only 31% of DVT patients were treated on an outpatient basis between 2001 and 2011.²¹ To our knowledge, this is the first study to document the uptake of outpatient DVT treatment in the United States across multiple states, regions, and health systems well after the safety and efficacy of outpatient treatment of DVT was established by randomized controlled trials.^3-5

The strengths of this study are that these data are derived from a contemporary cohort with a large geographic and racial distribution in the United States and are well characterized with a mean of 4.6 years follow-up.¹⁹ We are limited by a relatively small number of DVT events that were eligible for outpatient treatment (n = 141) and so may miss modest associations. Further, while the geographic scope of the cohort is a tremendous strength of our study, we may have missed some events and did not have complete record retrieval of reported events and could not assess access to healthcare in detail. These data were recorded before the use of DOACs became common. DOACs are an effective and safe alternative to conventional anticoagulation treatment for acute DVT.²² Their use might result in increased outpatient treatment, as they are not parenteral; however, cost considerations (~$400.00 per month), especially with high-deductible insurance plans, may limit their impact on VTE treatment location.²³ This study cannot account for why the racial, sex, and urban–rural differences exist, and by extension if hospitalization rates differ due to associated comorbidities or if this represents a healthcare disparity. While it is reasonable from a healthcare perspective that younger individuals would more likely be treated as outpatients, there is no data to suggest that differences in DVT by sex, race, and residential location support decreased outpatient treatment. Due to the age of the cohort, most individuals had some form of insurance and a primary care provider. However, we were unable to assess the quality of insurance and the ease of access to their primary care providers. More research is needed to determine whether patients were hospitalized on medical grounds or because of a lack of coordinated healthcare systems to care for them as outpatients.

In conclusion, only a minority of patients who were potentially eligible for outpatient DVT treatment (28%) were treated as outpatients in this study, and there were significant racial and socioeconomic differences in who received inpatient and outpatient treatment. While outpatient treatment rates were below 40% in all groups, we identified groups with especially low likelihoods of receiving outpatient treatment. While all eligible individuals should be offered outpatient DVT treatment, these data highlight the need for specific efforts to overcome barriers to outpatient treatment in the elderly, rural areas, black patients, and men. Even modest increases in the rate of outpatient DVT treatment could result in substantial cost savings and increased patient convenience without compromising the efficacy or safety of medical care.

Acknowledgements

The authors thank the staff and participants of REGARDS for their important contributions. The executive committee of REGARDS reviewed and approved this manuscript for publication. This research project is supported by cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. Additional funding was provided by an investigator-initiated grant in aid from the American Recovery and Reinvestment Act grant RC1HL099460 from the National Heart, Lung, and Blood Institute. Work for the manuscript was supported in part by the Lake Champlain Cancer Research Organization (Burlington, Vermont).

Disclosure

The authors have no conflicts of interest to report.

With some areas of the country spending close to 3 times more on healthcare than others, regional variation in healthcare spending has been the focus of national attention.^1-7 Since 1973, the Dartmouth Institute has studied regional variation in healthcare utilization and spending and concluded that variation is “unwarranted” because it is driven by providers’ practice patterns rather than differences in medical need, patient preferences, or evidence-based medicine.^8-11 However, critics of the Dartmouth Institute’s findings argue that their approach does not adequately adjust for community-level income, and that higher costs in some areas reflect greater patient needs that are not reflected in illness acuity alone.^12-14

While Medicare data have made it possible to study variations in spending for the senior population, fragmentation of insurance coverage and nonstandardized data structures make studying the pediatric population more difficult. However, the Children’s Hospital Association’s (CHA) Pediatric Health Information System (PHIS) has made large-scale comparisons more feasible. To overcome challenges associated with using charges and nonuniform cost data, PHIS-derived standardized costs provide new opportunities for comparisons.^15,16 Initial analyses using PHIS data showed significant interhospital variations in costs of care,¹⁵ but they did not adjust for differences in populations and assess the drivers of variation. A more recent study that controlled for payer status, comorbidities, and illness severity found that intensive care unit (ICU) utilization varied significantly for children hospitalized for asthma, suggesting that hospital practice patterns drive differences in cost.¹⁷

This study uses PHIS data to analyze regional variations in standardized costs of care for 3 conditions for which children are hospitalized. To assess potential drivers of variation, the study investigates the effects of patient-level demographic and illness-severity variables as well as encounter-level variables on costs of care. It also estimates cost savings from reducing variation.

Data Source

This retrospective cohort study uses the PHIS database (CHA, Overland Park, KS), which includes 48 freestanding children’s hospitals located in noncompeting markets across the United States and accounts for approximately 20% of pediatric hospitalizations. PHIS includes patient demographics, International Classification of Diseases, 9th Revision (ICD-9) diagnosis and procedure codes, as well as hospital charges. In addition to total charges, PHIS reports imaging, laboratory, pharmacy, and “other” charges. The “other” category aggregates clinical, supply, room, and nursing charges (including facility fees and ancillary staff services).

Inclusion Criteria

Inpatient- and observation-status hospitalizations for asthma, diabetic ketoacidosis (DKA), and acute gastroenteritis (AGE) at 46 PHIS hospitals from October 2014 to September 2015 were included. Two hospitals were excluded because of missing data. Hospitalizations for patients >18 years were excluded.

Hospitalizations were categorized by using All Patient Refined-Diagnosis Related Groups (APR-DRGs) version 24 (3M Health Information Systems, St. Paul, MN)¹⁸ based on the ICD-9 diagnosis and procedure codes assigned during the episode of care. Analyses included APR-DRG 141 (asthma), primary diagnosis ICD-9 codes 250.11 and 250.13 (DKA), and APR-DRG 249 (AGE). ICD-9 codes were used for DKA for increased specificity.¹⁹ These conditions were chosen to represent 3 clinical scenarios: (1) a diagnosis for which hospitals differ on whether certain aspects of care are provided in the ICU (asthma), (2) a diagnosis that frequently includes care in an ICU (DKA), and (3) a diagnosis that typically does not include ICU care (AGE).¹⁹

Study Design

To focus the analysis on variation in resource utilization across hospitals rather than variations in hospital item charges, each billed resource was assigned a standardized cost.^15,16 For each clinical transaction code (CTC), the median unit cost was calculated for each hospital. The median of the hospital medians was defined as the standardized unit cost for that CTC.

The primary outcome variable was the total standardized cost for the hospitalization adjusted for patient-level demographic and illness-severity variables. Patient demographic and illness-severity covariates included age, race, gender, ZIP code-based median annual household income (HHI), rural-urban location, distance from home ZIP code to the hospital, chronic condition indicator (CCI), and severity-of-illness (SOI). When assessing drivers of variation, encounter-level covariates were added, including length of stay (LOS) in hours, ICU utilization, and 7-day readmission (an imprecise measure to account for quality of care during the index visit). The contribution of imaging, laboratory, pharmacy, and “other” costs was also considered.

Median annual HHI for patients’ home ZIP code was obtained from 2010 US Census data. Community-level HHI, a proxy for socioeconomic status (SES),^20,21 was classified into categories based on the 2015 US federal poverty level (FPL) for a family of 4²²: HHI-1 = ≤ 1.5 × FPL; HHI-2 = 1.5 to 2 × FPL; HHI-3 = 2 to 3 × FPL; HHI-4 = ≥ 3 × FPL. Rural-urban commuting area (RUCA) codes were used to determine the rural-urban classification of the patient’s home.²³ The distance from home ZIP code to the hospital was included as an additional control for illness severity because patients traveling longer distances are often more sick and require more resources.²⁴

The Agency for Healthcare Research and Quality CCI classification system was used to identify the presence of a chronic condition.²⁵ For asthma, CCI was flagged if the patient had a chronic condition other than asthma; for DKA, CCI was flagged if the patient had a chronic condition other than DKA; and for AGE, CCI was flagged if the patient had any chronic condition.

The APR-DRG system provides a 4-level SOI score with each APR-DRG category. Patient factors, such as comorbid diagnoses, are considered in severity scores generated through 3M’s proprietary algorithms.¹⁸

For the first analysis, the 46 hospitals were categorized into 7 geographic regions based on 2010 US Census Divisions.²⁶ To overcome small hospital sample sizes, Mountain and Pacific were combined into West, and Middle Atlantic and New England were combined into North East. Because PHIS hospitals are located in noncompeting geographic regions, for the second analysis, we examined hospital-level variation (considering each hospital as its own region).

Data Analysis

To focus the analysis on “typical” patients and produce more robust estimates of central tendencies, the top and bottom 5% of hospitalizations with the most extreme standardized costs by condition were trimmed.²⁷ Standardized costs were log-transformed because of their nonnormal distribution and analyzed by using linear mixed models. Covariates were added stepwise to assess the proportion of the variance explained by each predictor. Post-hoc tests with conservative single-step stepwise mutation model corrections for multiple testing were used to compare adjusted costs. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). P values < 0.05 were considered significant. The Children’s Hospital of Philadelphia Institutional Review Board did not classify this study as human subjects research.

During the study period, there were 26,430 hospitalizations for asthma, 5056 for DKA, and 16,274 for AGE (Table 1).

Variation Across Census Regions

After adjusting for patient-level demographic and illness-severity variables, differences in adjusted total standardized costs remained between regions (P < 0.001). Although no region was an outlier compared to the overall mean for any of the conditions, regions were statistically different in pairwise comparison. The East North Central, South Atlantic, and West South Central regions had the highest adjusted total standardized costs for each of the conditions. The East South Central and West North Central regions had the lowest costs for each of the conditions. Adjusted total standardized costs were 120% higher for asthma ($1920 vs $4227), 46% higher for DKA ($7429 vs $10,881), and 150% higher for AGE ($3316 vs $8292) in the highest-cost region compared with the lowest-cost region (Table 2A).

Variation Within Census Regions

After controlling for patient-level demographic and illness-severity variables, standardized costs were different across hospitals in the same region (P < 0.001; panel A in Figure). This was true for all conditions in each region. Differences between the lowest- and highest-cost hospitals within the same region ranged from 111% to 420% for asthma, 101% to 398% for DKA, and 166% to 787% for AGE (Table 3).

Variation Across Hospitals (Each Hospital as Its Own Region)

One hospital had the highest adjusted standardized costs for all 3 conditions ($9087 for asthma, $28,564 for DKA, and $23,387 for AGE) and was outside of the 95% confidence interval compared with the overall means. The second highest-cost hospitals for asthma ($5977) and AGE ($18,780) were also outside of the 95% confidence interval. After removing these outliers, the difference between the highest- and lowest-cost hospitals was 549% for asthma ($721 vs $4678), 491% for DKA ($2738 vs $16,192), and 681% for AGE ($1317 vs $10,281; Table 2B).

Drivers of Variation Across Census Regions

Patient-level demographic and illness-severity variables explained very little of the variation in standardized costs across regions. For each of the conditions, age, race, gender, community-level HHI, RUCA, and distance from home to the hospital each accounted for <1.5% of variation, while SOI and CCI each accounted for <5%. Overall, patient-level variables explained 5.5%, 3.7%, and 6.7% of variation for asthma, DKA, and AGE.

Encounter-level variables explained a much larger percentage of the variation in costs. LOS accounted for 17.8% of the variation for asthma, 9.8% for DKA, and 8.7% for AGE. ICU utilization explained 6.9% of the variation for asthma and 12.5% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. The combination of patient-level and encounter-level variables explained 27%, 24%, and 15% of the variation for asthma, DKA, and AGE.

Drivers of Variation Across Hospitals

For each of the conditions, patient-level demographic variables each accounted for <2% of variation in costs between hospitals. SOI accounted for 4.5% of the variation for asthma and CCI accounted for 5.2% for AGE. Overall, patient-level variables explained 6.9%, 5.3%, and 7.3% of variation for asthma, DKA, and AGE.

Encounter-level variables accounted for a much larger percentage of the variation in cost. LOS explained 25.4% for asthma, 13.3% for DKA, and 14.2% for AGE. ICU utilization accounted for 13.4% for asthma and 21.9% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. Together, patient-level and encounter-level variables explained 40%, 36%, and 22% of variation for asthma, DKA, and AGE.

Imaging, Laboratory, Pharmacy, and “Other” Costs

The largest contributor to total costs adjusted for patient-level factors for all conditions was “other,” which aggregates room, nursing, clinical, and supply charges (panel B in Figure). When considering drivers of variation, this category explained >50% for each of the conditions. The next largest contributor to total costs was laboratory charges, which accounted for 15% of the variation across regions for asthma and 11% for DKA. Differences in imaging accounted for 18% of the variation for DKA and 15% for AGE. Differences in pharmacy charges accounted for <4% of the variation for each of the conditions. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 78%, and 72% of the variation across census regions for asthma, DKA, and AGE.

For the hospital-level analysis, differences in “other” remained the largest driver of cost variation. For asthma, “other” explained 61% of variation, while pharmacy, laboratory, and imaging each accounted for <8%. For DKA, differences in imaging accounted for 18% of the variation and laboratory charges accounted for 12%. For AGE, imaging accounted for 15% of the variation. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 72%, and 67% of the variation for asthma, DKA, and AGE.

Cost Savings

If all hospitals in this cohort with adjusted standardized costs above the national PHIS average achieved costs equal to the national PHIS average, estimated annual savings in adjusted standardized costs for these 3 conditions would be $69.1 million. If each hospital with adjusted costs above the average within its census region achieved costs equal to its regional average, estimated annual savings in adjusted standardized costs for these conditions would be $25.2 million.

This study reported on the regional variation in costs of care for 3 conditions treated at 46 children’s hospitals across 7 geographic regions, and it demonstrated that variations in costs of care exist in pediatrics. This study used standardized costs to compare utilization patterns across hospitals and adjusted for several patient-level demographic and illness-severity factors, and it found that differences in costs of care for children hospitalized with asthma, DKA, and AGE remained both between and within regions.

These variations are noteworthy, as hospitals strive to improve the value of healthcare. If the higher-cost hospitals in this cohort could achieve costs equal to the national PHIS averages, estimated annual savings in adjusted standardized costs for these conditions alone would equal $69.1 million. If higher-cost hospitals relative to the average in their own region reduced costs to their regional averages, annual standardized cost savings could equal $25.2 million for these conditions.

The differences observed are also significant in that they provide a foundation for exploring whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes.²⁸ If so, studying what those hospitals do to achieve outcomes more efficiently can serve as the basis for the establishment of best practices.²⁹ Standardizing best practices through protocols, pathways, and care-model redesign can reduce potentially unnecessary spending.³⁰

Our findings showed that patient-level demographic and illness-severity covariates, including community-level HHI and SOI, did not consistently explain cost differences. Instead, LOS and ICU utilization were associated with higher costs.^17,19 When considering the effect of the 4 cost components on the variation in total standardized costs between regions and between hospitals, the fact that the “other” category accounted for the largest percent of the variation is not surprising, because the cost of room occupancy and nursing services increases with longer LOS and more time in the ICU. Other individual cost components that were major drivers of variation were laboratory utilization for asthma and imaging for DKA and AGE³¹ (though they accounted for a much smaller proportion of total adjusted costs).¹⁹

To determine if these factors are modifiable, more information is needed to explain why practices differ. Many factors may contribute to varying utilization patterns, including differences in capabilities and resources (in the hospital and in the community) and patient volumes. For example, some hospitals provide continuous albuterol for status asthmaticus only in ICUs, while others provide it on regular units.³² But if certain hospitals do not have adequate resources or volumes to effectively care for certain populations outside of the ICU, their higher-value approach (considering quality and cost) may be to utilize ICU beds, even if some other hospitals care for those patients on non-ICU floors. Another possibility is that family preferences about care delivery (such as how long children stay in the hospital) may vary across regions.³³

Other evidence suggests that physician practice and spending patterns are strongly influenced by the practices of the region where they trained.³⁴ Because physicians often practice close to where they trained,^35,36 this may partially explain how regional patterns are reinforced.

Even considering all mentioned covariates, our model did not fully explain variation in standardized costs. After adding the cost components as covariates, between one-third and one-fifth of the variation remained unexplained. It is possible that this unexplained variation stemmed from unmeasured patient-level factors.

In addition, while proxies for SES, including community-level HHI, did not significantly predict differences in costs across regions, it is possible that SES affected LOS differently in different regions. Previous studies have suggested that lower SES is associated with longer LOS.³⁷ If this effect is more pronounced in certain regions (potentially because of differences in social service infrastructures), SES may be contributing to variations in cost through LOS.

Our findings were subject to limitations. First, this study only examined 3 diagnoses and did not include surgical or less common conditions. Second, while PHIS includes tertiary care, academic, and freestanding children’s hospitals, it does not include general hospitals, which is where most pediatric patients receive care.³⁸ Third, we used ZIP code-based median annual HHI to account for SES, and we used ZIP codes to determine the distance to the hospital and rural-urban location of patients’ homes. These approximations lack precision because SES and distances vary within ZIP codes.³⁹ Fourth, while adjusted standardized costs allow for comparisons between hospitals, they do not represent actual costs to patients or individual hospitals. Additionally, when determining whether variation remained after controlling for patient-level variables, we included SOI as a reflection of illness-severity at presentation. However, in practice, SOI scores may be assigned partially based on factors determined during the hospitalization.¹⁸ Finally, the use of other regional boundaries or the selection of different hospitals may yield different results.

This study reveals regional variations in costs of care for 3 inpatient pediatric conditions. Future studies should explore whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes. To the extent that variation is driven by modifiable factors and lower spending does not compromise outcomes, these data may prompt reviews of care models to reduce unwarranted variation and improve the value of care delivery at local, regional, and national levels.

Disclosure

Internal funds from the CHA and The Children’s Hospital of Philadelphia supported the conduct of this work. The authors have no financial interests, relationships, or affiliations relevant to the subject matter or materials discussed in the manuscript to disclose. The authors have no potential conflicts of interest relevant to the subject matter or materials discussed in the manuscript to disclose

With some areas of the country spending close to 3 times more on healthcare than others, regional variation in healthcare spending has been the focus of national attention.^1-7 Since 1973, the Dartmouth Institute has studied regional variation in healthcare utilization and spending and concluded that variation is “unwarranted” because it is driven by providers’ practice patterns rather than differences in medical need, patient preferences, or evidence-based medicine.^8-11 However, critics of the Dartmouth Institute’s findings argue that their approach does not adequately adjust for community-level income, and that higher costs in some areas reflect greater patient needs that are not reflected in illness acuity alone.^12-14

While Medicare data have made it possible to study variations in spending for the senior population, fragmentation of insurance coverage and nonstandardized data structures make studying the pediatric population more difficult. However, the Children’s Hospital Association’s (CHA) Pediatric Health Information System (PHIS) has made large-scale comparisons more feasible. To overcome challenges associated with using charges and nonuniform cost data, PHIS-derived standardized costs provide new opportunities for comparisons.^15,16 Initial analyses using PHIS data showed significant interhospital variations in costs of care,¹⁵ but they did not adjust for differences in populations and assess the drivers of variation. A more recent study that controlled for payer status, comorbidities, and illness severity found that intensive care unit (ICU) utilization varied significantly for children hospitalized for asthma, suggesting that hospital practice patterns drive differences in cost.¹⁷

This study uses PHIS data to analyze regional variations in standardized costs of care for 3 conditions for which children are hospitalized. To assess potential drivers of variation, the study investigates the effects of patient-level demographic and illness-severity variables as well as encounter-level variables on costs of care. It also estimates cost savings from reducing variation.

Data Source

This retrospective cohort study uses the PHIS database (CHA, Overland Park, KS), which includes 48 freestanding children’s hospitals located in noncompeting markets across the United States and accounts for approximately 20% of pediatric hospitalizations. PHIS includes patient demographics, International Classification of Diseases, 9th Revision (ICD-9) diagnosis and procedure codes, as well as hospital charges. In addition to total charges, PHIS reports imaging, laboratory, pharmacy, and “other” charges. The “other” category aggregates clinical, supply, room, and nursing charges (including facility fees and ancillary staff services).

Inclusion Criteria

Inpatient- and observation-status hospitalizations for asthma, diabetic ketoacidosis (DKA), and acute gastroenteritis (AGE) at 46 PHIS hospitals from October 2014 to September 2015 were included. Two hospitals were excluded because of missing data. Hospitalizations for patients >18 years were excluded.

Hospitalizations were categorized by using All Patient Refined-Diagnosis Related Groups (APR-DRGs) version 24 (3M Health Information Systems, St. Paul, MN)¹⁸ based on the ICD-9 diagnosis and procedure codes assigned during the episode of care. Analyses included APR-DRG 141 (asthma), primary diagnosis ICD-9 codes 250.11 and 250.13 (DKA), and APR-DRG 249 (AGE). ICD-9 codes were used for DKA for increased specificity.¹⁹ These conditions were chosen to represent 3 clinical scenarios: (1) a diagnosis for which hospitals differ on whether certain aspects of care are provided in the ICU (asthma), (2) a diagnosis that frequently includes care in an ICU (DKA), and (3) a diagnosis that typically does not include ICU care (AGE).¹⁹

Study Design

To focus the analysis on variation in resource utilization across hospitals rather than variations in hospital item charges, each billed resource was assigned a standardized cost.^15,16 For each clinical transaction code (CTC), the median unit cost was calculated for each hospital. The median of the hospital medians was defined as the standardized unit cost for that CTC.

The primary outcome variable was the total standardized cost for the hospitalization adjusted for patient-level demographic and illness-severity variables. Patient demographic and illness-severity covariates included age, race, gender, ZIP code-based median annual household income (HHI), rural-urban location, distance from home ZIP code to the hospital, chronic condition indicator (CCI), and severity-of-illness (SOI). When assessing drivers of variation, encounter-level covariates were added, including length of stay (LOS) in hours, ICU utilization, and 7-day readmission (an imprecise measure to account for quality of care during the index visit). The contribution of imaging, laboratory, pharmacy, and “other” costs was also considered.

Median annual HHI for patients’ home ZIP code was obtained from 2010 US Census data. Community-level HHI, a proxy for socioeconomic status (SES),^20,21 was classified into categories based on the 2015 US federal poverty level (FPL) for a family of 4²²: HHI-1 = ≤ 1.5 × FPL; HHI-2 = 1.5 to 2 × FPL; HHI-3 = 2 to 3 × FPL; HHI-4 = ≥ 3 × FPL. Rural-urban commuting area (RUCA) codes were used to determine the rural-urban classification of the patient’s home.²³ The distance from home ZIP code to the hospital was included as an additional control for illness severity because patients traveling longer distances are often more sick and require more resources.²⁴

The Agency for Healthcare Research and Quality CCI classification system was used to identify the presence of a chronic condition.²⁵ For asthma, CCI was flagged if the patient had a chronic condition other than asthma; for DKA, CCI was flagged if the patient had a chronic condition other than DKA; and for AGE, CCI was flagged if the patient had any chronic condition.

The APR-DRG system provides a 4-level SOI score with each APR-DRG category. Patient factors, such as comorbid diagnoses, are considered in severity scores generated through 3M’s proprietary algorithms.¹⁸

For the first analysis, the 46 hospitals were categorized into 7 geographic regions based on 2010 US Census Divisions.²⁶ To overcome small hospital sample sizes, Mountain and Pacific were combined into West, and Middle Atlantic and New England were combined into North East. Because PHIS hospitals are located in noncompeting geographic regions, for the second analysis, we examined hospital-level variation (considering each hospital as its own region).

Data Analysis

To focus the analysis on “typical” patients and produce more robust estimates of central tendencies, the top and bottom 5% of hospitalizations with the most extreme standardized costs by condition were trimmed.²⁷ Standardized costs were log-transformed because of their nonnormal distribution and analyzed by using linear mixed models. Covariates were added stepwise to assess the proportion of the variance explained by each predictor. Post-hoc tests with conservative single-step stepwise mutation model corrections for multiple testing were used to compare adjusted costs. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). P values < 0.05 were considered significant. The Children’s Hospital of Philadelphia Institutional Review Board did not classify this study as human subjects research.

During the study period, there were 26,430 hospitalizations for asthma, 5056 for DKA, and 16,274 for AGE (Table 1).

Variation Across Census Regions

After adjusting for patient-level demographic and illness-severity variables, differences in adjusted total standardized costs remained between regions (P < 0.001). Although no region was an outlier compared to the overall mean for any of the conditions, regions were statistically different in pairwise comparison. The East North Central, South Atlantic, and West South Central regions had the highest adjusted total standardized costs for each of the conditions. The East South Central and West North Central regions had the lowest costs for each of the conditions. Adjusted total standardized costs were 120% higher for asthma ($1920 vs $4227), 46% higher for DKA ($7429 vs $10,881), and 150% higher for AGE ($3316 vs $8292) in the highest-cost region compared with the lowest-cost region (Table 2A).

Variation Within Census Regions

After controlling for patient-level demographic and illness-severity variables, standardized costs were different across hospitals in the same region (P < 0.001; panel A in Figure). This was true for all conditions in each region. Differences between the lowest- and highest-cost hospitals within the same region ranged from 111% to 420% for asthma, 101% to 398% for DKA, and 166% to 787% for AGE (Table 3).

Variation Across Hospitals (Each Hospital as Its Own Region)

One hospital had the highest adjusted standardized costs for all 3 conditions ($9087 for asthma, $28,564 for DKA, and $23,387 for AGE) and was outside of the 95% confidence interval compared with the overall means. The second highest-cost hospitals for asthma ($5977) and AGE ($18,780) were also outside of the 95% confidence interval. After removing these outliers, the difference between the highest- and lowest-cost hospitals was 549% for asthma ($721 vs $4678), 491% for DKA ($2738 vs $16,192), and 681% for AGE ($1317 vs $10,281; Table 2B).

Drivers of Variation Across Census Regions

Patient-level demographic and illness-severity variables explained very little of the variation in standardized costs across regions. For each of the conditions, age, race, gender, community-level HHI, RUCA, and distance from home to the hospital each accounted for <1.5% of variation, while SOI and CCI each accounted for <5%. Overall, patient-level variables explained 5.5%, 3.7%, and 6.7% of variation for asthma, DKA, and AGE.

Encounter-level variables explained a much larger percentage of the variation in costs. LOS accounted for 17.8% of the variation for asthma, 9.8% for DKA, and 8.7% for AGE. ICU utilization explained 6.9% of the variation for asthma and 12.5% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. The combination of patient-level and encounter-level variables explained 27%, 24%, and 15% of the variation for asthma, DKA, and AGE.

Drivers of Variation Across Hospitals

For each of the conditions, patient-level demographic variables each accounted for <2% of variation in costs between hospitals. SOI accounted for 4.5% of the variation for asthma and CCI accounted for 5.2% for AGE. Overall, patient-level variables explained 6.9%, 5.3%, and 7.3% of variation for asthma, DKA, and AGE.

Encounter-level variables accounted for a much larger percentage of the variation in cost. LOS explained 25.4% for asthma, 13.3% for DKA, and 14.2% for AGE. ICU utilization accounted for 13.4% for asthma and 21.9% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. Together, patient-level and encounter-level variables explained 40%, 36%, and 22% of variation for asthma, DKA, and AGE.

Imaging, Laboratory, Pharmacy, and “Other” Costs

The largest contributor to total costs adjusted for patient-level factors for all conditions was “other,” which aggregates room, nursing, clinical, and supply charges (panel B in Figure). When considering drivers of variation, this category explained >50% for each of the conditions. The next largest contributor to total costs was laboratory charges, which accounted for 15% of the variation across regions for asthma and 11% for DKA. Differences in imaging accounted for 18% of the variation for DKA and 15% for AGE. Differences in pharmacy charges accounted for <4% of the variation for each of the conditions. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 78%, and 72% of the variation across census regions for asthma, DKA, and AGE.

For the hospital-level analysis, differences in “other” remained the largest driver of cost variation. For asthma, “other” explained 61% of variation, while pharmacy, laboratory, and imaging each accounted for <8%. For DKA, differences in imaging accounted for 18% of the variation and laboratory charges accounted for 12%. For AGE, imaging accounted for 15% of the variation. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 72%, and 67% of the variation for asthma, DKA, and AGE.

Cost Savings

If all hospitals in this cohort with adjusted standardized costs above the national PHIS average achieved costs equal to the national PHIS average, estimated annual savings in adjusted standardized costs for these 3 conditions would be $69.1 million. If each hospital with adjusted costs above the average within its census region achieved costs equal to its regional average, estimated annual savings in adjusted standardized costs for these conditions would be $25.2 million.

This study reported on the regional variation in costs of care for 3 conditions treated at 46 children’s hospitals across 7 geographic regions, and it demonstrated that variations in costs of care exist in pediatrics. This study used standardized costs to compare utilization patterns across hospitals and adjusted for several patient-level demographic and illness-severity factors, and it found that differences in costs of care for children hospitalized with asthma, DKA, and AGE remained both between and within regions.

These variations are noteworthy, as hospitals strive to improve the value of healthcare. If the higher-cost hospitals in this cohort could achieve costs equal to the national PHIS averages, estimated annual savings in adjusted standardized costs for these conditions alone would equal $69.1 million. If higher-cost hospitals relative to the average in their own region reduced costs to their regional averages, annual standardized cost savings could equal $25.2 million for these conditions.

The differences observed are also significant in that they provide a foundation for exploring whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes.²⁸ If so, studying what those hospitals do to achieve outcomes more efficiently can serve as the basis for the establishment of best practices.²⁹ Standardizing best practices through protocols, pathways, and care-model redesign can reduce potentially unnecessary spending.³⁰

Our findings showed that patient-level demographic and illness-severity covariates, including community-level HHI and SOI, did not consistently explain cost differences. Instead, LOS and ICU utilization were associated with higher costs.^17,19 When considering the effect of the 4 cost components on the variation in total standardized costs between regions and between hospitals, the fact that the “other” category accounted for the largest percent of the variation is not surprising, because the cost of room occupancy and nursing services increases with longer LOS and more time in the ICU. Other individual cost components that were major drivers of variation were laboratory utilization for asthma and imaging for DKA and AGE³¹ (though they accounted for a much smaller proportion of total adjusted costs).¹⁹

To determine if these factors are modifiable, more information is needed to explain why practices differ. Many factors may contribute to varying utilization patterns, including differences in capabilities and resources (in the hospital and in the community) and patient volumes. For example, some hospitals provide continuous albuterol for status asthmaticus only in ICUs, while others provide it on regular units.³² But if certain hospitals do not have adequate resources or volumes to effectively care for certain populations outside of the ICU, their higher-value approach (considering quality and cost) may be to utilize ICU beds, even if some other hospitals care for those patients on non-ICU floors. Another possibility is that family preferences about care delivery (such as how long children stay in the hospital) may vary across regions.³³

Other evidence suggests that physician practice and spending patterns are strongly influenced by the practices of the region where they trained.³⁴ Because physicians often practice close to where they trained,^35,36 this may partially explain how regional patterns are reinforced.

Even considering all mentioned covariates, our model did not fully explain variation in standardized costs. After adding the cost components as covariates, between one-third and one-fifth of the variation remained unexplained. It is possible that this unexplained variation stemmed from unmeasured patient-level factors.

In addition, while proxies for SES, including community-level HHI, did not significantly predict differences in costs across regions, it is possible that SES affected LOS differently in different regions. Previous studies have suggested that lower SES is associated with longer LOS.³⁷ If this effect is more pronounced in certain regions (potentially because of differences in social service infrastructures), SES may be contributing to variations in cost through LOS.

Our findings were subject to limitations. First, this study only examined 3 diagnoses and did not include surgical or less common conditions. Second, while PHIS includes tertiary care, academic, and freestanding children’s hospitals, it does not include general hospitals, which is where most pediatric patients receive care.³⁸ Third, we used ZIP code-based median annual HHI to account for SES, and we used ZIP codes to determine the distance to the hospital and rural-urban location of patients’ homes. These approximations lack precision because SES and distances vary within ZIP codes.³⁹ Fourth, while adjusted standardized costs allow for comparisons between hospitals, they do not represent actual costs to patients or individual hospitals. Additionally, when determining whether variation remained after controlling for patient-level variables, we included SOI as a reflection of illness-severity at presentation. However, in practice, SOI scores may be assigned partially based on factors determined during the hospitalization.¹⁸ Finally, the use of other regional boundaries or the selection of different hospitals may yield different results.

This study reveals regional variations in costs of care for 3 inpatient pediatric conditions. Future studies should explore whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes. To the extent that variation is driven by modifiable factors and lower spending does not compromise outcomes, these data may prompt reviews of care models to reduce unwarranted variation and improve the value of care delivery at local, regional, and national levels.

Disclosure

Internal funds from the CHA and The Children’s Hospital of Philadelphia supported the conduct of this work. The authors have no financial interests, relationships, or affiliations relevant to the subject matter or materials discussed in the manuscript to disclose. The authors have no potential conflicts of interest relevant to the subject matter or materials discussed in the manuscript to disclose

With some areas of the country spending close to 3 times more on healthcare than others, regional variation in healthcare spending has been the focus of national attention.^1-7 Since 1973, the Dartmouth Institute has studied regional variation in healthcare utilization and spending and concluded that variation is “unwarranted” because it is driven by providers’ practice patterns rather than differences in medical need, patient preferences, or evidence-based medicine.^8-11 However, critics of the Dartmouth Institute’s findings argue that their approach does not adequately adjust for community-level income, and that higher costs in some areas reflect greater patient needs that are not reflected in illness acuity alone.^12-14

While Medicare data have made it possible to study variations in spending for the senior population, fragmentation of insurance coverage and nonstandardized data structures make studying the pediatric population more difficult. However, the Children’s Hospital Association’s (CHA) Pediatric Health Information System (PHIS) has made large-scale comparisons more feasible. To overcome challenges associated with using charges and nonuniform cost data, PHIS-derived standardized costs provide new opportunities for comparisons.^15,16 Initial analyses using PHIS data showed significant interhospital variations in costs of care,¹⁵ but they did not adjust for differences in populations and assess the drivers of variation. A more recent study that controlled for payer status, comorbidities, and illness severity found that intensive care unit (ICU) utilization varied significantly for children hospitalized for asthma, suggesting that hospital practice patterns drive differences in cost.¹⁷

This study uses PHIS data to analyze regional variations in standardized costs of care for 3 conditions for which children are hospitalized. To assess potential drivers of variation, the study investigates the effects of patient-level demographic and illness-severity variables as well as encounter-level variables on costs of care. It also estimates cost savings from reducing variation.

Data Source

This retrospective cohort study uses the PHIS database (CHA, Overland Park, KS), which includes 48 freestanding children’s hospitals located in noncompeting markets across the United States and accounts for approximately 20% of pediatric hospitalizations. PHIS includes patient demographics, International Classification of Diseases, 9th Revision (ICD-9) diagnosis and procedure codes, as well as hospital charges. In addition to total charges, PHIS reports imaging, laboratory, pharmacy, and “other” charges. The “other” category aggregates clinical, supply, room, and nursing charges (including facility fees and ancillary staff services).

Inclusion Criteria

Inpatient- and observation-status hospitalizations for asthma, diabetic ketoacidosis (DKA), and acute gastroenteritis (AGE) at 46 PHIS hospitals from October 2014 to September 2015 were included. Two hospitals were excluded because of missing data. Hospitalizations for patients >18 years were excluded.

Hospitalizations were categorized by using All Patient Refined-Diagnosis Related Groups (APR-DRGs) version 24 (3M Health Information Systems, St. Paul, MN)¹⁸ based on the ICD-9 diagnosis and procedure codes assigned during the episode of care. Analyses included APR-DRG 141 (asthma), primary diagnosis ICD-9 codes 250.11 and 250.13 (DKA), and APR-DRG 249 (AGE). ICD-9 codes were used for DKA for increased specificity.¹⁹ These conditions were chosen to represent 3 clinical scenarios: (1) a diagnosis for which hospitals differ on whether certain aspects of care are provided in the ICU (asthma), (2) a diagnosis that frequently includes care in an ICU (DKA), and (3) a diagnosis that typically does not include ICU care (AGE).¹⁹

Study Design

To focus the analysis on variation in resource utilization across hospitals rather than variations in hospital item charges, each billed resource was assigned a standardized cost.^15,16 For each clinical transaction code (CTC), the median unit cost was calculated for each hospital. The median of the hospital medians was defined as the standardized unit cost for that CTC.

The primary outcome variable was the total standardized cost for the hospitalization adjusted for patient-level demographic and illness-severity variables. Patient demographic and illness-severity covariates included age, race, gender, ZIP code-based median annual household income (HHI), rural-urban location, distance from home ZIP code to the hospital, chronic condition indicator (CCI), and severity-of-illness (SOI). When assessing drivers of variation, encounter-level covariates were added, including length of stay (LOS) in hours, ICU utilization, and 7-day readmission (an imprecise measure to account for quality of care during the index visit). The contribution of imaging, laboratory, pharmacy, and “other” costs was also considered.

Median annual HHI for patients’ home ZIP code was obtained from 2010 US Census data. Community-level HHI, a proxy for socioeconomic status (SES),^20,21 was classified into categories based on the 2015 US federal poverty level (FPL) for a family of 4²²: HHI-1 = ≤ 1.5 × FPL; HHI-2 = 1.5 to 2 × FPL; HHI-3 = 2 to 3 × FPL; HHI-4 = ≥ 3 × FPL. Rural-urban commuting area (RUCA) codes were used to determine the rural-urban classification of the patient’s home.²³ The distance from home ZIP code to the hospital was included as an additional control for illness severity because patients traveling longer distances are often more sick and require more resources.²⁴

The Agency for Healthcare Research and Quality CCI classification system was used to identify the presence of a chronic condition.²⁵ For asthma, CCI was flagged if the patient had a chronic condition other than asthma; for DKA, CCI was flagged if the patient had a chronic condition other than DKA; and for AGE, CCI was flagged if the patient had any chronic condition.

The APR-DRG system provides a 4-level SOI score with each APR-DRG category. Patient factors, such as comorbid diagnoses, are considered in severity scores generated through 3M’s proprietary algorithms.¹⁸

For the first analysis, the 46 hospitals were categorized into 7 geographic regions based on 2010 US Census Divisions.²⁶ To overcome small hospital sample sizes, Mountain and Pacific were combined into West, and Middle Atlantic and New England were combined into North East. Because PHIS hospitals are located in noncompeting geographic regions, for the second analysis, we examined hospital-level variation (considering each hospital as its own region).

Data Analysis

To focus the analysis on “typical” patients and produce more robust estimates of central tendencies, the top and bottom 5% of hospitalizations with the most extreme standardized costs by condition were trimmed.²⁷ Standardized costs were log-transformed because of their nonnormal distribution and analyzed by using linear mixed models. Covariates were added stepwise to assess the proportion of the variance explained by each predictor. Post-hoc tests with conservative single-step stepwise mutation model corrections for multiple testing were used to compare adjusted costs. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). P values < 0.05 were considered significant. The Children’s Hospital of Philadelphia Institutional Review Board did not classify this study as human subjects research.

During the study period, there were 26,430 hospitalizations for asthma, 5056 for DKA, and 16,274 for AGE (Table 1).

Variation Across Census Regions

After adjusting for patient-level demographic and illness-severity variables, differences in adjusted total standardized costs remained between regions (P < 0.001). Although no region was an outlier compared to the overall mean for any of the conditions, regions were statistically different in pairwise comparison. The East North Central, South Atlantic, and West South Central regions had the highest adjusted total standardized costs for each of the conditions. The East South Central and West North Central regions had the lowest costs for each of the conditions. Adjusted total standardized costs were 120% higher for asthma ($1920 vs $4227), 46% higher for DKA ($7429 vs $10,881), and 150% higher for AGE ($3316 vs $8292) in the highest-cost region compared with the lowest-cost region (Table 2A).

Variation Within Census Regions

After controlling for patient-level demographic and illness-severity variables, standardized costs were different across hospitals in the same region (P < 0.001; panel A in Figure). This was true for all conditions in each region. Differences between the lowest- and highest-cost hospitals within the same region ranged from 111% to 420% for asthma, 101% to 398% for DKA, and 166% to 787% for AGE (Table 3).

Variation Across Hospitals (Each Hospital as Its Own Region)

One hospital had the highest adjusted standardized costs for all 3 conditions ($9087 for asthma, $28,564 for DKA, and $23,387 for AGE) and was outside of the 95% confidence interval compared with the overall means. The second highest-cost hospitals for asthma ($5977) and AGE ($18,780) were also outside of the 95% confidence interval. After removing these outliers, the difference between the highest- and lowest-cost hospitals was 549% for asthma ($721 vs $4678), 491% for DKA ($2738 vs $16,192), and 681% for AGE ($1317 vs $10,281; Table 2B).

Drivers of Variation Across Census Regions

Patient-level demographic and illness-severity variables explained very little of the variation in standardized costs across regions. For each of the conditions, age, race, gender, community-level HHI, RUCA, and distance from home to the hospital each accounted for <1.5% of variation, while SOI and CCI each accounted for <5%. Overall, patient-level variables explained 5.5%, 3.7%, and 6.7% of variation for asthma, DKA, and AGE.

Encounter-level variables explained a much larger percentage of the variation in costs. LOS accounted for 17.8% of the variation for asthma, 9.8% for DKA, and 8.7% for AGE. ICU utilization explained 6.9% of the variation for asthma and 12.5% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. The combination of patient-level and encounter-level variables explained 27%, 24%, and 15% of the variation for asthma, DKA, and AGE.

Drivers of Variation Across Hospitals

For each of the conditions, patient-level demographic variables each accounted for <2% of variation in costs between hospitals. SOI accounted for 4.5% of the variation for asthma and CCI accounted for 5.2% for AGE. Overall, patient-level variables explained 6.9%, 5.3%, and 7.3% of variation for asthma, DKA, and AGE.

Encounter-level variables accounted for a much larger percentage of the variation in cost. LOS explained 25.4% for asthma, 13.3% for DKA, and 14.2% for AGE. ICU utilization accounted for 13.4% for asthma and 21.9% for DKA; ICU use was not a major driver for AGE. Seven-day readmissions accounted for <0.5% for each of the conditions. Together, patient-level and encounter-level variables explained 40%, 36%, and 22% of variation for asthma, DKA, and AGE.

Imaging, Laboratory, Pharmacy, and “Other” Costs

The largest contributor to total costs adjusted for patient-level factors for all conditions was “other,” which aggregates room, nursing, clinical, and supply charges (panel B in Figure). When considering drivers of variation, this category explained >50% for each of the conditions. The next largest contributor to total costs was laboratory charges, which accounted for 15% of the variation across regions for asthma and 11% for DKA. Differences in imaging accounted for 18% of the variation for DKA and 15% for AGE. Differences in pharmacy charges accounted for <4% of the variation for each of the conditions. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 78%, and 72% of the variation across census regions for asthma, DKA, and AGE.

For the hospital-level analysis, differences in “other” remained the largest driver of cost variation. For asthma, “other” explained 61% of variation, while pharmacy, laboratory, and imaging each accounted for <8%. For DKA, differences in imaging accounted for 18% of the variation and laboratory charges accounted for 12%. For AGE, imaging accounted for 15% of the variation. Adding the 4 cost components to the other patient- and encounter-level covariates, the model explained 81%, 72%, and 67% of the variation for asthma, DKA, and AGE.

Cost Savings

If all hospitals in this cohort with adjusted standardized costs above the national PHIS average achieved costs equal to the national PHIS average, estimated annual savings in adjusted standardized costs for these 3 conditions would be $69.1 million. If each hospital with adjusted costs above the average within its census region achieved costs equal to its regional average, estimated annual savings in adjusted standardized costs for these conditions would be $25.2 million.

This study reported on the regional variation in costs of care for 3 conditions treated at 46 children’s hospitals across 7 geographic regions, and it demonstrated that variations in costs of care exist in pediatrics. This study used standardized costs to compare utilization patterns across hospitals and adjusted for several patient-level demographic and illness-severity factors, and it found that differences in costs of care for children hospitalized with asthma, DKA, and AGE remained both between and within regions.

These variations are noteworthy, as hospitals strive to improve the value of healthcare. If the higher-cost hospitals in this cohort could achieve costs equal to the national PHIS averages, estimated annual savings in adjusted standardized costs for these conditions alone would equal $69.1 million. If higher-cost hospitals relative to the average in their own region reduced costs to their regional averages, annual standardized cost savings could equal $25.2 million for these conditions.

The differences observed are also significant in that they provide a foundation for exploring whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes.²⁸ If so, studying what those hospitals do to achieve outcomes more efficiently can serve as the basis for the establishment of best practices.²⁹ Standardizing best practices through protocols, pathways, and care-model redesign can reduce potentially unnecessary spending.³⁰

Our findings showed that patient-level demographic and illness-severity covariates, including community-level HHI and SOI, did not consistently explain cost differences. Instead, LOS and ICU utilization were associated with higher costs.^17,19 When considering the effect of the 4 cost components on the variation in total standardized costs between regions and between hospitals, the fact that the “other” category accounted for the largest percent of the variation is not surprising, because the cost of room occupancy and nursing services increases with longer LOS and more time in the ICU. Other individual cost components that were major drivers of variation were laboratory utilization for asthma and imaging for DKA and AGE³¹ (though they accounted for a much smaller proportion of total adjusted costs).¹⁹

To determine if these factors are modifiable, more information is needed to explain why practices differ. Many factors may contribute to varying utilization patterns, including differences in capabilities and resources (in the hospital and in the community) and patient volumes. For example, some hospitals provide continuous albuterol for status asthmaticus only in ICUs, while others provide it on regular units.³² But if certain hospitals do not have adequate resources or volumes to effectively care for certain populations outside of the ICU, their higher-value approach (considering quality and cost) may be to utilize ICU beds, even if some other hospitals care for those patients on non-ICU floors. Another possibility is that family preferences about care delivery (such as how long children stay in the hospital) may vary across regions.³³

Other evidence suggests that physician practice and spending patterns are strongly influenced by the practices of the region where they trained.³⁴ Because physicians often practice close to where they trained,^35,36 this may partially explain how regional patterns are reinforced.

Even considering all mentioned covariates, our model did not fully explain variation in standardized costs. After adding the cost components as covariates, between one-third and one-fifth of the variation remained unexplained. It is possible that this unexplained variation stemmed from unmeasured patient-level factors.

In addition, while proxies for SES, including community-level HHI, did not significantly predict differences in costs across regions, it is possible that SES affected LOS differently in different regions. Previous studies have suggested that lower SES is associated with longer LOS.³⁷ If this effect is more pronounced in certain regions (potentially because of differences in social service infrastructures), SES may be contributing to variations in cost through LOS.

Our findings were subject to limitations. First, this study only examined 3 diagnoses and did not include surgical or less common conditions. Second, while PHIS includes tertiary care, academic, and freestanding children’s hospitals, it does not include general hospitals, which is where most pediatric patients receive care.³⁸ Third, we used ZIP code-based median annual HHI to account for SES, and we used ZIP codes to determine the distance to the hospital and rural-urban location of patients’ homes. These approximations lack precision because SES and distances vary within ZIP codes.³⁹ Fourth, while adjusted standardized costs allow for comparisons between hospitals, they do not represent actual costs to patients or individual hospitals. Additionally, when determining whether variation remained after controlling for patient-level variables, we included SOI as a reflection of illness-severity at presentation. However, in practice, SOI scores may be assigned partially based on factors determined during the hospitalization.¹⁸ Finally, the use of other regional boundaries or the selection of different hospitals may yield different results.

This study reveals regional variations in costs of care for 3 inpatient pediatric conditions. Future studies should explore whether lower-cost regions or lower-cost hospitals achieve comparable quality outcomes. To the extent that variation is driven by modifiable factors and lower spending does not compromise outcomes, these data may prompt reviews of care models to reduce unwarranted variation and improve the value of care delivery at local, regional, and national levels.

Disclosure

Internal funds from the CHA and The Children’s Hospital of Philadelphia supported the conduct of this work. The authors have no financial interests, relationships, or affiliations relevant to the subject matter or materials discussed in the manuscript to disclose. The authors have no potential conflicts of interest relevant to the subject matter or materials discussed in the manuscript to disclose